



# Louisiana Board of Pharmacy

3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ Facsimile 225.925.6499  
[www.pharmacy.la.gov](http://www.pharmacy.la.gov) ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



## Board Meeting

November 13, 2014

---

**NOTE:** Pursuant to the Open Meetings Law at La. R.S. 42:16, the Board may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, (4) discussions regarding personnel matters, or other purposes itemized at La. R.S. 42:17.



# Louisiana Board of Pharmacy

3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ Facsimile 225.925.6499  
[www.pharmacy.la.gov](http://www.pharmacy.la.gov) ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



**NOTICE IS HEREBY GIVEN** that a meeting of the Board has been ordered and called for 9:00 a.m. on Thursday, November 13, 2014 at the Board office, for the purpose to wit:

## AGENDA

NOTE: This agenda is tentative until 24 hours in advance of the meeting, at which time the most recent revision becomes official.

**Revised 11-10-2014**

1. Call to Order
2. Invocation & Pledge of Allegiance
3. Quorum Call
4. Call for Additional Agenda Items & Adoption of Agenda
5. Consideration of Minutes
6. Report on Action Items
7. Confirmation of Acts
8. Opportunity for Public Comment
- \* Special Order of the Day – Presentation of Pharmacist Gold Certificate  
PST.008851 – Edwin Earl Britt
9. Election of Officers
10. Committee Reports
  - A. Finance – Mr. Pitre
    - Consideration of Interim Report for Fiscal Year 2014-2015
    - Consideration of Proposed Budget for Fiscal Year 2015-2016
  - B. Application Review – Mr. Soileau
    - Consideration of Committee Recommendations re Applications
  - C. Reciprocity – Ms. Hall
  - D. Violations – Mr. Bond
    - Consideration of Proposed Voluntary Consent Agreements
  - E. Impairment – Mr. Rabb
    - Consideration of Committee Recommendations re Applications
  - F. Reinstatement – Ms. Melancon
    - Consideration of Committee Recommendations re Applications
  - G. Tripartite – Mr. Burch
  - H. Regulation Revision – Mr. McKay
    - Consideration of Comments & Testimony from October 30, 2014 Public Hearing re Regulatory Project 2014-4 ~ Pharmacy Compounding, Regulatory Project 2014-5 ~ Prescriptions, and Regulatory Project 2014-6 ~ Special Event Pharmacy Permit.
    - Consideration of Regulatory Proposal 2015-B ~ Dispenser Reporting to PMP & Drugs of Concern
    - Consideration of Regulatory Proposal 2015-C ~ Expiration Date of Schedule II Prescriptions

---

**NOTE:** Pursuant to the Open Meetings Law at La. R.S. 42:16, the Board may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, (4) discussions regarding personnel matters, or other purposes itemized at La. R.S. 42:17.

10. Committee Reports (cont.)
  - I. Executive – Mr. Aron
    - Consideration of Bank Box Access Resolution
    - Consideration of Resolutions for Professional Legal Services
    - Consideration of Proposed Revision to Policy I.A.2 re Declaratory Statements
    - Consideration of Proposed New Policy II.I.4 re Ebola Virus Disease
11. Staff Reports
  - J. Assistant Executive Director – Mr. Fontenot
  - K. General Counsel – Mr. Finalet
    - Consideration of Proposed Voluntary Consent Agreements
  - L. Executive Director – Mr. Broussard
12. Announcements
13. Adjourn

---

**NOTE:** Pursuant to the Open Meetings Law at La. R.S. 42:16, the Board may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, (4) discussions regarding personnel matters, or other purposes itemized at La. R.S. 42:17.



# Louisiana Board of Pharmacy

3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ Facsimile 225.925.6499  
[www.pharmacy.la.gov](http://www.pharmacy.la.gov) ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



## Table of Contents

1 – A.	Agenda	002
1 – B.	Table of Contents	004
1 – C.	Meeting Notice & Arrangements	005
1 – D.	Acronyms	006
2.	Invocation & Pledge of Allegiance	
3.	Quorum Call	
4.	Call for Additional Agenda Items & Adoption of Agenda	
5.	Consideration of Minutes from Previous Meetings ~ August 6, 2014	010
6.	Report on Action Items	
7.	Confirmation of Acts	
8.	Opportunity for Public Comment	
*	Special Order of the Day – Presentation of Pharmacist Gold Certificates	
9.	Election of Officers	
10.	Committee Reports	
A.	Finance – Mr. Pitre & Mr. Russell Champagne, CPA	035
	• Consideration of <i>Interim Report for Fiscal Year 2014-2015</i>	037
	• Consideration of <i>Proposed Budget for Fiscal Year 2015-2016</i>	048
B.	Application Review – Mr. Soileau	057
	• Consideration of Committee Recommendations re Applications	
C.	Reciprocity – Ms. Hall	058
D.	Violations – Mr. Bond	059
	• Consideration of Proposed Voluntary Consent Agreements	060
E.	Impairment – Mr. Rabb	143
	• Consideration of Committee Recommendations re Applications	
F.	Reinstatement – Ms. Melancon	145
	• Consideration of Committee Recommendations re Applications	
G.	Tripartite – Mr. Burch	152
H.	Regulation Revision – Mr. McKay	153
	• Consideration of Comments & Testimony from October 30 Public Hearing	154
	• Consideration of <i>Regulatory Proposal 2015-B ~ Dispenser Reporting to PMP &amp; Drugs of Concern</i>	159
	• Consideration of <i>Regulatory Proposal 2015-C ~ Expiration Date of Schedule II Prescriptions</i>	160
I.	Executive Committee – Mr. Aron	161
	• Consideration of Bank Box Access Resolution	163
	• Consideration of Resolutions for Professional Legal Services	164
	• Consideration of Proposed Revision to Policy I.A.2 re Declaratory Statements	166
	• Consideration of Proposed New Policy II.I.4 re Ebola Virus Disease	169
11.	Staff Reports	
J.	Assistant Executive Director – Mr. Fontenot	172
	• Consideration of Requests for Waivers from PMP Reporting Rule	180
K.	General Counsel – Mr. Finalet	193
	• Consideration of Proposed Voluntary Consent Agreements	194
L.	Executive Director – Mr. Broussard	221
12.	Announcements	306
13.	Adjourn	

---

**NOTE:** Pursuant to the Open Meetings Law at La. R.S. 42:16, the Board may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, (4) discussions regarding personnel matters, or other purposes itemized at La. R.S. 42:17.

## Acronyms

AACP	American Association of Colleges of Pharmacy
AAPS	American Association of Pharmaceutical Scientists
AAPT	American Association of Pharmacy Technicians
ACA	American College of Apothecaries
ACCME	Accreditation Council for Continuing Medical Education
ACCP	American College of Clinical Pharmacy
ACE	Advisory Committee on Examinations (NABP)
ACPE	Accreditation Council for Pharmacy Education
ADA	American Dental Association
ADC	automated dispensing cabinet
ADS	automated dispensing system
AFDO	Association of Food & Drug Officials
AFPE	American Foundation for Pharmaceutical Education
AIHP	American Institute of the History of Pharmacy
AMA	American Medical Association
AMCP	Academy of Managed Care Pharmacy
AMS	automated medication system
APEC	Australian Pharmacy Examining Council
APhA	American Pharmacists Association
APPE	advanced pharmacy practice experience
ASAE	American Society of Association Executives
ASAP	American Society for Automation in Pharmacy
ASCP	American Society of Consultant Pharmacists
ASHP	American Society of Health-System Pharmacists
ASPL	American Society for Pharmacy Law
AVMA	American Veterinary Medical Association
AWARxE	NABP consumer protection program
BNDD	Bureau of Narcotics and Dangerous Drugs
BPS	Board of Pharmacy Specialties
CAC	Citizen Advocacy Center
CCAPP	Canadian Council for Accreditation of Pharmacy Programs
CCGP	Commission for Certification in Geriatric Pharmacy
CDC	Centers for Disease Control and Prevention
CDER	Center for Drug Evaluation and Research
CDTM	collaborative drug therapy management
CDS	controlled dangerous substances
CE	continuing education
CFR	Code of Federal Regulations
CHPA	Consumer Healthcare Products Association
CLEAR	Council on Licensure, Enforcement and Regulation
CMI	consumer medication information
CMS	Centers for Medicare and Medicaid Services
CPD	continuing professional development
CPhA	Canadian Pharmacists Association
CPPA	Center for Pharmacy Practice Accreditation
CPSC	Consumer Product Safety Commission
DEA	Drug Enforcement Administration
DEQ	La. Department of Environmental Quality
DHH	La. Department of Health and Hospitals

DME	durable medical equipment
DMEPOS	durable medical equipment, prosthetics, orthotics, and supplies
DNV	Det Norske Veritas (Norwegian accreditation organization)
DSM	disease state management
EDK	emergency drug kit
ELTP	Electronic Licensure Transfer Program (NABP)
EPA	Federal Environmental Protection Agency
EPCS	Electronic Prescribing of Controlled Substances (DEA)
ETS	Educational Testing Service
EU	European Union
ExCPT	Examination for the Certification of Pharmacy Technicians
FARB	Federation of Associations of Regulatory Boards
FBI	Federal Bureau of Investigation
FD&C	Federal Food, Drug & Cosmetic Act
FDA	Federal Food & Drug Administration
FIP	Federation Internationale Pharmaceutique
FMI	Food Marketing Institute
FPGEC	Foreign Pharmacy Graduate Examination Committee (NABP)
FPGEE	Foreign Pharmacy Graduate Equivalency Examination (NABP)
FSBPT	Federation of State Boards of Physical Therapy
FSMB	Federation of State Medical Boards
FRC	Foreign Pharmacy Graduate Equivalency Examination Review Committee (NABP)
FTC	Federal Trade Commission
GPhA	Generic Pharmaceutical Association
GPO	US Government Printing Office
gTLD	generic top level domain (Internet addresses)
HCFA	Health Care Financing Administration
HDMA	Healthcare Distribution Management Association
HIPAA	Health Insurance Portability and Accountability Act (of 1996)
HIPDB	Healthcare Integrity and Protection Data Bank
HMO	health maintenance organization
IACP	International Academy of Compounding Pharmacists
ICANN	Internet Corporation for Assigned Numbers and Names
ICPT	Institute for the Certification of Pharmacy Technicians
IDOI	Internet Drug Outlet Identification (NABP)
INEOA	International Narcotic Enforcement Officers Association
IOM	Institute of Medicine
IPPE	introductory pharmacy practice experience
ISMP	Institute for Safe Medication Practices
JCPP	Joint Commission of Pharmacy Practitioners
LAMP	Louisiana Academy of Medical Psychologists
LANP	Louisiana Association of Nurse Practitioners
LAPA	Louisiana Academy of Physician Assistants
LBP	Louisiana Board of Pharmacy
LDA	Louisiana Dental Association
LIPA	Louisiana Independent Pharmacies Association
LPA	Louisiana Pharmacists Association
LPTA	Louisiana Physical Therapy Association
LPTB	Louisiana Physical Therapy Board
LSBD	Louisiana State Board of Dentistry
LSBME	Louisiana State Board of Medical Examiners

LSBN	Louisiana State Board of Nursing
LSBOE	Louisiana State Board of Optometry Examiners
LSBPNE	Louisiana State Board of Practical Nurse Examiners
LSBVM	Louisiana State Board of Veterinary Medicine
LSBWDD	Louisiana State Board of Wholesale Drug Distributors
LSHP	Louisiana Society of Health-System Pharmacists
LSMS	Louisiana State Medical Society
LSNA	Louisiana State Nurses Association
LTC	long term care
LTCF	long term care facility
LVMA	Louisiana Veterinary Medical Association
MPJE	Multistate Pharmacy Jurisprudence Examination (NABP)
MRC	MPJE Review Committee (NABP)
NABP	National Association of Boards of Pharmacy
NABP-F	National Association of Boards of Pharmacy Foundation
NABPLAW	National Association of Boards of Pharmacy – Law Database
NACDS	National Association of Chain Drug Stores
NAMSDL	National Alliance for Model State Drug Laws
NAPLEX	North American Pharmacist Licensure Examination (NABP)
NAPRA	National Association of Pharmacy Regulatory Authorities (Canada)
NASCSA	National Association of State Controlled Substance Authorities
NASPA	National Alliance of State Pharmacy Associations
NASPER	National All Schedules Prescription Electronic Reporting Act
NCC MERP	National Coordinating Council for Medication Error Reporting and Prevention
NCPA	National Community Pharmacists Association
NCPDP	National Council for Prescription Drug Programs
NCPIE	National Council on Patient Information and Education
NCPO	National Conference of Pharmaceutical Organizations
NCSBN	National Council of State Boards of Nursing
NCVHS	National Committee on Vital and Health Statistics
NDC	National Drug Code
NDMA	Nonprescription Drug Manufacturing Association
NIPCO	National Institute for Pharmacist Care Outcomes
NISPC	National Institute for Standards in Pharmacist Credentialing
NOCA	National Organization for Competency Assurance
NPA	National Pharmacy Association
NPC	National Pharmaceutical Council
NPDB	National Practitioner Data Bank
NPTA	National Pharmacy Technician Association
NRC	NAPLEX Review Committee (NABP) Federal Nuclear Regulatory Commission
OAL	Optometry Association of Louisiana
OBRA	Omnibus Budget Reconciliation Act
OIG	Office of Inspector General
ONDCP	Office of National Drug Control Policy
ONDD	Office of Narcotics and Dangerous Drugs
OSHA	Occupational Safety and Health Administration
PARE	Pharmacy Assessment, Remediation and Evaluation (NABP)
PBM	pharmacy benefit management
PCAB	Pharmacy Compounding Accreditation Board
PCCA	Professional Compounding Centers of America

PCMA	Pharmaceutical Care Management Association
PCOA	Pharmacy Curriculum Outcomes Assessment (NABP)
PDMA	Prescription Drug Marketing Act
PEBC	Pharmacy Examining Board of Canada
PhRMA	Pharmaceutical Research and Manufacturers of America
PMP	Prescription Monitoring Program
PMP-i	Prescription Monitoring Program Interconnect (NABP)
PTCB	Pharmacy Technician Certification Board
PTCE	Pharmacy Technician Certification Examination
PTEC	Pharmacy Technician Educators Council
RFID/EPC	Radio Frequency Identification / Electronic Product Code
SAMSHA	Federal Substance Abuse & Mental Health Services Administration
TJC	The Joint Commission
TOEFL	Test of English as a Foreign Language
TOEFL iBT	Test of English as a Foreign Language Internet-based Test
TSE	Test of Spoken English
URAC	Utilization Review Accreditation Commission
USP	United States Pharmacopeia / United States Pharmacopeial Convention
USP DI	US Pharmacopeia Dispensing Information
USP-NF	US Pharmacopeia – National Formulary
VAWD	Verified-Accredited Wholesale Distributors (NABP)
Vet-VIPPS	Veterinary-Verified Internet Pharmacy Practice Sites (NABP)
VIPPS	Verified Internet Pharmacy Practice Sites (NABP)
VPP	Verified Pharmacy Practice (NABP)
WHO	World Health Organization
WHPA	World Health Professions Alliance



# Louisiana Board of Pharmacy

3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ Facsimile 225.925.6499  
[www.pharmacy.la.gov](http://www.pharmacy.la.gov) ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



## Minutes

### **Regular Meeting**

Wednesday, August 6, 2014 at 9:00 a.m.

Louisiana Board of Pharmacy  
3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700

### **Administrative Hearing**

Thursday, August 7, 2014 at 8:30 a.m.

Louisiana Board of Pharmacy  
3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700

## Table of Contents

<u>Agenda Item No.</u>	<u>Description</u>	<u>Page No.</u>
<i>Wednesday, August 6, 2014</i>		
1.	Call to Order	4
2.	Invocation & Pledge of Allegiance	4
3.	Quorum Call	4
4.	Call for Additional Agenda Items	5
5.	Consideration of Minutes	5
6.	Report on Action Items	5
7.	Confirmation of Acts	5
8.	Opportunity for Public Comment	6
*	Statement of Purpose	6
*	Special Orders of the Day	
	Presentation of Pharmacist Gold Certificates	9
	Presentation of Distinguished Service Award	9
9.	Committee Reports	
	A. Finance	10
	B. Application Review	8
	C. Reciprocity	10
	D. Violations	6
	E. Impairment	10
	F. Reinstatement	12
	G. Tripartite	13
	H. Regulation Revision	13
	I. Executive	13
10.	Staff Reports	
	J. Assistant Executive Director	15
	K. General Counsel	7
	L. Executive Director	16
11.	Petition for Advisory Opinion or Declaratory Statement – Ms. Angelle Huff & The Wellness Corner	9
12.	Request for Approval of Life Safety Program – Emergency University	18
13.	Announcements	19
14.	Recess	19

## Table of Contents

<u>Agenda Item No.</u>	<u>Description</u>	<u>Page No.</u>
<i>Thursday, August 7, 2014</i>		
A.	Call to Order	19
B.	Invocation & Pledge of Allegiance	19
C.	Quorum Call	20
D.	Call for Additional Agenda Items	20
E.	Opportunity for Public Comment	20
	Appearances	20
F.	Formal Hearings	21
G.	Immunizations & Pharmacy Recordkeeping	25
H.	Adjourn	25

A regular meeting of the Louisiana Board of Pharmacy was held on Wednesday, August 6, 2014 in the Boardroom of the Board's office, located at 3388 Brentwood Drive in Baton Rouge, Louisiana. The meeting was held pursuant to public notice, each member received notice, and notice was properly posted.

*1. Call to Order*

Mr. Carl Aron, President, called the meeting to order at 9:10 a.m.

*2. Invocation & Pledge*

Mr. Aron called upon Mr. Brian Bond, and he delivered the invocation. Mr. Richard Soileau then led the group in the recitation of the Pledge of Allegiance.

*3. Quorum Call*

Mr. Aron then called upon the Secretary, Mr. Bond, to call the roll.

**Members Present:**

Mr. Carl W. Aron  
Mr. Brian A. Bond  
Mr. Ryan M. Dartez  
Ms. Jacqueline L. Hall  
Mr. Richard M. Indovina  
Mr. Marty R. McKay  
Ms. Chris B. Melancon  
Ms. Diane G. Milano  
Mr. Ronald E. Moore  
Mr. Blake P. Pitre  
Mr. T. Morris Rabb  
Ms. Pamela G. Reed  
Mr. Don L. Resweber (*late arrival*)  
Dr. Deborah H. Simonson  
Mr. Richard A. Soileau  
Mr. Rhonny K. Valentine

**Members Absent:**

Mr. Clovis S. Burch

**Staff Present:**

Mr. Malcolm J. Broussard, Executive Director  
Mr. Carlos M. Finalet, III, General Counsel  
Mr. M. Joseph Fontenot, Assistant Executive Director

**Guests:**

Mr. Joseph Adams – National Association of Boards of Pharmacy  
Mr. Kevin LaGrange – Professional Arts Pharmacy  
Ms. Rosamaend Oglesbee – CVS Pharmacies  
Mr. Nick Cahanin – NACDS  
Mr. Clark Cosse – La. Hospital Association

Ms. Crystal Carter – La. Pharmacists Association  
Mr. David Ruckman – Target Pharmacies  
Mr. Bryan Jones – LifePoint Hospitals  
Mr. Ronald Rome  
Ms. Elizabeth Lankford – HDMA  
Ms. Angelle Huff – The Wellness Corner  
Mr. Max Huff – The Wellness Corner  
Mr. Brad Reed – Wal-Mart Pharmacies  
Ms. Linda Spradley – Spradley & Spradley  
Mr. Irby Bourque  
Mr. Bud Courson – Courson Nickel  
Ms. Penny Scruggins – Kolder, Champagne, Slaven & Co.  
Mr. Russell Champagne – Kolder, Champagne, Slaven & Co.  
Mr. Pete Chambliss  
Mr. Lyle Bulger  
Mr. Danny Donato – Omnicare Pharmacies

Mr. Bond certified 15 of the 17 members were present, constituting a quorum for the conduct of official business.

*4. Call for Additional Agenda Items*

Mr. Aron asked if there were any additional agenda items, but none were offered. With no requests for any additions, and without objection, the Board adopted the posted agenda for that meeting. Mr. Aron then requested authority from the Board to reorder the agenda as necessary for the purpose of adjusting the sequence of various reports or guests. There were no objections to that request.

*5. Consideration of Minutes*

Mr. Aron reminded the members they had received the draft minutes from the Regular Board Meeting on May 7, 2014 which was held in Baton Rouge, Louisiana. With no objections, he waived the reading thereof. Hearing no requests for amendment or any objection to their approval, Mr. Aron declared the minutes were approved as presented. Mr. Bond reminded the members to sign the Minute Book.

*6. Report on Action Items*

Mr. Broussard reminded the members of their four rulemaking projects underway at that time. He reported on the progress and status of each of those initiatives.

*7. Confirmation of Acts*

Pursuant to Mr. Aron's declaration that the officers, committees, and executive director had attended to the business of the Board since the last meeting in accordance with policies and procedures previously approved by the Board, Mr. Rabb moved,

**Resolved**, that the actions taken and decisions made by the Board officers, Board committees, and Executive Director in the general conduct and transactions of Board business since May 7, 2014 are approved, adopted, and ratified by the entire Board.

The motion was adopted after a unanimous vote in the affirmative.

## 8. *Opportunity for Public Comment*

Mr. Aron reminded the members and guests the Open Meetings Law requires all public bodies to provide an opportunity for public comment at all meetings and for each agenda item upon which a vote is to be taken. He solicited general comments on non-agenda items from the guests present, and no comments were offered.

### *Statement of Purpose*

Mr. Aron reminded the members of the purpose and mission of the Board of Pharmacy by reciting the relevant portion of the Louisiana Pharmacy Practice Act. He urged the members to keep their mission in mind as they considered all the matters before them.

Before moving to the formal agenda items, Mr. Aron indicated he wished to take a moment on personal privilege for the following announcements:

- He reminded the members and guests that five of the member positions were slated for expiration the previous month. He then announced the governor had recently re-appointed all five of the incumbents to another six year term: Mr. Indovina for District 1, Ms. Hall for District 2, Mr. Soileau for District 3, Mr. Moore for District 6, and himself for District 5. The rest of the members and the guests congratulated the appointees with a round of applause.
- He recognized former member Mr. Joseph Adams and his wife Tina in the audience, congratulating Mr. Adams on his current position as President of the National Association of Boards of Pharmacy (NABP).
- He informed the members Mr. Soileau was celebrating his birthday by attending the meeting, and the members feted him with the birthday song.

At this point, Mr. Aron indicated he would re-order the sequence of various reports in order to accommodate certain guests.

## 9. *Committee Reports*

### *D. Violations Committee*

Mr. Aron called upon Mr. Bond for the committee report. Mr. Bond reported the committee held an informal conference on June 4 to consider their posted agenda which included 13 cases: 4 pharmacists, 4 pharmacy technicians, 4 pharmacy permits, and one pharmacy technician candidate. Following their interviews and deliberations, the committee took no action on 8 of the 13 cases. He then presented the following proposed voluntary consent agreements for their consideration.

#### **Walgreen Louisiana Co., Inc. d/b/a Walgreen Pharmacy No. 07083**

**(PHY.005320)** Mr. Bond moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board assessed the permit owner a fine of \$10,000 plus administrative and investigative costs.

#### **Community Pharmacy #1, Inc. d/b/a Community Pharmacy #1**

**(PHY.002908)** Mr. Bond moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the

affirmative. The Board revoked the permit effective March 18, 2014.

**Mona Patrice Carter (PST.014953)** Mr. Bond moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board accepted the voluntary surrender of her credential, resulting in the active suspension of the license for an indefinite period of time effective June 4, 2014, and further, the Board imposed a lifetime restriction on holding any ownership interest in any pharmacy licensed by the Board.

**Louis Charles Gambina (PST.011145)** Mr. Bond moved to approve the proposed non-disciplinary modification of a previous order. The motion was adopted after a unanimous vote in the affirmative.

**Shantelle Dionne Payton (CPT.010037)** Mr. Bond moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board accepted the voluntary surrender of her credential, resulting in the active suspension of the certificate for an indefinite period of time effective June 4, 2014.

Mr. Bond reported the committee will meet on September 10-11 to consider that docket, which included 9 pharmacists, 2 pharmacy technicians, one pharmacy technician candidate, 19 pharmacy permits, and one applicant for a pharmacy permit.

Finally, Mr. Bond concluded his report with appreciation to the other committee members for their ongoing efforts.

#### 10. *Staff Reports*

##### *K. Report of General Counsel*

Mr. Aron called upon Mr. Finalet for the report. He then presented the following files to the members for their consideration.

**Advanced Pharmacy, LLC d/b/a Advanced Pharmacy (PHY.006472)** Mr. Pitre moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board issued a Letter of Warning, and further, assessed the permit owner a fine of \$10,000 plus administrative costs.

**Transition Pharmacy, LLC d/b/a Transition Pharmacy (PHY.006813)** Mr. Rabb moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board issued a Letter of Warning, and further, assessed the permit owner a fine of \$5,000 plus administrative costs.

**Velva Boles (CDS.024112-MD)** Ms. Melancon moved to suspend the license for an indefinite period of time, based on the revocation of her medical license by the La. State Board of Medical Examiners. The motion was

adopted after a unanimous vote in the affirmative. The Board suspended the license for an indefinite period of time effective April 14, 2014.

**Rafael Orlando Robledo (CDS.039898-MD)** Ms. Melancon moved to suspend the license for an indefinite period of time, based on the voluntary surrender of his federal registration to the U.S. Drug Enforcement Administration. The motion was adopted after a unanimous vote in the affirmative. The Board suspended the license for an indefinite period of time effective April 28, 2014.

**James Edward Hines, III (CDS.033895-MD)** Ms. Melancon moved to suspend the license for an indefinite period of time, based on the voluntary surrender of his federal registration to the U.S. Drug Enforcement Administration. The motion was adopted after a unanimous vote in the affirmative. The Board suspended the license for an indefinite period of time effective May 20, 2014.

**Sidney Joseph Dupuy, III (CDS.001317-MD)** Ms. Melancon moved to suspend the license for an indefinite period of time, based on the voluntary surrender of his federal registration to the U.S. Drug Enforcement Administration. The motion was adopted after a unanimous vote in the affirmative. The Board suspended the license for an indefinite period of time effective June 10, 2014.

**Peter Randall Galvan (CDS.021410-MD)** Ms. Melancon moved to suspend the license for an indefinite period of time, based on the suspension of his medical license for an indefinite period of time by the La. State Board of Medical Examiners. The motion was adopted after a unanimous vote in the affirmative. The Board suspended the license for an indefinite period of time effective May 19, 2014.

**Lana Geannie Ford (Savell) (CPT.010235)** Mr. Rabb moved to accept the voluntary surrender of the credential. The motion was adopted after a unanimous vote in the affirmative. The Board accepted the voluntary surrender, resulting in the active suspension of the certificate for an indefinite period of time effective August 5, 2014.

Finally, Mr. Finalet indicated the conclusion of his report.

## 9. *Committee Reports*

### *B. Application Review Committee*

Mr. Aron called upon Mr. Soileau for the committee report. Mr. Soileau reported the committee met on July 10 to consider three referrals from the staff. Following the committee's interviews and deliberations, they authorized the issuance of two credentials without restriction. He then reported the following file to the members for their consideration.

**Spencer Landis Gauthreaux (Applicant for CDTM Registration)** Mr. Soileau moved to issue the registration without restriction. The motion was adopted after a unanimous vote in the affirmative. The Board issued the registration without restriction.

Finally, Mr. Soileau expressed his appreciation to the other members of the committee for their ongoing efforts.

At this point, Mr. Aron re-ordered the agenda to accommodate certain guests.

*11. Petition for Advisory Opinion or Declaratory Statement – Ms. Angelle Huff & The Wellness Corner*

Mr. Aron recognized Ms. Angelle Huff and her attorney, Mr. Karl Koch, and they approached the witness table. Mr. Aron informed the members the Executive Committee had met the previous evening to review an initial draft of a declaratory statement prepared by staff and recommended revisions before voting to recommend the approval of the second draft. Mr. Aron requested a hard copy be provided to Mr. Koch and Ms. Huff, and then directed the members to a copy in their electronic meeting binder. He then requested Mr. Broussard to review the circumstances surrounding the petition, and then to review the document in detail. Following the explanation, Mr. McKay moved,

**Resolved**, that the Board approve the proposed Declaratory Statement – Medication Therapy Management in the Practice of Pharmacy as recommended by the Executive Committee. During the discussion, the members agreed by consensus to an editorial formatting revision. Mr. McKay then moved to amend the original proposal by deleting lines 122 through 128. The motion to amend was adopted after a unanimous vote in the affirmative.

The motion to approve the amended statement was adopted after a unanimous vote in the affirmative.

*\* Special Order of the Day – Presentation of Pharmacist Gold Certificate*

Mr. Aron informed the members the Board had issued new licenses to 85 pharmacists during Calendar Year 1964 and that 26 of those had maintained their licensure for fifty continuous years, thus qualifying for a Pharmacist Gold Certificate. He reminded the members that recipients were free to choose how they wished to receive the certificate, and further, that four of the 26 had requested to receive their certificates during that Board meeting. He then presented the Pharmacist Gold Certificate to the following pharmacists, expressing the Board's appreciation for their years of service to the public and the profession of pharmacy:

- PST.008850 – Irby R. Bourque
- PST.008889 – Lyle Joseph Bulger
- PST.008898 – Ronald Joseph Rome
- PST.008925 – Thomas Joseph "Pete" Chambliss

Each recipient offered brief remarks, and the members and guests present congratulated each of them with standing ovations.

\* *Special Order of the Day – Presentation of Distinguished Service Award*

Mr. Aron then recognized Mr. Joseph Adams, a former member of the Board and currently serving as President of the National Association of Boards of Pharmacy. Mr. Aron noted that this was the Board's first opportunity to formally recognize his years of service to the Board from 2000-2013. He then presented the service award to Mr. Adams. The members and guests present congratulated him with a standing ovation.

At this point, Mr. Aron declared a brief recess. It was noted the members recessed at 10:30 am and then reconvened at 10:55 am. Mr. Aron then resumed the sequence of the posted agenda.

9. *Committee Reports*

A. *Finance Committee*

Mr. Aron recognized Mr. Russell Champagne, CPA, from Kolder, Champagne, Slaven & Co. for his presentation of the final report from the previous fiscal year. Mr. Champagne directed the members to the copy of the report in their meeting binder. He reviewed the report and responded to questions from the members. Mr. Pitre noted the committee had met the previous day to review the report; he then moved,

**Resolved**, that the Board accept the *Final Report for Fiscal Year 2013-2014*, subject to legislative audit.

The motion was adopted after a unanimous vote in the affirmative. Mr. Pitre then directed the members to a proposal to amend the budget for the current fiscal year. He noted the committee had met the previous day to review the staff recommendations; he then moved.

**Resolved**, that the Board approve the *Proposed Budget Amendment No. 1 for Fiscal Year 2014-2015*.

The motion was adopted after a unanimous vote in the affirmative. Mr. Aron expressed his appreciation to Mr Champagne for his continued service as a financial advisor to the Board.

Finally, Mr. Pitre expressed his appreciation to the other members of the committee for their work the previous day.

C. *Reciprocity Committee*

Mr. Aron called upon Ms. Hall for the committee report. She reported the staff had evaluated 35 applications for pharmacist licensure by reciprocity and that none of them contained information that warranted a committee-level review. Therefore, the committee had not met since the previous board meeting. In conformance with policies and procedures previously approved by the Board, the staff approved the applications and issued the credentials.

E. *Impairment Committee*

Mr. Aron called upon Mr. Rabb for the committee report. Mr. Rabb reported the committee met the previous day to consider nine referrals from staff. Following interviews and deliberations, the committee disposed of two cases without the necessity of further Board action. Mr. Rabb then presented the following files for Board action.

**Beverly Ann West (PST.016651)** Mr. Rabb moved to accept the voluntary surrender of the credential. The motion was adopted after a unanimous vote in the affirmative. The Board accepted the voluntary surrender, resulting in active suspension of the license for an indefinite period of time effective May 12, 2014.

**Matthew Marston Lane (PST.018065)** Mr. Rabb moved to deny the request for the reinstatement of the previously suspended license. The motion was adopted after a unanimous vote in the affirmative. The Board denied the request for reinstatement of the previously suspended license, and further, conditioned the acceptance of any future reinstatement application upon the satisfaction of certain requirements identified in the order.

**Sharron Renee Barnes Michael (PST.017155)** Mr. Rabb moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board granted the respondent's request for reinstatement of the previously suspended license, converted the duration of the suspensive period from an indefinite term to a term of 15 years and suspended the execution of the suspension, then placed the license on probation for 15 years, effective August 6, 2014, subject to certain terms enumerated in the consent agreement.

**Donald Wayne Crawley (PST.010199)** Mr. Rabb moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board granted the respondent's request for reinstatement of the previously suspended license, converted the duration of the suspensive period from an indefinite term to a term of five years and suspended the execution of the suspension, then placed the license on probation for five years, effective August 6, 2014, subject to certain terms enumerated in the consent agreement.

**Jason Conrad Dove (PST.015811)** Mr. Rabb moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board granted the respondent's request for reinstatement of the previously suspended license, contingent upon the satisfaction of certain requirements identified in the order, then converted the duration of the suspensive period from an indefinite term to a term of 15 years and suspended the execution of the suspension, then placed the license and any other interim credential on probation for 15 years, effective August 6, 2014.

**Paul Ryan Lemaire (PST.018503)** Mr. Rabb moved to approve the probation modification request. The motion was adopted after a unanimous vote in the affirmative. The Board granted the respondent's request to remove the term of probation that prohibited him from accepting an appointment as the pharmacist-in-charge of a pharmacy, and further, left all other terms of

probation in effect.

**Ginger Allen Teekell (PST.016606)** Mr. Rabb moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board ordered the active suspension of the license for a 15-day period beginning on September 1, 2014, and thereafter ordered the continuation of the probationary period imposed in her previous order from February 1, 2012.

Finally, Mr. Rabb closed his report with appreciation to his fellow committee members for their work the previous day and for the ongoing staff support.

*F. Reinstatement Committee*

Mr. Aron called upon Ms. Melancon for the committee report. She reported the committee had met earlier that day to consider four referrals from the staff. She then presented the following files for Board action.

**Torey Elizabeth Daigle Bonin (CPT.004830)** Ms. Melancon moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board granted the respondent's request for reinstatement of the previously lapsed certificate, contingent upon the satisfaction of certain conditions identified in the consent agreement.

**Donna Fragala White (PST.013041)** Ms. Melancon moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board granted the respondent's request for reinstatement of the previously lapsed license, contingent upon the satisfaction of certain conditions identified in the consent agreement.

**John Phillip McIntyre (PST.011242)** Ms. Melancon moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board granted the respondent's request for reinstatement of the previously lapsed license, contingent upon the satisfaction of certain conditions identified in the consent agreement.

**Dorian Edward Dunmiles (CPT.006836)** Ms. Melancon moved to approve the proposed voluntary consent agreement. The motion was adopted after a unanimous vote in the affirmative. The Board granted the respondent's request for reinstatement of the previously lapsed certificate, contingent upon the satisfaction of certain conditions identified in the consent agreement.

Ms. Melancon closed her report with appreciation to the other committee members for their work the previous day.

### G. Tripartite Committee

Mr. Aron noted the committee had not met since the last Board meeting.

### I. Executive Committee

Mr. Aron informed the members the committee had met the previous day to consider the matters on their posted agenda. He noted the committee spent most of their time on the proposed Declaratory Statement which the Board had just approved. He also informed the members the staff had made progress on a new basic inspection form to be used. Mr. Broussard indicated when the new form was ready he would circulate it to the members for any feedback before placing the form in use.

Finally, Mr. Aron completed his report with appreciation to his fellow officers for their ongoing efforts.

At this point, Mr. Aron declared a luncheon recess. It was noted the members recessed at 11:40 am and then reconvened in open session at 12:25 pm.

## 9. Committee Reports

### H. Regulation Revision Committee

Mr. Aron called upon Mr. McKay for the committee report. He reported the committee met in July and that the committee had voted to recommend the approval of two new regulatory proposals as well as a proposal for a pilot project. Prior to considering those, he suggested reviewing the comments and testimony offered during the July 28 public hearing.

Mr. McKay directed the members to the meeting binder containing a summary of the comments and testimony offered during the July 28 public hearing concerning Regulatory Project 2014-5 ~ Prescriptions. He noted the letter received from NACDS after the deadline for receipt of comments, and in particular, he noted the two requests for suggested changes to the original proposal. Following some discussion, Mr. McKay moved to reject the first suggested change to §2511.C.4. The motion was adopted after a unanimous vote in the affirmative. Following additional discussion, Mr. McKay suggested the propriety of accepting some of the second set of revisions suggested by NACDS, and he moved,

**Resolved**, on consideration of the public comments and testimony, the Board authorizes the amendment of the original proposal by amending §2511.E.2 to read as follows:

*“The pharmacist shall not select an equivalent drug product when the prescriber indicates “Dispense as Written”, “DAW”, or “Brand Medically Necessary” and transmits his electronic signature. Otherwise, the pharmacist may select an equivalent drug product, provided the patient has been informed of, and consents to, the proposed cost saving interchange.”;*

and further, authorize staff to respond to the public commentators in the manner directed by the Board, and further, to submit the proposed revisions to the original proposal for publication in the

State Register, and to schedule a public hearing on the proposed revisions.

The motion was adopted after a unanimous vote in the affirmative.

Mr. McKay reminded the members of their past work on the issue of pharmacy compounding, beginning with the New England Compounding Center (NECC) tragedy in late 2012. He reported the committee had completed its work on a revision to the Board's compounding rules at about the same time the US Congress adopted the new federal legislation. Staff had suggested a delay until the FDA issued its final guidance to compounding pharmacies, which was recently released. He then moved,

**Resolved**, to approve Regulatory Proposal 2014-C ~ Compounding (Draft #4), and further, to authorize the Executive Director to promulgate the proposed rule amendments upon the instruction of the President, and further, to authorize the President to approve acceptable amendments as may become necessary during the promulgation process.

The motion was adopted after a unanimous vote in the affirmative. Mr. McKay then reminded the members the Emergency Rule first adopted in January 2013 had been re-published continuously since then but had recently expired on August 2. With the expiration of the Emergency Rule, that left the Board's current rule, which contains no limits on the compounding of preparations for office use, in effect. He suggested the potential for some pharmacists to believe they had authority to resume unlimited compounding for office use under the state rule even though the more stringent federal law prohibits such activity. Given the potential hazard to public health from unlimited compounding for office use, he suggested the propriety of declaring an emergency and then adopting the proposed revision just adopted as a new emergency rule. He then moved,

**Resolved**, to approve the Declaration of Emergency ~ Pharmacy Compounding.

The motion was adopted after a unanimous vote in the affirmative. Mr. McKay then moved,

**Resolved**, to approve Regulatory Proposal 2014-C ~ Compounding (Draft #4), to become effective as an **Emergency Rule** effective August 8, 2014, and further, to authorize the Executive Director to re-publish this Emergency Rule as may become necessary during the promulgation process.

The motion was adopted after a unanimous vote in the affirmative.

Mr. McKay reminded the members of the request from the Louisiana Dental Association (LDA) during the Board's previous meeting to develop a special event pharmacy permit to assist the LDA during a planned medical mission event scheduled for February 2015 in New Orleans. Mr. McKay reported staff had developed a proposal that appeared to address those needs as well as several other types of potential events that need a pharmacy permit for a short period of time. The committee voted to recommend the approval of the proposal. Therefore, he moved,

**Resolved**, to approve Regulatory Proposal 2014-D ~ Special Event

*Pharmacy Permit (Draft #1)*, and further, to authorize the Executive Director to promulgate the proposed rule amendments upon the instruction of the President, and further, to authorize the President to approve acceptable amendments as may become necessary during the promulgation process.

The motion was adopted after a unanimous vote in the affirmative.

Mr. McKay then reported on the committee's development of a pilot project relative to the processing of medical orders by pharmacists working at small hospitals that would allow such processing to be performed from the pharmacists' homes in lieu of requiring such processing to be performed by remote processors. The proposal for the pilot project described the facilities eligible to participate in the project as those small facilities with an average census of less than 25, and further, specifically identified the first ten facilities who had agreed to participate in the project. The proposal identified the operational requirements for the project, including the data to be collected. Mr. McKay then moved,

**Resolved**, to approve the proposed *Pilot Project – Remote Processing of Medical Orders in Small Hospitals*. During the discussion, the members voted to amend the proposal to remove some specific time frames in favor of more general language.

The motion for approval of the amended proposal was adopted after a unanimous vote in the affirmative.

Finally, Mr. McKay concluded his report with appreciation to the other committee members for their ongoing efforts as well as for the staff support.

At this point, Mr. Aron re-ordered the agenda to return to the staff reports.

## 10. Staff Reports

### J. Prescription Monitoring Program

He reminded the members about the 2009 change in the PMP law that authorized the Board to issue waivers to the duty to report data to the program. He then directed the members to a list of 31 pharmacies requesting such a waiver. Mr. McKay moved,

**Resolved**, to authorize the issuance of PMP reporting waivers to:

- > PHY.006888-NR – Andover Group (TN);
- > PHY.005646-NR – Bet Pharm (KY);
- > PHY.006901-NU – Cardinal Health – Lafayette (LA);
- > PHY.005019-NRN – Cardinal Health – Flowood (MS);
- > PHY.005028-NU – Cardinal Health – New Orleans (LA);
- > PHY.002789-NU – Cardinal Health – West Monroe (LA);
- > PHY.006897-NU – Cardinal Health – Baton Rouge (LA);
- > PHY.006895-NU – Cardinal Health – Shreveport (LA);
- > PHY.006917-NU – Cardinal Health – Houma (LA);
- > PHY.006696-NRN – Cardinal Health – Denver (CO);
- > PHY.006866-NR – Community Healthcare Services (CA);
- > PHY.006333-HOS – Cypress Pointe Surg Hosp – Hammond (LA)
- > PHY.006710-NR – Goodlife Pharmacy – Boca Raton (FL);

- > PHY.006887-NR – Hawkins Pharmacy (MS);
  - > PHY.005169-IR – Institutional Pharmacies of La. (LA);
  - > PHY.000624-HOS – Lafayette Gen Hosp Pharmacy (LA);
  - > PHY.000627-HOS – Lane Reg Med Ctr Pharmacy (LA);
  - > PHY.006704-NR – Liberty Medical Supply (FL);
  - > PHY.006788-HOS – LifeCare Hosp of Shreveport (LA);
  - > PHY.006797-HOS – Longleaf Hosp Pharmacy (LA);
  - > PHY.006258-NR – Meds for Vets (UT);
  - > PHY.006380-HOS – NorthShore Spec Hosp Pharmacy (LA);
  - > PHY.006912-HOS – Park Place Surgical Hospital (LA);
  - > PHY.006739-NR – Physician Choice Pharmacy (FL);
  - > PHY.006374-NU – Pioneer Pharmacy (TX);
  - > PHY.006716-HOS – Post Acute Spec Hosp of Hammond (LA);
  - > PHY.006753-HOS – Post Acute Spec Hosp of Lafayette (LA);
  - > PHY.000194-HOS – Riverland Med Ctr Pharmacy (LA);
  - > PHY.006614-NR – Sinus Dynamics Pharmacy (CA);
  - > PHY.006892-NR – SmartPractice Allergan Bank (AZ); and
  - > PHY.006713-HOS – W. O. Moss Memorial Health Clinic (LA)
- once they have executed the standard consent agreement for that purpose.

The motion was adopted after a unanimous vote in the affirmative. Mr. Fontenot then reported three pharmacies who had previously obtained waivers from the Board had subsequently undergone a change of ownership but maintained similar professional practice patterns and had applied for waivers. He recommended their approval to the Board. Mr. McKay then moved,

- Resolved**, to authorize the issuance of PMP reporting waivers to:
- > PHY.006908-NR – Fresenius Medical Care North America (SC);
  - > PHY.006939-NR – Fresenius Medical Care North America (TX);
- and
- > PHY.001090-HOS – Terrebonne General Medical Center (LA),
- once they have executed the standard consent agreement for that purpose.

The motion was adopted after a unanimous vote in the affirmative.

Mr. Fontenot then reported on the technical adjustments being made by the program vendor to implement the recent rule changes relative to the shorter deadline for reporting transactions to the database as well as the appointment of delegates by prescribers and dispensers. Finally, he referred the members to the recently-released Annual Report for the usual metrics on prescription transactions and queries to the PMP database.

Finally, Mr. Fontenot indicated the completion of his report.

At this point, Mr. Aron declared a brief recess. It was noted the members recessed at 2:30 pm and then reconvened in open session at 2:55 pm.

*L. Report of Executive Director*

Mr. Aron called upon Mr. Broussard for the report. Mr. Broussard directed

the members to his report which was posted in the Boardroom Library prior to the meeting; it was also included in the meeting binder. He reviewed the following topics:

- Meeting Activity
- Reports

Census Reports – Credentials & Compliance Divisions  
Production Reports – Credentials Division  
Exceptions Report  
Compliance Division Statistical Summary  
Annual Report

Mr. McKay moved,

**Resolved**, to approve the 2014 Annual Report, and further, to authorize the Executive Director to send a copy to the Office of the Governor, and further, to post a copy on the Board's website.

The motion was adopted after a unanimous vote in the affirmative.

- Examinations

MPJE  
NAPLEX  
PARE  
PTCB

- Operations

Credentials Division  
Compliance Division  
Administrative Division

Mr. McKay moved,

**Resolved**, to approve the Louisiana Compliance Questionnaire for 2014, and further, to authorize the President and Secretary to execute the document for the Board.

The motion was adopted after a unanimous vote in the affirmative. Mr. McKay then moved,

**Resolved**, to approve the June 2014 Roster of Colleges & Schools of Pharmacy for Fiscal Year 2014-2015.

The motion was adopted after a unanimous vote in the affirmative.

- State Activities

2014 Legislature

Mr. Broussard reviewed the Final Brief of the 2014 Legislative Session which detailed the successful legislation from the session. The Board took formal notice of all the items reported in the Final Brief. Mr. Broussard reported on the communications sent to all of its licensees about the measures. Finally, he suggested referrals of some items to the Board's Regulation Revision Committee for their

consideration of potential rule changes to comply with the new legislation. Mr. Aron referred the following items to the Regulation Revision Committee:

- Act 442 – relative to the Louisiana Telehealth Access Act.
- Act 865 – relative to changes in the expiration date of prescriptions for controlled substances listed in Schedule II.
- Act 472 – relative to changes in the reporting deadline for dispensers reporting transactions to the PMP database.

#### Dept. of Health & Hospitals

Mr. Broussard reported one of the legislative items from the 2014 session was a study resolution directing DHH to establish a working group to develop strategies to decrease primary care utilization in emergency rooms across the state. He indicated DHH had requested assistance from the Board of Pharmacy relative to the PMP program. Several of the strategies being developed relate to reducing use of emergency rooms to access controlled substances. He reported one of the group's first deliverables is a guideline document encouraging emergency rooms to decrease the amount of controlled substances prescribed in emergency rooms, including encouraging greater use of the PMP database prior to prescribing controlled substances. He reported the group had scheduled a vote on the guideline document at their next meeting and requested either an approval or endorsement from all of the working group members. Mr. McKay then moved,

**Resolved**, that the Board endorse the Louisiana Emergency Department Opioid Prescribing Guidelines published by the La. Dept. of Health and Hospitals.

The motion was adopted after a unanimous vote in the affirmative.

- National Activities
  - National Association of Boards of Pharmacy (NABP)
  - NABP-AACP District 6 Annual Meeting
  - MALTAGON
  - U.S. Food & Drug Administration (FDA)
  - U.S. Drug Enforcement Administration (DEA)
- International Activities
  - International Pharmaceutical Federation (FIP)

#### 12. Request for Approval of Life Safety Program – Emergency University

In the absence of any representatives at the meeting, Mr. Aron called upon Mr. Broussard, who directed the members to the materials in their meeting binders. He

provided the historical information relevant to the requests and noted the staff recommendation. Mr. McKay then moved,

**Resolved**, that the Board approve the life safety program for healthcare professionals (CPR Pro) as offered by Emergency University.

The motion was adopted after a unanimous vote in the affirmative. Mr. Aron directed Mr. Broussard to notify the organization of the approval and to modify the Board's relevant forms as appropriate.

### 13. *Announcements*

Mr. Aron directed the members to the announcements in their meeting binder. In addition, Mr. Broussard and Mr. McKay made the following recognition announcements:

- > In response to a resolution adopted at their 2014 Annual Meeting, NABP established the Task Force on Standards for the Use of PMP Data. NABP President Joseph Adams appointed **Mr. Joseph Fontenot**, Assistant Executive Director of the Louisiana Board of Pharmacy, to serve as Chair of the Task Force.
- > The Pharmacy Technician Accreditation Commission (PTAC), which is a collaborative effort of the Accreditation Council on Pharmacy Education (ACPE) and the American Society of Health-System Pharmacists (ASHP), has announced their inaugural slate of 12 commissioners, one of whom is **Ms. Jackie Hall**, a member of the Louisiana Board of Pharmacy since 2002.
- > The American Society of Health-System Pharmacists (ASHP) bestowed Fellow recognitions (FASHP) to 28 pharmacists during their 2014 Annual Meeting, one of whom was **Mr. Morris Rabb**, a member of the Louisiana Board of Pharmacy since 1996.
- > During their 2014 Annual Meeting, the Louisiana Pharmacists Association awarded its Pharmacist of the Year Award to **Mr. Carl Aron**, a member of the Louisiana Board of Pharmacy since 1971.

### 14. *Recess*

Having completed the tasks itemized on the posted agenda, with no further business pending before the Board, and without objection, Mr. Aron recessed the meeting at 3:55 p.m.

\* \* \* \* \*

An Administrative Hearing was convened on Thursday, August 7, 2014 in the Boardroom of the Board's office, located at 3388 Brentwood Drive in Baton Rouge, Louisiana. The hearing was held pursuant to public notice, each member received notice, each respondent received notice (unless specifically stated otherwise in the official transcript), and notice was properly posted.

#### A. *Call to Order*

Mr. Rabb called the meeting to order at 8:30 a.m.

#### B. *Invocation & Pledge of Allegiance*

Mr. Rabb called upon Mr. Bond for the invocation, then Mr. Moore led the group in the recitation of the Pledge of Allegiance

### *C. Quorum Call*

Mr. Rabb called upon Secretary Bond and he called the roll. After doing so, he certified 15 of the 17 members were present, constituting a quorum for the conduct of official business. Mr. Aron and Mr. Burch were absent.

### *D. Call for Additional Agenda Items*

Mr. Rabb asked if there were any additional agenda items, and Mr. McKay requested the addition of one item of new business. He moved to amend the agenda by adding Immunization & Pharmacy Recordkeeping to the agenda. He noted the Board issued guidance on this topic in 2010. As noted during the meeting the previous day, the state legislature amended the immunization law, and those changes took effect on August 1. Pharmacists have been asking whether the 2010 guidance is still valid under the new law. A delay by the Board in providing guidance to immunizers could have the effect of discouraging immunizers out of compliance concerns. The motion was properly seconded, received no public comments, and was adopted after a unanimous vote in the affirmative. Mr. Rabb indicated he would schedule the discussion of the new business item following the scheduled hearings. With no requests for any further additions, and without objection, the Board adopted the posted agenda as amended for that meeting.

At his request, the members granted Mr. Rabb authority to re-order the agenda with respect to the sequence of cases, witnesses, and other items of business.

### *E. Opportunity for Public Comment*

Mr. Rabb reminded the members and guests the Open Meetings Law requires all public bodies to provide an opportunity for public comment at all meetings and prior to the vote on each agenda item. He solicited comments from the guests, but none were offered.

### *Appearances*

Mr. Rabb indicated his appointment of Mr. Wade Shows to serve as the Hearing Officer. Ms. Celia Cangelosi and Mr. Carlos Finalet served as Prosecuting Attorneys, Mr. Mark LaCour was the Official Recorder, and Mr. Malcolm Broussard served as the Hearing Clerk. Without objection, Mr. Rabb waived the reading of the posted agenda and instead directed the insertion thereof into these minutes. The posted agenda, as amended, is re-created here.

## **A G E N D A**

NOTE: This agenda is tentative until 24 hours in advance of the meeting, at which time the most recent revision becomes official.

**Revised 08-03-2014**

- A. Call to Order
- B. Invocation & Pledge of Allegiance
- C. Quorum Call
- D. Call for Additional Agenda Items & Adoption of Agenda
- E. Opportunity for Public Comment

- F. Formal Hearings
  - 01. PHY.000077 – Robert Blake Vidrine *d/b/a*  
Blake’s Family Pharmacy Case No. 14-0193
  - 02. CPT.011485 – Theresa Renee’ Cosby Case No. 13-0463
  - 03. CPT.009769 – Kaelynn Michael Williams Case No. 14-0063
- G. Added Item: Immunization & Pharmacy Recordkeeping
- H. Adjourn

*F. Formal Hearings*

Mr. Rabb called Mr. Shows to preside over the formal hearings and then joined the other members of the hearing panel.

Mr. Shows asked Ms. Cangelosi if she was prepared, and she replied in the affirmative. He then called the first case listed on the agenda.

**Robert Blake Vidrine *d/b/a* Blake’s Family Pharmacy (PHY.000077)** Ms. Cangelosi appeared for the Board and noted the absence of the respondent or his counsel. After verifying the respondent’s absence, Mr. Shows ruled the hearing would continue as scheduled in the form of a default proceeding. Ms. Cangelosi presented an opening statement, two witnesses and twelve exhibits. She then offered a closing statement, proffered proposed findings of fact, conclusions of law and board order, and then tendered the matter to the hearing panel for its consideration. Mr. Resweber moved to enter into executive session for the purpose of deliberating the disciplinary matter and discussing the respondent’s professional competency. The motion was adopted after a unanimous roll call vote in the affirmative.

It was noted the hearing panel entered into executive session at 9:10 a.m. and then returned to open session at 10:00 a.m.

Ms. Hall moved,

**Resolved**, that the Board’s hearing panel, having heard the testimony and considered the evidence, accept the Findings of Fact as proposed by the Prosecuting Attorney, modify them by amending Item 5 to correct the date of the Final Order to May 7, Item 14 to substitute the word “confirmed” for the word “learned”, Item 20 to reflect his presence through his counsel, Mr. Karl Koch, Item 21 to insert the cost of \$1,162.60, and Item 22 to insert the cost of \$1,656.50, adopt the amended findings as our own, and then enter them into the hearing record.

The motion was adopted after a unanimous vote in the affirmative. Ms. Hall then moved,

**Resolved**, that the Board’s hearing panel accept the Conclusions of Law as proposed by the Prosecuting Attorney, adopt them as

our own, and then enter them into the hearing record. The motion was adopted after a unanimous vote in the affirmative. Ms. Hall then moved,

**Resolved**, that the hearing panel enter the following order at this time:

It is ordered, adjudged, and decreed that the Emergency Summary Suspension order dated June 3, 2014 is hereby ratified; and further,

It is ordered, adjudged, and decreed that Louisiana Pharmacy Permit No. PHY.000077, held by Robert Blake Vidrine d/b/a Blake's Family Pharmacy shall be revoked, and further, the respondent shall pay the following assessments:

- (1) A fine of \$1,000;
- (2) The administrative hearing fee of \$250; and
- (3) The investigative and hearing costs, including the costs of the prosecuting attorney, the advisor to the hearing officer, and the official recorder; and further,

It is ordered, the acceptance of any future application for any credential issued by the Board shall be conditioned upon the satisfaction of the following terms:

- (1) Respondent shall have paid all assessments levied herein;
- (2) Respondent shall have no legal or disciplinary matters pending against him in any jurisdiction; and
- (3) Respondent shall have received a favorable recommendation for his return to the practice of pharmacy without posing a threat to the public's health, safety, or welfare pursuant to a medical evaluation from an addictionist approved by the Board.

During the discussion on the motion, Mr. McKay moved to amend the proposed order to increase the amount of the fine from \$1,000 to \$10,000. That motion to amend the amount of the fine was adopted after a unanimous vote in the affirmative. He then moved to amend the proposed order to add the Controlled Dangerous Substance License No. CDS.038544, held by the pharmacy in addition to its pharmacy permit. That motion to include the CDS license was adopted after a unanimous vote in the affirmative. The motion for the proposed order as amended was adopted after a unanimous vote in the affirmative.

**Theresa Renee' Cosby (CPT.011485)** Mr. Finalet appeared for the Board and noted the absence of the respondent or counsel. After verifying the absence of the respondent, Mr. Shows ruled the hearing would proceed as scheduled in the form of a default proceeding. He presented an opening statement, no witnesses, and six exhibits. He then offered a closing statement, proffered proposed findings of fact, conclusions of law, and board order, and then tendered the matter to the hearing panel for its consideration. Mr. Soileau moved to enter into executive session for the purpose of deliberating the disciplinary matter and discussing the respondent's professional competency. The motion was adopted

after a unanimous roll call vote in the affirmative.

It was noted the hearing panel entered executive session at 10:20 a.m. and then reconvened in open session at 10:40 a.m.

Ms. Hall moved,

**Resolved**, that the Board's hearing panel, having heard the testimony and considered the evidence, accept the Findings of Fact as proposed by the Prosecuting Attorney, modify them by amending Item 3 to remove the dates in the last paragraph and Item 7 to reflect the absence of the respondent from these proceedings, adopt the amended findings as our own, and then enter them into the hearing record.

The motion was adopted after a unanimous vote in the affirmative. Ms. Hall then moved,

**Resolved**, that the Board's hearing panel accept the Conclusions of Law as proposed by the Prosecuting Attorney, adopt them as our own, and then enter them into the hearing record.

The motion was adopted after a unanimous vote in the affirmative. Ms. Hall then moved,

**Resolved**, that the hearing panel enter the following order at this time:

It is ordered, adjudged, and decreed that Louisiana Pharmacy Technician Certificate No. 11485, held by Theresa Renee' Cosby, shall be and is hereby revoked, effective on the entry of this order, and further, the respondent shall pay the following assessments:

- (1) A fine of \$5,000;
- (2) The administrative hearing fee of \$250; and
- (3) The investigative and hearing costs, including the costs of the prosecuting attorney, the advisor to the hearing officer, and the official recorder; and

It is further ordered the acceptance of any future application for the reinstatement of this certificate, or any application for any other credential issued by the Board, shall be conditioned upon the satisfaction of the following terms:

- (1) Respondent shall have paid all assessments levied herein; and
- (2) Respondent shall have no pending legal or disciplinary actions against her in any jurisdiction.

The motion was adopted after a majority vote in the affirmative; while Dr. Simonson agreed with the revocation decision, she objected to the amount of the fine, believing it to be excessive.

**Kaelynn Michael Williams (CPT.009769)** Mr. Finalet appeared for the Board and noted the absence of the respondent or counsel. After verifying the absence of the respondent, Mr. Shows ruled the hearing would proceed in the form of a

default proceeding. Mr. Finalet presented an opening statement, no witnesses, and five exhibits. He then offered a closing statement, proffered proposed findings of fact, conclusions of law, and board order, and then tendered the matter to the hearing panel for its consideration. Mr. McKay moved to enter into executive session for the purpose of deliberating the disciplinary matter and discussing the respondent's professional competency. The motion was adopted after a unanimous roll call vote in the affirmative.

It was noted the hearing panel entered into executive session at 10:55 a.m. and then reconvened in open session at 11:20 a.m.

Ms. Hall moved,

**Resolved**, that the Board's hearing panel, having heard the testimony and considered the evidence, accept the Findings of Fact as proposed by the Prosecuting Attorney, modify them by amending Item 7 to reflect the absence of the respondent from these proceedings, adopt the amended findings as our own, and then enter them into the hearing record.

The motion was adopted after a unanimous vote in the affirmative. Ms. Hall then moved,

**Resolved**, that the Board's hearing panel accept the Conclusions of Law as proposed by the Prosecuting Attorney, adopt them as our own, and then enter them into the hearing record.

The motion was adopted after a unanimous vote in the affirmative. Ms. Hall then moved,

**Resolved**, that the hearing panel enter the following order at this time:

It is ordered, adjudged, and decreed that Louisiana Pharmacy Technician Certificate No. 9769, held by Kaelynn Michael Williams, shall be suspended for an indefinite period of time, effective on the entry of this order, and further, the respondent shall pay the following assessments:

- (1) The administrative hearing fee of \$250; and
- (2) The investigative and hearing costs, including the costs of the prosecuting attorney, the advisor to the hearing officer, and the official recorder; and

It is further ordered the acceptance of any future application for the reinstatement of this certificate, or any application for any other credential issued by the Board, shall be conditioned upon the satisfaction of the following terms:

- (1) Respondent shall have paid all assessments levied herein; and
- (2) Respondent shall have no pending legal or disciplinary actions against her in any jurisdiction.

The motion was adopted after a unanimous vote in the affirmative.

Mr. Finalet indicated the completion of the formal hearings. Mr. Broussard expressed

his appreciation to Mr. Shows for his service as hearing officer that day. Mr. Rabb resumed his duty as the presiding officer.

*G. Added Item – Immunization Recordkeeping*

Mr. Rabb called upon Mr. McKay, who presented the prior history from 2010 relative to the adoption of legislation authorizing pharmacists to administer influenza immunizations without prescriptions or medical orders and the subsequent guidance statement adopted by the Board during its August 2010 meeting. He then reminded the members of the 2014 legislation expanding the immunizations that could be administered without prescriptions or medical orders, and suggested the propriety of adopting an updated guidance statement for pharmacist immunizers. He then moved,

**Resolved**, for the purpose of recordkeeping and facilitating access to immunizations for the public, and in the interest of the public's health, safety, and welfare, pharmacists administering immunizations without a prescription or medical order shall create a record in their prescription files which contains a prescription number and lists the immunizing pharmacist as the prescriber.

The motion was adopted after a unanimous vote in the affirmative.

*H. Adjourn*

Having completed the tasks itemized on the posted agenda, with no further business pending before the Board, and without objection, Mr. Rabb adjourned the hearing at 11:30 a.m.

Respectfully submitted,

---

Brian A. Bond  
Secretary



# Louisiana Board of Pharmacy

3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ Facsimile 225.925.6499  
[www.pharmacy.la.gov](http://www.pharmacy.la.gov) ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



## Finance Committee

---

**NOTE:** Pursuant to the Open Meetings Law, at LRS 42:6.1, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, or (4) discussions regarding personnel matters.



# Louisiana Board of Pharmacy

3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ Facsimile 225.925.6499  
[www.pharmacy.la.gov](http://www.pharmacy.la.gov) ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



**NOTICE IS HEREBY GIVEN** that a meeting of the Finance Committee has been ordered and called for 3:00 p.m. on Wednesday, November 12, 2014 in the Board office, for the purpose to wit:

## AGENDA

NOTE: This agenda is tentative until 24 hours in advance of the meeting, at which time the most recent revision becomes final.

**Revised 10-21-2014**

1. Call to Order
2. Quorum Call
3. Call for Additional Agenda Items & Adoption of Agenda
4. Opportunity for Public Comment
5. Consideration of Interim Report for Fiscal Year 2014-2015
6. Consideration of Proposed Budget for Fiscal Year 2015-2016
7. Adjourn

---

**NOTE:** Pursuant to the Open Meetings Law, at LRS 42:6.1, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, or (4) discussions regarding personnel matters.



# Louisiana Board of Pharmacy

3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ Facsimile 225.925.6499  
[www.pharmacy.la.gov](http://www.pharmacy.la.gov) ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



## Finance Committee

### Interim Report Fiscal Year 2014-2015

November 13, 2014

Blake P. Pitre  
Chair

Louisiana Board of Pharmacy  
FY 2014-2015  
Statement of Assets, Liabilities, Equity

FY 13-14	FY 14-15
Q4 06/30/2014	Q1 09/30/2014

**ASSETS**

> Current Assets		
* Cash		
General Operations		
Whitney Bank	160,352	160,393
Iberia Bank	829,409	449,575
Hurricane Relief Fund - Whitney Bank	83,137	83,158
Reserve Funds		
General Account	1,504,183	1,494,489
OPEB Account	<u>985,716</u>	<u>1,033,009</u>
* <i>Total Cash</i>	<i>3,562,797</i>	<i>3,220,624</i>
<i>Total Current Assets</i>	<i>3,562,797</i>	<i>3,220,624</i>
> Fixed Assets		
Land: Lot 5-A, Towne Center Business Park	709,080	709,080
Land: Lot 1-A-2, Leonard Place Subdivision	295,860	295,860
Office Building - 3388 Brentwood Drive	1,052,255	1,053,861
Office Equipment	195,598	214,496
Furniture	152,750	152,750
Software: Licensure & Website	408,560	408,560
Accumulated Depreciation	<u>(675,066)</u>	<u>(693,018)</u>
<i>Total Fixed Assets</i>	<i>2,139,037</i>	<i>2,141,589</i>
<u><i>TOTAL ASSETS</i></u>	<u><i>5,701,834</i></u>	<u><i>5,362,213</i></u>

**LIABILITIES**

> Current Liabilities		
Accrued salaries and benefits	72,047	0
Unemployment taxes payable	26	16
State taxes withheld	3,098	2,989
State retirement withheld	0	0
Accounts payable	3,536	0
Interest payable	5,338	0
Compensated absences (ST)	56,065	56,065
Building Loan @ Iberia Bank (ST)	<u>75,795</u>	<u>75,795</u>
<i>Total Current Liabilities</i>	<i>215,905</i>	<i>134,865</i>
> Long Term Liabilities		
Compensated absences (LT)	63,228	63,228
Building Loan @ Iberia Bank (LT)	885,109	866,570
Other Post Employment Benefits (OPEB) Payable	<u>1,016,868</u>	1,016,868
<i>Total Long Term Liabilities</i>	<i>1,965,205</i>	<i>1,946,666</i>
<u><i>TOTAL LIABILITIES</i></u>	<u><i>2,181,110</i></u>	<u><i>2,081,531</i></u>

Louisiana Board of Pharmacy  
FY 2014-2015  
Statement of Assets, Liabilities, Equity

FY 13-14	FY 14-15
Q4 06/30/2014	Q1 09/30/2014

**EQUITY**

Fund Balance at End of Prior Fiscal Year	1,872,264	2,146,545
Fund Balance - designated	174,954	174,954
Invested in Fixed Assets	1,178,132	1,199,225
Net Income/Loss	<u>295,374</u>	<u>(240,042)</u>
<i>TOTAL EQUITY</i>	<i>3,520,724</i>	<i>3,280,682</i>
<i><u>TOTAL LIABILITIES &amp; EQUITY</u></i>	<i><u>5,701,834</u></i>	<i><u>5,362,213</u></i>

Louisiana Board of Pharmacy  
 FY 2014-2015  
 Statement of Revenue, Expenses, and Budget Performance

	<b>Revenue</b>		
	FY 13-14 Q4 06/30/2014	FY 14-15 Q1 09/30/2014	FY 14-15 Budget (A#1)
<i>Licenses &amp; Permits</i>			
Pharmacist Renewals	755,775	3,300	755,000
New Pharmacist Licensing Fee	164,400	35,100	161,000
Technician Renewals	312,350	8,200	312,000
Technician Candidate Registrations	37,375	9,125	35,000
Lapsed Credential Fees	57,000	17,000	50,000
Student Registrations	3,070	900	3,000
Permits - Pharmacies	264,200	23,725	260,000
Permits - CDS	437,860	93,160	440,000
Permits - Emergency Drug Kits	12,525	1,000	12,500
Permits - Automated Medication Systems	17,700	3,750	18,000
Permits - Durable Medical Equipment	68,975	57,450	70,000
<i>Examinations</i>			
Reciprocity	47,700	14,250	45,000
Technicians	61,300	14,800	63,000
<i>Penalties</i>			
Licenses and Certificates	8,187	1,737	8,000
Permits	11,473	4,550	11,000
<i>Administrative Fees</i>			
Documents: Copies and Certification Fees	8,820	1,493	7,500
Duplicate Credentials	3,665	1,355	4,000
Silver Certificates	400	100	500
Original Certificates	9,750	3,225	10,000
NSF Fees	425	100	500
Handling & Mailing Fees	170	48	0
<i>Sale of Goods &amp; Services</i>			
Law Books	5,095	625	6,000
Official Lists of Licensees	6,750	2,400	6,000
USCPSC Inspection Fee	1,650	2,400	2,000
<i>Enforcement Actions</i>			
Hearing Fees	22,000	3,500	24,000
Fines	215,000	35,000	250,000
Investigative Costs	39,198	5,836	40,000
<i>Prescription Monitoring Program</i>			
Assessments	462,825	91,850	465,000
Grants	0	0	0
<i>Miscellaneous</i>			
	820	115	1,000
<b>TOTAL REVENUE</b>	<b>3,036,458</b>	<b>436,094</b>	<b>3,060,000</b>

Louisiana Board of Pharmacy  
 FY 2014-2015  
 Statement of Revenue, Expenses, and Budget Performance

		<b>Expenses</b>		
		FY 13-14	FY 14-15	FY 14-15
		Q4 06/30/2014	Q1 09/30/2014	Budget (A#1)
<i>Operations</i>	Rentals - Office & Equipment	2,952	3,070	18,000
	Equipment Maintenance	2,681	2,180	4,000
	Telephone	15,629	5,015	15,000
	Printing	56,235	5,330	25,000
	Postage	51,628	25,032	45,000
	Civil Service Assessment	4,236	6,074	6,100
	Office Insurance (ORM)	6,272	7,112	7,500
	Dues & Subscriptions	20,354	5,834	23,000
	Office Supply Expenses	17,630	4,716	20,000
	Financial Service Charges	52,466	2,193	50,000
	Depreciation of Fixed Assets	141,772	29,751	141,000
	Interest Payments on Building Loan	63,000	9,753	63,000
	Office Meeting Expenses	47	47	500
	Utilities	10,655	1,947	10,000
	Miscellaneous	0	0	0
<i>Acquisitions</i>		345	0	52,500
<i>Personal Services</i>	Salaries	1,193,177	275,264	1,334,100
	Payroll Taxes (FICA + FUTA)	21,330	4,744	27,100
	Retirement Contributions	371,283	101,848	494,000
	Health Insurance (SEGBP)	119,974	31,843	160,200
	Other Post Employment Benefits (OPEB)	91,464	0	91,500
	Board Member Per Diem	27,900	5,325	31,000
<i>Professional Services</i>	Accounting	23,961	11,459	25,000
	Legal	35,908	3,556	30,000
	Information Systems	97,303	71,702	98,000
	Property Management	16,375	6,857	35,000
	Temp. Labor	20,354	4,320	20,000
	Prescription Monitoring Program	195,791	19,500	80,000
<i>Staff Expenses</i>	ED - Travel	1,178	83	10,000
	GC - Travel	12	0	10,000
	AED - Travel	1,964	0	10,000
	CO - Travel	3,912	1,598	7,000
	CO - Rental Cars & Fuel	15,522	3,745	17,500
	CO - Education	7,079	2,395	15,000
	House Staff - Travel	0	199	1,000
	Mileage	15,491	2,702	20,000
<i>Board Expenses</i>	Meeting Expenses	13,637	3,603	15,000
	Committee Expenses	6,460	1,446	8,000
	Conventions	14,829	0	15,000
	Mileage	12,268	2,350	15,000
	President's Expenses	10,946	1,283	10,000
<b>TOTAL EXPENSES</b>		<b>2,764,020</b>	<b>663,876</b>	<b>3,060,000</b>

Louisiana Board of Pharmacy  
 FY 2014-2015  
 Summary of Income Fund Balance Changes

**Summary**

	FY 13-14 Q4 06/30/2014	FY 14-15 Q1 09/30/2014	FY 14-15 Budget (A#1)
<b>Income Statement</b>			
Total Revenue	3,036,458	436,094	2,817,000
Total Expenses	2,764,020	663,876	2,817,000
Net Ordinary Income	272,438	(227,782)	0
Other Income & Expenses			
Investment	22,936	(12,260)	0
Disposl of assets	0	0	0
Net Income	295,374	(240,042)	0

	FY 13-14 Q4 06/30/2014	FY 14-15 Q1 09/30/2014	FY 14-15 Budget (A#1)
<b>Fund Balance</b>			
Beginning Fund Balance	3,225,350	3,520,724	3,520,724
Total Income	3,059,394	436,094	3,060,000
Total Expenses	2,764,020	676,136	3,060,000
Ending Fund Balance	3,520,724	3,280,682	3,520,724
Reservations of Fund Balance	2,162,000	2,102,000	2,102,000
Unreserved Fund Balance	1,358,724	1,178,682	1,418,724

*Notes on Reservation of Fund Balance*

<b>FY 13-14</b>	Other Post-Employment Benefits Payable	929,700
	Debt Service Payable	1,032,300
	Continuing Payroll Obligations	150,000
	Homeland Maintenance	<u>50,000</u>
	<i>TOTAL</i>	2,162,000

<b>FY 14-15</b>	Other Post Employment Benefits Payable	1,017,000
	Debt Service Payable	885,000
	Continuing Payroll Obligations	150,000
	Homeland Maintenance	<u>50,000</u>
	<i>TOTAL</i>	2,102,000

Louisiana Board of Pharmacy  
 FY 2014-2015  
 Schedule A - Hurricane Katrina/Rita Pharmacy Relief Fund

<b>Statement of Assets, Liabilities &amp; Equity</b>	<b>FY 13-14</b>	<b>FY 14-15</b>
	<b>Q4 06/30/2014</b>	<b>Q1 09/30/2014</b>
<b>ASSETS</b>		
Current Assets		
Hancock Bank - Checking Account	<u>83,137</u>	<u>83,158</u>
<b><u>TOTAL ASSETS</u></b>	<b><u>83,137</u></b>	<b><u>83,158</u></b>
<b>LIABILITIES</b>		
Current Liabilities	0	0
<b>EQUITY</b>		
Retained Earnings	82,970	83,137
Net Income	<u>167</u>	<u>21</u>
<b><u>TOTAL LIABILITIES &amp; EQUITY</u></b>	<b><u>83,137</u></b>	<b><u>83,158</u></b>
<b>Statement of Receipts &amp; Disbursements</b>		
	<b>FY 13-14</b>	<b>FY 14-15</b>
	<b>Q4 06/30/2014</b>	<b>Q1 09/30/2014</b>
<b>RECEIPTS</b>		
FEMA - Funds for payment of claims	8,920,812	8,920,812
FEMA - Administrative allowance	81,103	81,103
Pharmacies - reversal of claims	430,138	430,138
Interest income	<u>22,062</u>	<u>22,083</u>
<b><u>TOTAL RECEIPTS</u></b>	<b><u>9,454,115</u></b>	<b><u>9,454,136</u></b>
<b>DISBURSEMENTS</b>		
Claims paid to pharmacies	8,920,812	8,920,812
Reversed claim funds returned	430,138	430,138
Reversed administrative allowance returned	7,338	7,338
Interest earned on reversed admin. allowance returned	<u>12,690</u>	<u>12,690</u>
<b><u>TOTAL DISBURSEMENTS</u></b>	<b><u>9,370,978</u></b>	<b><u>9,370,978</u></b>
<b>FUND BALANCE</b>	<b><u>83,137</u></b>	<b><u>83,158</u></b>

*Note:* These funds are held in an account separate and apart from the Board's operating funds. Further, all recordkeeping is kept separate from the Board's general fund records. At the conclusion of the audit exposure period, any funds remaining will be transferred to the Board's operating account.

Louisiana Board of Pharmacy  
FY 2014-2015  
Summary of Board Actions

<b>Date</b>	<b>Action</b>
11/5/2013	Original Budget - Finance Committee Approval
11/6/2013	Original Budget - Board Approval
8/5/2014	Budget Amendment #1 - Finance Committee Approval
8/6/2014	Budget Amendment #1 - Board Approval
	Budget Amendment #2 - Finance Committee Approval
	Budget Amendment #2 - Board Approval
	Acceptance of Final Report



Securities and advisory services are offered through Essex National Securities, LLC, member FINRA/SIPC, an independent broker/dealer and Registered Investment Advisor. Insurance products are offered through Essex National Insurance Agency, Inc. Neither are affiliated with IBERIABANK. Not Guaranteed by IBERIABANK. Not FDIC Insured. Not a Bank Deposit. Not Insured by Any Federal Government Agency. May Lose Value Including Loss of Principal.

Portfolio Snapshot  
**Louisiana Board of Pharmacy Portfolio**  
July 01, 2014 through September 30, 2014


Prepared By

JOSEPH BARRECA, JR.  
Iberia Financial Services, LLC  
Ridgelake  
2900 Ridgelake Drive  
Metairie, LA 70002  
Work/Business Phone: (504) 310-7346  
E-Mail: [jbarreca@iberiabank.com](mailto:jbarreca@iberiabank.com)

### Accounts and Holdings

### Portfolio by Holding Type

	Shares/Units	NAV/Price	Value	% of Portfolio
<b>Non-Qualified Accounts</b>				
H5E049797, Pershing Louisiana Board of Pharmacy Nonprofit Organization		<b>General Reserve Fund</b>	\$1,494,417.06	100.00 %
Pershing General Money Market Fund cl B Money Market (GMMB)	487,696.380	\$1.00	\$487,696.38	32.63 %
HSBC BK USA N A MC LEAN VA CTF DEP ACT/365 INCOME OPPTY Fixed Income - CDs (40434AHV4)	250,000.000	\$97.40	\$243,500.00	16.29 %
BMO HARRIS BK NATL ASSN CHICAGO ILL CTF DEP ACT/365 ANNUAL Fixed Income - CDs (05573JVN1)	250,000.000	\$97.10	\$242,760.00	16.24 %
JPMORGAN CHASE BK NA COLUMBUS OH CTF DEP CTF DEP LKD J P Fixed Income - CDs (48125TDG7)	125,000.000	\$94.39	\$117,987.50	7.90 %
UNION BK N A SAN FRANCISCO CALIF CTF DEP ACT/365 Fixed Income - CDs (90521AHP6)	88,000.000	\$119.99	\$105,591.20	7.07 %
UNION BK N A SAN FRANCISCO CALIF CTF DEP ACT/365 Fixed Income - CDs (90521AHS0)	88,000.000	\$106.01	\$93,288.80	6.24 %
BANK OF THE WEST INSTL CTF DEP PROGRAM BOOK ENTRY Fixed Income - CDs (06426XCL2)	89,000.000	\$96.61	\$85,984.68	5.75 %
UNION BK N A SAN FRANCISCO CALIF CTF DEP ACT/365 Fixed Income - CDs (90521AQG6)	74,000.000	\$98.63	\$72,986.20	4.88 %
UNITED STATES TREAS NTS INFLATION INDEXED NOTES TIPS Fixed Income - Govt (912828NM8)	25,000.000	\$106.17	\$28,997.70	1.94 %
IBERIABANK LAFAYETTE LA CTF DEP ACT/365 0.000% 05/31/16 B/E Fixed Income - CDs (45083AAV4)	10,000.000	\$105.83	\$10,582.60	0.71 %
BARCLAYS BK DEL WILMINGTON CTF DEP ACT/365 ANNUALLY Fixed Income - CDs (06740AA41)	5,000.000	\$100.84	\$5,042.00	0.34 %
			<b>\$1,494,417.06</b>	<b>100.00 %</b>
<b>Total Portfolio Value</b>			<b>\$1,494,417.06</b>	<b>100.00 %</b>




	Value	Value
Fixed Income - CDs	\$977,722.98	65.43 %
Money Market	\$487,696.38	32.63 %
Fixed Income - Govt	\$28,997.70	1.94 %

### Accounts and Holdings

### Portfolio by Holding Type

	Shares/Units	NAV/Price	Value	% of Portfolio
<b>Non-Qualified Accounts</b>				
H5E077160, Pershing Louisiana Board of Pharmacy Nonprofit Organization	<b>OPEB Fund</b>		\$1,031,277.83	100.00 %
FCR Money Market (FCR)	173,733.730	\$1.00	\$173,733.73	16.85 %
BARCLAYS BK DEL WILMINGTON CTF DEP ACT/365 Fixed Income - CDs (06740AYS2)	160,000.000	\$92.82	\$148,512.00	14.40 %
BANK OF THE WEST INSTL CTF DEP PROGRAM BOOK ENTRY Fixed Income - CDs (06426XGL8)	155,000.000	\$95.30	\$147,718.10	14.32 %
GOLDMAN SACHS BK USA NEW YORK CTF DEP ACT/365 Fixed Income - CDs (38143ASV8)	120,000.000	\$101.59	\$121,905.60	11.82 %
DISCOVER BK GREENWOOD DEL CTF DEP ACT/365 Fixed Income - CDs (254671BG4)	120,000.000	\$100.90	\$121,077.60	11.74 %
ALLY BANK MIDVALE UTAH CTF DEP ACT/365 1.000% 05/26/15 B/E Fixed Income - CDs (02005QF57)	120,000.000	\$100.45	\$120,538.80	11.69 %
JPMORGAN CHASE BK NA COLUMBUS OHIO CTF DEP DTD 07/31/2013 Fixed Income - CDs (48124JS41)	125,000.000	\$96.05	\$120,062.50	11.64 %
BARCLAYS BK DEL WILMINGTON CTF DEP ACT/365 ZERO CPN LKD Fixed Income - CDs (06740ATS8)	83,000.000	\$93.65	\$77,729.50	7.54 %
			<b>\$1,031,277.83</b>	<b>100.00 %</b>
<b>Total Portfolio Value</b>			<b>\$1,031,277.83</b>	<b>100.00 %</b>



	Value	Value
Fixed Income - CDs	\$857,544.10	83.15 %
Money Market	\$173,733.73	16.85 %



# Louisiana Board of Pharmacy

3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ Facsimile 225.925.6499  
[www.pharmacy.la.gov](http://www.pharmacy.la.gov) ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



## Finance Committee

### Proposed Budget for Fiscal Year 2015-2016

November 13, 2014

Blake P. Pitre  
Chair

Louisiana Board of Pharmacy  
FY 2015-2016 ~ Original Budget

	<b>Revenue</b>				<i>Notes</i>
	FY 13-14 6/30/2014	FY 14-15 9/30/2014	FY 14-15 Budget (A#1)	FY 15-16 Proposed	
<i>Licenses &amp; Permits</i>					
Pharmacist Renewals	755,775	3,300	755,000	755,000	1
New Pharmacist Licensing Fee	164,400	35,100	161,000	161,000	2
Technician Renewals	312,350	8,200	312,000	312,000	3
Technician Candidate Registrations	37,375	9,125	35,000	35,000	4
Lapsed Credential Fees	57,000	17,000	50,000	55,000	5
Student Registrations	3,070	900	3,000	3,000	6
Permits - Pharmacies	264,200	23,725	260,000	260,000	7
Permits - CDS	437,860	93,160	440,000	440,000	8
Permits - Emergency Drug Kits	12,525	1,000	12,500	12,500	9
Permits - AMS	17,700	3,750	18,000	18,000	10
Permits - Durable Medical Equipment	68,975	57,450	70,000	70,000	11
<i>Examinations</i>					
Reciprocity	47,700	14,250	45,000	45,000	12
Technicians	61,300	14,800	63,000	50,000	13
<i>Penalties</i>					
Licenses and Certificates	8,187	1,737	8,000	8,000	14
Permits	11,473	4,550	11,000	11,000	15
<i>Administrative Fees</i>					
Documents: Copies & Certification Fees	8,820	1,493	7,500	7,500	16
Duplicate Credentials	3,665	1,355	4,000	4,000	17
Silver Certificates	400	100	500	500	18
Original Certificates	9,750	3,225	10,000	10,000	19
NSF Fees	425	100	500	500	20
Handling & Mailing Fees	170	48	0	0	21
<i>Sale of Goods &amp; Services</i>					
Law Books	5,095	625	6,000	6,000	22
Official Lists of Licensees	6,750	2,400	6,000	6,000	23
USCPSC Inspection Fee	1,650	2,400	2,000	2,000	24
<i>Enforcement Actions</i>					
Hearing Fees	22,000	3,500	24,000	22,000	25
Fines	215,000	35,000	250,000	215,000	26
Investigative Costs	39,198	5,836	40,000	35,000	27
<i>Prescription Monitoring Program</i>					
Assessments	462,825	91,850	465,000	465,000	28
<i>Miscellaneous</i>					
	820	115	1,000	1,000	29
<b>TOTAL REVENUE</b>	<b>3,036,458</b>	<b>436,094</b>	<b>3,060,000</b>	<b>3,010,000</b>	<b>30</b>

Louisiana Board of Pharmacy  
FY 2015-2016 ~ Original Budget

		<b>Expenses</b>				
		FY 13-14 6/30/2014	FY 14-15 9/30/2014	FY 14-15 Budget (A#1)	FY 15-16 Proposed	<i>Notes</i>
<i>Operations</i>						
	Rentals - Office & Equipment	2,952	3,070	18,000	15,000	31
	Equipment Maintenance	2,681	2,180	4,000	3,000	32
	Telephone	15,629	5,015	15,000	18,000	33
	Printing	56,235	5,330	25,000	17,000	34
	Postage	51,628	25,032	45,000	52,000	35
	Civil Service Assessment	4,236	6,074	6,100	6,100	36
	Office Insurance (ORM)	6,272	7,112	7,500	7,500	37
	Dues & Subscriptions	20,354	5,834	23,000	10,000	38
	Office Supply Expenses	17,630	4,716	20,000	20,000	39
	Financial Service Charges	52,466	2,193	50,000	53,000	40
	Depreciation of Fixed Assets	141,772	29,751	141,000	142,000	41
	Interest Payments on Building Loan	63,000	9,753	63,000	60,000	42
	Office Meeting Expenses	47	47	500	500	43
	Utilities	10,655	1,947	10,000	11,000	44
	Miscellaneous	0	0	0	0	45
<i>Acquisitions</i>		345	0	52,500	12,500	46
<i>Personal Services</i>						
	Salaries	1,193,177	275,264	1,334,100	1,334,100	47
	Payroll Taxes (FICA + FUTA)	21,330	4,744	27,100	27,100	48
	Retirement Contributions	371,283	101,848	494,000	494,000	49
	Health Insurance (SEGBP)	119,974	31,843	160,200	160,200	50
	Other Post Employment Benefits (OPEB)	91,464	0	91,500	91,500	51
	Board Member Per Diem	27,900	5,325	31,000	31,000	52
<i>Professional Services</i>						
	Accounting	23,961	11,459	25,000	25,000	53
	Legal	35,908	3,556	30,000	30,000	54
	Information Systems	97,303	71,702	98,000	108,000	55
	Property Management	16,375	6,857	35,000	35,000	56
	Temp. Labor	20,354	4,320	20,000	20,000	57
	Prescription Monitoring Program	195,791	19,500	80,000	80,000	58
<i>Staff Expenses</i>						
	ED - Travel	1,178	83	10,000	10,000	59
	GC - Travel	12	0	10,000	10,000	60
	AED - Travel	1,964	0	10,000	10,000	61
	CO - Travel	3,912	1,598	7,000	5,000	62
	CO - Rental Cars & Fuel	15,522	3,745	17,500	17,500	63
	CO - Education	7,079	2,395	15,000	10,000	64
	House Staff - Travel	0	199	1,000	1,000	65
	Mileage	15,491	2,702	20,000	20,000	66
<i>Board Expenses</i>						
	Meeting Expenses	13,637	3,603	15,000	15,000	67
	Committee Expenses	6,460	1,446	8,000	8,000	68
	Conventions	14,829	0	15,000	15,000	69
	Mileage	12,268	2,350	15,000	15,000	70
	President's Expenses	10,946	1,283	10,000	10,000	71
<b>TOTAL EXPENSES</b>		<b>2,764,020</b>	<b>663,876</b>	<b>3,060,000</b>	<b>3,010,000</b>	<b>72</b>

Louisiana Board of Pharmacy  
FY 2015-2016 ~ Original Budget

**Summary**

	FY 13-14 6/30/2014	FY 14-15 9/30/2014	FY 14-15 Budget (A#1)	FY 15-16 Proposed	Notes
<b>Income Statement</b>					
Total Revenue	3,036,458	436,094	2,817,000	3,010,000	
Total Expenses	2,764,020	663,876	2,817,000	3,010,000	
Net Ordinary Income	272,438	(227,782)	0	0	
Other Income & Expenses					
Investment	22,936	(12,260)	0	0	
Disposl of assets	0	0	0	0	
Net Income	295,374	(240,042)	0	0	

	FY 13-14 6/30/2014	FY 14-15 9/30/2014	FY 14-15 Budget (A#1)	FY 15-16 Proposed
<b>Fund Balance</b>				
Beginning Fund Balance	3,225,350	3,520,724	3,520,724	3,520,724
Total Income	3,059,394	436,094	3,060,000	3,010,000
Total Expenses	2,764,020	676,136	3,060,000	3,010,000
Ending Fund Balance	3,520,724	3,280,682	3,520,724	3,520,724
Reservations of Fund Balance	2,162,000	2,102,000	2,102,000	2,100,000
Unreserved Fund Balance	1,358,724	1,178,682	1,418,724	1,420,724

	FY 13-14 6/30/2014	FY 14-15 9/30/2014	FY 14-15 Budget (A#1)	FY 15-16 Proposed
<i>Notes on Reservation of Fund Balance</i>				
Other Post Employment Benefits	929,700	1,017,000	1,017,000	1,150,000
Debt Service Payable	1,032,300	885,000	885,000	750,000
Continuing Payroll Obligations	150,000	150,000	150,000	150,000
Land & Bldg Maintenance	<u>50,000</u>	<u>50,000</u>	<u>50,000</u>	<u>50,000</u>
<i>TOTAL</i>	<i>2,162,000</i>	<i>2,102,000</i>	<i>2,102,000</i>	<i>2,100,000</i>

Louisiana Board of Pharmacy  
FY 2015-2016 ~ Original Budget

**NOTES**

Revenue

- 1 Estimate 7,550 pharmacists to apply for renewal, at \$100 each
- 2 Estimate 235 new graduates + 300 reciprocity applicants, for total of 535 new PST, at \$300 each
- 3 Estimate 6,240 technicians to apply for renewal, at \$50 each
- 4 Estimate 1,400 persons to apply for pharmacy technician candidate registration, at \$25 each
- 5 Estimate 275 reinstatement applications for lapsed credentials, at \$200 each
- 6 Estimate 300 pharmacy interns to apply for registration, at \$10 each
- 7 Estimate 1,830 pharmacies to renew, at \$15 each + 200 new permits, at \$150 each
- 8 Using historical data
- 9 Using historical data
- 10 Using historical data
- 11 Using historical data
- 12 Estimate 300 pharmacists to apply for reciprocity, at \$150 each
- 13 Estimate 500 people to apply for technician certificate, at \$100 each
- 14 Using historical data for penalty fees applied to renewal of lapsed credentials for people
- 15 Using historical data for penalty fees applied to renewal of lapsed credentials for places
- 16 Using historical data
- 17 Using historical data
- 18 Estimate 5 pharmacists to order silver certificates, at \$100 each
- 19 Estimate 130 new pharmacists to order wall certificates, at \$75 each
- 20 Using historical data
- 21 Using historical data
- 22 Includes sales of \$40 binders plus \$15 supplements
- 23 Estimate sales of 40 lists, at \$150 each
- 24 Using historical data for contract with U.S. Consumer Product Safety Commission
- 25 Impairment, Reinstatement, & Violations Committees + Administrative Hearings, at \$250 each
- 26 Using historical data
- 27 Using historical data
- 28 Estimate 18,600 clients, at \$25 each
- 29 Using historical data
- 30 Reflects 0.9% decrease from FY 14 actual as well as 1.6% decrease from FY 15 budget

Louisiana Board of Pharmacy  
FY 2015-2016 ~ Original Budget

Expenses

- 31 Using historical data for two copiers, postage machine, and folding machine (Data Worksheet)
- 32 Using historical data for all office equipment
- 33 Using historical data for all telephone systems maintenance and call volumes
- 34 Includes office products and NABP e-Newsletter; excludes printed version of newsletter
- 35 Using historical data, with focus on reducing use of snail mail in favor of email
- 36 Using historical data, with premium determined by State Div. of Administration
- 37 Using historical data, with premium determined by State Div. of Administration
- 38 Using historical data, with reduction of certain subscriptions
- 39 Using historical data
- 40 Using historical data for service charges applied to credit cards used for online renewals
- 41 Using historical data from depreciation schedule of fixed assets maintained by accountant
- 42 Using historical data from loan amortization schedule
- 43 Using historical data
- 44 Using historical data
- 45 Using historical data
- 46 Planned reduction of acquisitions (Data Worksheet)
- 47 Includes no performance adjustments for staff
- 48 Calculated value: 2% of salaries + temp labor
- 49 Calculated value: 37% of salaries
- 50 Calculated value: 12% of salaries
- 51 Actual obligation provided to agency at end of fiscal year; this entry is historical data
- 52 Using historical data
- 53 Using historical data, for accountant and legislative auditor
- 54 Using historical data, for prosecuting attorney and advisor to hearing officer, + collections
- 55 Annual maintenance fees for eLicense, network support, and medical assessments
- 56 Routine services for property + anticipated repairs (Data Worksheet)
- 57 Using historical data, for high school COE workers
- 58 Professional services from program vendor, per contract
- 59 Committee recommendation
- 60 Committee recommendation
- 61 Committee recommendation
- 62 Using historical data for routine travel during inspections and investigations
- 63 Cost of rental cars and fuel for compliance officers
- 64 \$2,000 allowance for each of 5 pharmacist compliance officers
- 65 For educational development of office staff
- 66 Using historical data, for entire staff
- 67 Using historical data
- 68 Using historical data
- 69 Using historical data
- 70 Using historical data
- 71 Using historical data
- 72 Reflects 8.9% increase over FY 14 actual as well as 1.6% decrease from FY 15 budget

Louisiana Board of Pharmacy  
FY 2015-2016 ~ Original Budget

<b>Date</b>	<b>Action</b>
11/12/2014	Original Budget - Finance Committee Approval
	Original Budget - Board Approval
	Budget Amendment #1 - Finance Committee Approval
	Budget Amendment #1 - Board Approval
	Acceptance of Final Report

**Louisiana Board of Pharmacy  
FY 2015-2016  
Budget Proposal**

Data Worksheet

<u>Acct</u>			<u>Name</u>	
	<b>Operations</b>			
5321	Equipment Rentals			15,000
	Copier #1	300/month	03,600	
	Copier #2	300/month	03,600	
	Postage + folder	650/month	07,800	
5370	Telephone System			17,980
	Annual Maintenance Fee	1,600/year	01,600	
	AT&T charges	390/month	04,680	
	State OTM charges	675/month	08,100	
	Administrative officers	300/month	03,600	
5305	Printing			17,000
	Office products	historical basis/year	15,000	
	NABP e-Newsletter	4 issues/year	01,000	
	Board member elections	2016 term expirations	01,000	
5125	Civil Service Assessment			06,100
		FY 14-15 actual	06,074	
5230	Office Insurance (ORM)			07,500
		FY 14-15 actual	07,112	
5190	Dues & Subscriptions			10,000
		FY 13-14 actual	20,354	
		(included approx. \$10K for Westlaw)		
5385	Interest Payments on Loan			60,000
		From amortization schedule		
5390	Utilities			10,000
		Electric	09,000	
		Water	00,900	
	<b>Acquisitions</b>			
5105	Acquisitions			12,500
		Desktop rotations 2 @	02,500	

***Personal Services***

5350	Salaries			1,334,100
		Includes no performance adjustments		
5340	Retirement			494,000
		FY 13-14 Rate – 31%		
		FY 14-15 Rate – 37%		
		FY 15-16 Rate – Won't be released until late-March or early-April		

***Professional Services***

5295	Information Systems			108,000
		Iron Data Maintenance	58,000	
		Essential Solutions (support)	45,000	
		Medical assessments	05,000	
5297	Property Management			35,100
	Security	236/month	02,800	
	Interior Maintenance	250/month	03,000	
	Groundskeeping + Pest	460/month	05,500	
	Trash & Recycling	140/month	01,680	
	General Maintenance	165/month	02,000	
	A/C Unit Replacement	10,000/each	10,000	
	General Repairs (roof replacement)		10,000	



# Louisiana Board of Pharmacy

3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ Facsimile 225.925.6499  
[www.pharmacy.la.gov](http://www.pharmacy.la.gov) ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



## Application Review Committee

---

**NOTE:** Pursuant to the Open Meetings Law, at LRS 42:6.1, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, or (4) discussions regarding personnel matters.



# Louisiana Board of Pharmacy

3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ Facsimile 225.925.6499  
[www.pharmacy.la.gov](http://www.pharmacy.la.gov) ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



## Reciprocity Committee

---

**NOTE:** Pursuant to the Open Meetings Law, at LRS 42:6.1, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, or (4) discussions regarding personnel matters.



# Louisiana Board of Pharmacy

3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ Facsimile 225.925.6499  
[www.pharmacy.la.gov](http://www.pharmacy.la.gov) ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



## Violations Committee

---

**NOTE:** Pursuant to the Open Meetings Law, at LRS 42:6.1, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, or (4) discussions regarding personnel matters.



# Louisiana Board of Pharmacy

3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ Facsimile 225.925.6499  
[www.pharmacy.la.gov](http://www.pharmacy.la.gov) ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



## Impairment Committee

---

**NOTE:** Pursuant to the Open Meetings Law, at LRS 42:6.1, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, or (4) discussions regarding personnel matters.



# Louisiana Board of Pharmacy

3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ Facsimile 225.925.6499  
[www.pharmacy.la.gov](http://www.pharmacy.la.gov) ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



**NOTICE IS HEREBY GIVEN** that a meeting of the Impairment Committee has been ordered and called for 1:00 p.m. on Wednesday, November 12, 2014 at the Board office, for the purpose to wit:

## AGENDA

NOTE: This agenda is tentative until 24 hours in advance of the meeting, at which time the most recent revision becomes official.

**Revised 10-10-2014**

1. Call to Order
2. Quorum Call
3. Call for Additional Agenda Items & Adoption of Agenda
4. Opportunity for Public Comment
5. Review of Docket
  - A. *For Acceptance of Voluntary Surrenders of Credentials*
  - B. *Petitions For Reinstatement of Suspended Credentials*
    - i. Case No. 14-0328 ~ PST.018936 – Tiffany Cathleen Luse Upshaw
  - C. *Petitions for Modification of Previous Orders*
    - i. Case No. 14-0278 ~ PST.017305 – Casey Ann Kendall
    - ii. Case No. 14-0289 ~ PST.009897 – Edward John Rabalais
  - D. *Applications for a Credential*
    - i. Case No. 14-0267 ~ PST.A – Bobby Trondell Thompson
  - E. *Appearances for Informal Conference*
  - F. *Appearances for Guidance*
6. Adjourn

---

**NOTE:** Pursuant to the Open Meetings Law at La. R.S. 42:16, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, (4) discussions regarding personnel matters, or other purposes itemized at La. R.S. 42:17..



# Louisiana Board of Pharmacy

3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ Facsimile 225.925.6499  
[www.pharmacy.la.gov](http://www.pharmacy.la.gov) ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



## Reinstatement Committee

---

**NOTE:** Pursuant to the Open Meetings Law, at LRS 42:6.1, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, or (4) discussions regarding personnel matters.



# Louisiana Board of Pharmacy

3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ Facsimile 225.925.6499  
[www.pharmacy.la.gov](http://www.pharmacy.la.gov) ~ Email: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



**NOTICE IS HEREBY GIVEN** that a meeting of the Reinstatement Committee has been ordered and called for 8:00 a.m. on Wednesday, November 12, 2014 in the Board office, for the purpose to wit:

## AGENDA

NOTE: This agenda is tentative until 24 hours in advance of the meeting, at which time the most recent revision becomes official.

**Revised 10-31-2014**

1. Call to Order
  2. Quorum Call
  3. Call for Additional Agenda Items & Adoption of Agenda
  4. Opportunity for Public Comment
  5. Consideration of Applications
    - A. *Petitions for Reinstatement (suspended + lapsed > 5 years + chair's discretion)*
      - i. Case No. 14-0268 ~ PST.016284 – Charles Jude Mitchell, Jr.
      - ii. Case No. 14-0310 ~ PST.010721 – Motilall Soodeen
      - iii. Case No. 14-0335 ~ PST.014543 – Christian Allen Reuter, Jr.
      - iv. Case No. 14-0336 ~ CPT.001366 – Lequita LeJean Jackson
    - B. *Petitions for Modification of Previous Orders*
      - i. Case No. 14-0256 ~ PST.020467 – Harvey Lee Smith, Jr.
      - ii. Case No. 14-0327 ~ PST.010884 – James Robert Lang
      - iii. Case No. 14-0332 ~ PST.015107 – Robert Mark McGee
    - C. *Petitions for Return of Inactive Licenses to Active Status*
- [Note: Appearances are not required for the remaining applicants.]*
- D. *CDS Petitions for Reinstatement (lapsed > 5 years, appearance not required)*
    - i. CDS.013283.MD – Frank Raymond Cerniglia, Jr.
    - ii. CDS.031813.MD – Maurice Sholas
    - iii. CDS.032475.MD – Ernest David Autry
    - iv. CDS.030028.MD – Laura Lazarus
    - v. CDS.032100.EMS – St. Tammany Parish Fire Protection District
    - vi. CDS.015431.DVM – Thomas Christian Armstrong
    - vii. CDS.035112.MD – Marco A. Rodriguez
    - viii. CDS.011058.DDS – Kay C. Moser
    - ix. CDS.024674.MD – John Edward Dugaw

---

**NOTE:** Pursuant to the Open Meetings Law at La. R.S. 42:16, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, (4) discussions regarding personnel matters, or other purposes itemized at La. R.S. 42:17.

- x. CDS.023193.MD – Kevin Wayne Young
- xi. CDS.004056.MD – John W. Daly
- xii. CDS.016414.DDS – Kelly Wayne Braswell
- xiii. CDS.020160.DVM – Robert James Craig
- xiv. CDS.021624.DVM – Keith A. Cooper
- xv. CDS.022955.DVM – Beverly Coyle Bell
- xvi. CDS.031844.MD – Jason Lee West
- xvii. CDS.035921.APN – Joanne Iris Miller
- xviii. PST.013686 – Mark Anthony Window
- xix. CDS.031834.MD – Vincent DePaul Hayes
- xx. CDS.017540.MD – Cecile Marie Sherrod

*E. Reinstatement of CDS Licenses Previously Suspended Secondary to Action by Another Agency*

- i. CDS.007862.MD – Ciro R. Cerrato
- ii. CDS.025779.MD – Brian A. Heise
- iii. CDS.020143.MD – Richard Colon

*F. Discretionary Approvals by Committee Chair (lapsed > 1 year but < 5 years)*

- i. CDS.036828.MD – Ramesh Marahatta
- ii. CDS.039877.MD – Karen A. Purdy
- iii. CDS.036380.MD – Michael A. Wilson
- iv. CDS.034138.MD – Kenneth Anthony Dietrich
- v. CDS.040604.MD – Blazen Draguljic
- vi. CDS.041878.MD – Linda Marie Gosselin Chase
- vii. CDS.027681.MD – Amy Sheeder
- viii. CDS.011451.MD – Kathleen Elizabeth Walsh
- ix. CDS.041496.MD – Elizaneth Lynn Clemons
- x. CDS.035595.MD – Charles A. Caplis
- xi. CDS.039985.EMS – St. Tammany Parish Fire Protection District
- xii. CDS.036244.APN – Patricia Ann Dalferes
- xiii. CDS.005645.MD – Allan Cogle
- xiv. CDS.042064.APN – Perry D. Nichols
- xv. CDS.040112.MD – Christina Adel Michael
- xvi. PST.013686 – Mark Anthony Window
- xvii. CDS.018825.MD – Fredric Gary Regenstein
- xviii. CDS.31798.MD – Kareem Mohamed Elshatory
- xix. CPT.010399 – Jasmine Catrice Washington
- xx. CPT.008855 – Stanley Adam Dimattia
- xxi. DME.000251 – Gulf States Medical Supply
- xxii. CDS.026120.MD – James S. Dunnick
- xxiii. CDS.038334.MD – Theepa Thayalakulasingam
- xxiv. CDS.034795.DVM – Louren Theresa Carlino
- xxv. CDS.035197.APN – Lula Mae Johnson
- xxvi. CDS.035039.DVM – Rosanne Krupka Peters
- xxvii. CDS.041843.DDS – Erin Michele Maturin
- xxviii. CDS.01702.MD – Jean Desse
- xxix. CPT.005528 – Michelle Lee Jarvis
- xxx. PST.010381 – Billy Joe Reeves
- xxxi. CDS.038000.DDS – Rathana Lim
- xxxii. CDS.025100.MD – Laura Marie Gehrig

---

**NOTE:** Pursuant to the Open Meetings Law at La. R.S. 42:16, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, (4) discussions regarding personnel matters, or other purposes itemized at La. R.S. 42:17.

- xxxiii. CDS.0.38092.MD – Andrea Catherine Suen
- xxxiv. CDS.009967.MD – Whitney J. Gonsoulin
- xxxv. CPT.007984 – Shellene Lee Moseley
- xxxvi. CDS.036450.MD – Ana Belen DeRosales
- xxxvii. CPT.011190 – Chelsea Ann Webb
- xxxviii. CDS.019712.MD – Terry Glen Green
- xxxix. CPT.005407 – Dawn Colette Ducote

*G. Staff Approvals by Board Policy (lapsed < 1 year)*

- i. CPT.009149 – Samantha Johnette Mayo
- ii. CDS.033400.DVM – Stephen B. Bryan
- iii. CDS.030772.DDS – Michael N. Rabel
- iv. CDS.032846.DVM – Stacey Daigle
- v. CDS.032499.APN – Dedra Newton
- vi. CDS.037650.RES – Yan Dong
- vii. CDS.019772.DVM – Cheryl L. Matlock
- viii. CDS.017821.MD – Michael Kuang Hsu
- ix. CDS.033437.MD – Kendall Leigh Genre
- x. CDS.034389.MD – Neil David Stern
- xi. CDS.032466.MD – Diana McDermott
- xii. CDS.043153.MD – Luis Alberto Chavez
- xiii. PST.014495 – David Jon Slaughterbeck
- xiv. PST.020026 – Eric Dustin Ho
- xv. AMS.010062.X – Iberia Medical Center
- xvi. CDS.038337.DDS – Justin L. Wu
- xvii. CDS.035434.DDS – Jerry D. Veillon
- xviii. CDS.040430.APN – Amanda Verkuissen Burnett
- xix. CDS.031648.APN – Melinda Koonce Strickland
- xx. CDS.030569.DDS – Jennifer Laurin Banquer
- xxi. CDS.041536.MD – Dennis Patrick Lindfors
- xxii. CDS.013912.DVM – David C. McGraw
- xxiii. CDS.002160.MD – Melvil Bertrand Myers
- xxiv. CDS.043131.MD – Hari Bogabathina
- xxv. CDS.022583.EMS – Richard Morrison c/o Caddo Parish Fire District
- xxvi. CDS.027055.DDS – Louis C. Passauer, Jr.
- xxvii. CDS.03440.DDS – Mathieu K. Irby
- xxviii. CDS.023678.DVM – Anissa L. Peneguy
- xxix. CDS.034441.MP- Thomas W. Swanbon
- xxx. CDS.015183.DDS – John M. Barksdale Jr.
- xxxi. EDK.007511 – Allen Correctional Center
- xxxii. CPT.009675 – Tyler Dale Mhire
- xxxiii. CDS.029690.MD – Sterling Milton III
- xxxiv. CDS.022044.MD – Robert Dean Parker
- xxxv. CDS.037982.DVM – Morgan Fruge Bryant
- xxxvi. CDS.031453.DDS – Richard Edward Scipione
- xxxvii. CDS.028973.DDS – Marilyn Deville
- xxxviii. CDS.041571.MP – Amy L. Copeland
- xxxix. CDS.035235.MD – Roque I. Ferreyro
- xl. CDS.040424.MD – Kevin C. Buford
- xli. CDS.043412.MD – Evan Michael Atkinson
- xl. CDS.029725.DVM – Linnea Kathleen Collins

---

**NOTE:** Pursuant to the Open Meetings Law at La. R.S. 42:16, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, (4) discussions regarding personnel matters, or other purposes itemized at La. R.S. 42:17.

- xliii. CDS.032595.MD- Abdul Lateef Khan
- xliv. EDK.007429 – Heritage Manor Health & Rehabilitation
- xlv. CDS.016429.MD – Roger K. Hatchette
- xlvi. CDS.011244.MD – Gerals E. Stack
- xlvii. CDS.023836.MD – James Arthur Altick
- xlviii. CDS.033405.MD – Elsayed Magdy Elrakabawy
- xliv. CDS.034551.MD – Sean Richard Weiss
  - I. CDS.041968.MD – Huy Q. Nguyen
  - li. CDS.030455.DVM – Pamela Petty
  - lii. CDS.037989.MD – Christopher B. Willoughby
  - liii. CDS.026883.MD – John Jerius
  - liv. CDS.034416.RHC – Community Health Institute
  - lv. CDS.031650.MD – George Briggs
  - lvi. AMS.010718 – Interim LSU Hospital – DePaul Hospital
  - lvii. CDS.043896.AMS - Interim LSU Hospital – DePaul Hospital
  - lviii. AMS.010717 - Interim LSU Hospital – UMOB
  - lix. AMS.010713 - Interim LSU Hospital - OB/GYN Clinic
  - lx. AMS.010715 - Interim LSU Hospital - OP Clinic L & T Bldg
  - lxi. AMS.010714 - Interim LSU Hospital - LB Landry Clinic
  - lxii. AMS.010716 - Interim LSU Hospital - HIV OP Center
  - lxiii. AMS.010719 - University Medical Center Management Corporation
  - lxiv. CDS.014564.DDS - Hugh P. Champagne
  - lxv. CDS.034778.DDS – Jay C. Rutz
  - lxvi. CDS.006260.MD – Charles R. Pearson
  - lxvii. CDS.032575.MD – Douglas P. McBride
  - lxviii. CDS.012551.MD – Robert Ewing
  - lxix. CDS.021780.MD – Cheryl Bowers-Stephens
  - lxx. CDS.040650.MD – Seema Rohan Walvekar
  - lxxi. CDS.011724.MD – Daniel C. Murphy
  - lxxii. CDS.013823.DVM – Roger S. Boughton
  - lxxiii. CDS.009661.MD – Thomas Perdue Quaid
  - lxxiv. CDS.010639.DDS – Anthony Thentacoste, Jr.
  - lxxv. CDS.034481.MD – Patrick Michael Dennis
  - lxxvi. CDS.013682.MD – Martha Sabatier Hoag
  - lxxvii. CDS.005197.MD – Alfred Y. K. Hew, Jr.
  - lxxviii. CDS.005164.MD – Donald Jerome Palmisano
  - lxxix. CDS.013895.DVM – Warren Douglas Kent, Jr.
  - lxxx. CDS.012318.DDS – Monroe M. Howell
  - lxxxi. CDS.043303.APN – Kendra Paul Patrick
  - lxxxii. CDS.042039.MD – Evan S. Jacobs
  - lxxxiii. CDS.011132.DVM – James Matthew Crochet
  - lxxxiv. CDS.033237.DDS – Jovain S. Monette
  - lxxxv. CDS.034223.APN – Jackie L. Guidry
  - lxxxvi. CDS.011767.MD – Gayle Kennedy Stewart
  - lxxxvii. CDS.043350.MD – Ronnie Orlando Ortiz
  - lxxxviii. CDS.007143.MD - Rosemary Bolen Stage
  - lxxxix. CDS.026200.MD - Humberto Quintana
    - xc. CPT.009660 – Mustafa Benrahla
    - xc. CDS.036008.MD - Craig Jeffrey Coenson
    - xcii. EDK.007664 – Orleans Parish Prison (CTA)
    - xciii. EDK.007665 – Temporary Detention Center (TDC)

---

**NOTE:** Pursuant to the Open Meetings Law at La. R.S. 42:16, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, (4) discussions regarding personnel matters, or other purposes itemized at La. R.S. 42:17.

- xciv. EDK.007670 – Orleans Parish Prison (IPC)
- xcv. EDK.007672 – Orleans Parish Prison (PSYCH)
- xcvi. EDK.007817 – Orleans Parish Prison (TPS)
- xcvii. EDK.007832 – Tent Complex
- xcviii. EDK.007833 – Orleans Parish Prison (OPP)
- xcix. CPT.004564 – Tanya Maria Lewis
  - c. AMS.010628.X – Ft. Polk community Based Outpatient Clinic
  - ci. AMS.010629.X - Lafayette Community Based Outpatient Clinic
  - cii. AMS.010630.X - Jennings Community Based Outpatient Clinic
  - ciii. AMS.010631.X - Natchitoches Community Based Outpatient Clinic
  - civ. AMS.010632.X - VA Medical Center Pharmacy – Pineville
  - cv. AMS.010633.X - VA Medical Center Pharmacy – Pineville
  - cvi. CDS.041990.DDS – John N. Kent, III
  - cvii. CDS.010627.DDS - James Adam Moreau, Jr.
  - cviii. CDS.009146.MD - Laney Joseph Chouest
  - cix. CDS.009774.MD – Joan Blondin
  - cx. CDS.008593.MD - Fred E. Husserl
  - cxii. CDS.036821.DVM - Lauren Tucker-Taylor Harper
  - cxiii. CDS.040569.MD – Augustine Uzoma Njoku
  - cxiiii. CDS.021269.MD - Robert L. Fortier-Bensen
  - cxv. CDS.030588.DDS - Rupa Jolly
  - cxvi. CDS.040873.ETC – Melissa A. Butler
  - cxvii. CDS.0150038.DDS – Velma H. Jackson
  - cxviii. CDS.042778.DVM – Mark Anthony Gentry
  - cxix. CDS.010535.MD – Lynn M. Guidry
  - cxx. CDS.043500.PA – Roderick Kelly
  - cxxi. CDS.031077.MD – Melisa Gale Harrington
  - cxxii. CDS.020450.MD – Bruce H. Lobitz
  - cxxiii. CDS.034555.APN – Debralee Ann Populis
  - cxxiiii. CDS.012359.DVM – Mosey Edward Rausch
  - cxxv. CDS.040732.APN – Vonda Kay Wiley
  - cxxvi. CDS.026356.MD – Walter Ronald Skowsky
  - cxxvii. CDS.016333.MD – Kevin Ulysse Stephens
  - cxxviii. CDS.003499.MD – Milton L. Godley
  - cxxix. CDS.006039.MD – James Edward White
  - cxxx. CDS.008568.MD – Charles Douglas Blackmon
  - cxxx. PST.020394 – Aaron Bohn
  - cxxx. CDS.008129.HOX - LSU Veterinary Hospital and Clinic
  - cxxxii. CDS.036449.MD - Kosi James Avotri
  - cxxxiii. CDS.013364.MD - Richard Anthony Sachitano
  - cxxxiv. CDS.014720.DDS – Kyle R. Kennedy
  - cxxxv. CDS.028148.MD - Gary N. Toups
  - cxxxvi. CDS.031505.MD – Agmaise B. Woldie
  - cxxxvii. CDS.006305.HOS - Iberia General Hospital and Medical Center
  - cxxxviii. CDS.036537.APN – Shannon Troy Hidalgo
  - cxxxix. PST.019616 – Joseph Vincent Carter
    - cxl. CPT.011299 – Sean Michael Calloway
    - cxli. CPT.006849 – Latrice Arnell Cochran
    - cxlii. CDS.016475.DDS – Jack Marshall Owens Jr.
    - cxliii. CDS.022558.DVM - Michael Williams
    - cxliv. CDS.014459.DDS - Joseph W. Yerger

---

**NOTE:** Pursuant to the Open Meetings Law at La. R.S. 42:16, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, (4) discussions regarding personnel matters, or other purposes itemized at La. R.S. 42:17.

- cxlv. CDS.016456.DVM – Randall Roy Wegmann
- cxlvi. CDS.018065.MD - Barbara L. Hamm
- cxlvii. CDS.012846.DDS - Jonathan L. Kirkland
- cxlviii. CDS.032529.DVM - John Ira Edwards
- cxlix. CDS.027267.MD - Angelo Anthony Tarver
- cl. CDS.034743.MP - Bryan Louis Bolwahnn
- cli. CDS.042226.MD - Monica JoyceRoss Williams
- clii. CDS.043591.MD - Stacy Lane Lee
- cliii. CDS.020633.MD - Paul Gerard Pelts
- cliv. CDS.042119.DVM - Susan Talbert Bennett
- clv. CDS.041861.DDS - Chase Ray Martin
- clvi. CDS.042308.MD - James G. Caridi
- clvii. CDS.033189.MD – Erin K. Christensen
- clviii. DME.000005 – 02 Solutions
- clix. CDS.042237.PA - Cierra M. Hidalgo
- clx. CPT.007547 – Ashley Ann Owens
- clxi. CPT.011469 – Sherish Lashay Dabney
- clxii. CDS.043698.MD – Scott Franklin Steed
- clxiii. CDS.024021.MD – Susan Louise Vaught
- clxiv. CDS.042219.DDS – Keleigh Jady Quimby
- clxv. CDS.036948.OD – Paul Bradley Dupont
- clxvi. CDS.034574.MD – Sei-Jei Chen
- clxvii. CDS.040682.MD – Steven Xuan Nguyen
- clxviii. CDS.036890.DVM – Marc Darrell Bordelon
- clxix. CDS.014049.DVM – John Joseph Kahn
- clxx. CDS.033305.DVM – Johnie L Garrett
- clxxi. CDS.019926.MD - Huey A. Seyfarth Jr
- clxxii. CDS.033802.MD - Anthony James Martinez
- clxxiii. CPT.005344 – Delilah Sharon Firmin

6. Adjourn

---

**NOTE:** Pursuant to the Open Meetings Law at La. R.S. 42:16, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, (4) discussions regarding personnel matters, or other purposes itemized at La. R.S. 42:17.



# Louisiana Board of Pharmacy

3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ Facsimile 225.925.6499  
[www.pharmacy.la.gov](http://www.pharmacy.la.gov) ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



## Tripartite Committee

---

**NOTE:** Pursuant to the Open Meetings Law, at LRS 42:6.1, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, or (4) discussions regarding personnel matters.



# Louisiana Board of Pharmacy

3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ Facsimile 225.925.6499  
[www.pharmacy.la.gov](http://www.pharmacy.la.gov) ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



## Regulation Revision Committee

---

**NOTE:** Pursuant to the Open Meetings Law, at LRS 42:6.1, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, or (4) discussions regarding personnel matters.



# Louisiana Board of Pharmacy

3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ Facsimile 225.925.6499  
[www.pharmacy.la.gov](http://www.pharmacy.la.gov) ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



Summary of Testimony & Public Comments  
re  
Regulatory Project 2014-4 ~ Pharmacy Compounding  
at  
October 30, 2014 Public Hearing

There were no comments received prior to or during the public hearing. There was one question posed for clarification.

1. [email] Brianna Costales on behalf of Hartley Medical

Commentator noted the proposed revision to §2535.B relative to beyond use date suggested the deletion of the 180 day maximum dating; she asked what would be the replacement standard and questioned whether they should rely on the USP Chapter 797 standards.

## Malcolm J. Broussard

---

**From:** Malcolm J. Broussard  
**Sent:** Thursday, October 02, 2014 1:30 PM  
**To:** 'Compliance '  
**Subject:** RE: Regulatory Project 2014-4 questions

Ms. Costales,

Thank you for your interest in the Board's regulatory project relative to pharmacy compounding. Since publishing its *Notice of Intent* in the September 2014 edition of the state register, we are now in the public comment phase of the regulatory project. I will insert your communication into the record of the public hearing scheduled for October 30. The Board will consider the comments and testimony offered at that public hearing during their subsequent meeting on November 13. I will advise you of the Board's response to your question as soon as possible thereafter. In the interim, you should rely on the provisions of the appropriate USP chapter.

Malcolm J Broussard  
Executive Director  
Louisiana Board of Pharmacy  
3388 Brentwood Drive  
Baton Rouge, LA 70809-1700  
United States of America  
Telephone +1.225.925.6481  
Telecopier +1.225.923.5669  
[mbroussard@pharmacy.la.gov](mailto:mbroussard@pharmacy.la.gov)

---

**From:** Compliance [<mailto:compliance@hartleymedical.com>]  
**Sent:** Thursday, October 02, 2014 1:14 PM  
**To:** Malcolm J. Broussard  
**Subject:** Regulatory Project 2014-4 questions

Good afternoon Malcolm,

Regarding the proposed rule change to section 2535, subsection B regarding Beyond Use Date is removed. What is the new proposed BUD? The USP 797 definition?

Best regards,  
Brianna Costales  
Compliance Officer



113 W. Victoria Street

Long Beach, CA 90805  
P: 888.671.2888 Ext. 607  
F: 800.648.8550  
[www.hartleymedical.com](http://www.hartleymedical.com)

**CONFIDENTIALITY NOTICE:** This transmission and any attachments are confidential and are for the sole use of the intended recipient(s) identified above. If you are not the intended recipient, or employee or agent of the recipient, be notified that any use, reading, dissemination, distribution, copying, or storage of this information is strictly prohibited. If you have received this information in error, please notify the sender by return e-mail and delete the transmission and all attachments from your system.

This e-mail is covered by the Electronic Communications Privacy Act, 18 U.S.C. 2510-2521 and is legally privileged. It contains information from Hartley Medical Center Pharmacy Inc., which may be privileged, confidential and exempt from disclosure under applicable law. Dissemination or copying of this by anyone other than the addressee or the addressee's agent is strictly prohibited. If this electronic transmission is received in error, please notify Hartley Medical Center Pharmacy Inc. immediately at 562.595.7548. Thank you.



# Louisiana Board of Pharmacy

3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ Facsimile 225.925.6499  
[www.pharmacy.la.gov](http://www.pharmacy.la.gov) ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



Summary of Testimony & Public Comments  
re  
Regulatory Project 2014-5 ~ Prescriptions  
at  
October 30, 2014 Public Hearing

There were no comments received prior to or during the public hearing.



# Louisiana Board of Pharmacy

3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ Facsimile 225.925.6499  
[www.pharmacy.la.gov](http://www.pharmacy.la.gov) ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



Summary of Testimony & Public Comments  
re  
Regulatory Project 2014-6 ~ Special Event Pharmacy Permit  
at  
October 30, 2014 Public Hearing

There were no comments received prior to or during the public hearing.

**Louisiana Administrative Code**

**Title 46 – Professional and Occupational Standards**

**Part LIII – Pharmacists**

**Chapter 29. Prescription Monitoring Program**

**Subchapter A. General Operations**

**§2901. Definitions**

A. As used in this Chapter, the following terms shall have the meaning ascribed to them unless the context clearly indicates otherwise:

...

*Drugs of Concern* – drugs other than controlled substances as defined by rule which demonstrate a potential for abuse, including any material, compound, mixture, or preparation containing any quantity of the following substances, including its salts, esters, ethers, isomers, and salts of isomers [whenever the existence of such salts, esters, ethers, isomers, and salts of isomers is possible within the specific chemical designation];

- a. butalbital when in combination with at least 125 milligrams of acetaminophen per dosage unit; ~~and~~
- b. ~~tramadol.~~

...

AUTHORITY NOTE: Promulgated in accordance with R.S. 40:1011.

HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Pharmacy, LR 33:1345 (July 2007), amended LR 36:755 (April 2010), effective September 1, 2010, amended LR 39:314 (February 2013), amended LR

...

**Subchapter B. Data Collection**

**§2911. Reporting of Prescription Monitoring Information**

A. Each dispenser shall submit to the board information regarding each prescription dispensed for a controlled substance.

B. Each dispenser shall submit the required information by electronic means ~~as soon as possible but in no event more than seven days~~ no later than the next business day after the date of dispensing.

C. If the dispenser is unable to submit prescription information by electronic means, he may apply to the board for a waiver. The board may grant a waiver to that requirement; if so, the waiver shall state the format and frequency with which the dispenser shall submit the required information. The waiver shall expire one year after the date of issue, unless terminated sooner by the board.

AUTHORITY NOTE: Promulgated in accordance with R.S. 40:1011.

HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Pharmacy, LR 33:1346 (July 2007), amended LR 39:314 (February 2013), amended LR

...

**Louisiana Administrative Code**

**Title 46 – Professional and Occupational Standards**

**Part LIII: Pharmacists**

**Chapter 27. Controlled Dangerous Substances**

**Subchapter F. Production, Distribution and Utilization**

**§2745 Prescriptions**

F. Controlled Substances Listed in Schedule II

2. Expiration Date of Prescriptions

A prescription for a controlled substance listed in Schedule II shall expire ~~six months~~ ninety days after the date of issue. No pharmacist shall dispense any controlled substance pursuant to an expired prescription.

AUTHORITY NOTE: Promulgated in accordance with R.S. 40:972.

HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Pharmacy, LR 34:2149 (October 2008), amended LR

**§2747 Dispensing Requirements**

B. Prescriptions for Controlled Substances Listed in Schedule II

3. Expiration Date

A pharmacist shall not dispense a prescription for a controlled substance listed in Schedule II more than ~~six months~~ ninety days after the date of issue of the prescription.

AUTHORITY NOTE: Promulgated in accordance with R.S. 40:972.

HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Pharmacy, LR 34:2152 (October 2008), amended LR



# Louisiana Board of Pharmacy

3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ Facsimile 225.925.6499  
[www.pharmacy.la.gov](http://www.pharmacy.la.gov) ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



## Executive Committee

---

**NOTE:** Pursuant to the Open Meetings Law, at LRS 42:6.1, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, or (4) discussions regarding personnel matters.



# Louisiana Board of Pharmacy

3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ Facsimile 225.925.6499  
[www.pharmacy.la.gov](http://www.pharmacy.la.gov) ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



**NOTICE IS HEREBY GIVEN** that a meeting of the Executive Committee has been ordered and called for the late afternoon of Wednesday, November 12, 2014 [*to follow the meeting of the Finance Committee, at approximately 4:30 p.m.*] at the Board office, for the purpose to wit:

## AGENDA

NOTE: This agenda is tentative until 24 hours in advance of the meeting, at which time the most recent revision becomes official.

**Revised 11-10-2014**

1. Call to Order
2. Quorum Call
3. Call for Additional Agenda Items & Adoption of Agenda
4. Opportunity for Public Comment
5. Review of Administrative Operations
  - A. Consideration of Bank Box Access Resolution
  - B. Consideration of Resolutions Authorizing Professional Legal Services
  - C. Consideration of Board Member Expense Reports Submitted After Deadline
6. Review of Policies & Procedures
  - A. Proposed Revision to Board Policy re Declaratory Statements
  - B. Proposed New Policy re Ebola Virus Disease
7. Request for Interpretation of LAC 46:LIII.1115.B relative to .Pharmacy gTLD
8. Adjourn

---

**NOTE:** Pursuant to the Open Meetings Law at La. R.S. 42:16, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, (4) discussions regarding personnel matters, or other purposes itemized at La. R.S. 42:17.



# Louisiana Board of Pharmacy

3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ Facsimile 225.925.6499  
[www.pharmacy.la.gov](http://www.pharmacy.la.gov) ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



## RESOLUTION

The following Motion and Resolution was offered by \_\_\_\_\_ who moved for its adoption, and seconded by \_\_\_\_\_ at the November 13, 2014 meeting of the Louisiana Board of Pharmacy (the "Board"):

WHEREAS, the Board has one attorney on staff and he supervises the Board's compliance officers' investigations, and further, the Board desires to avoid any appearance of impropriety that might arise should that attorney also attempt to serve as the Board's prosecutor, and further, there is a need for an attorney experienced in administrative law to provide prosecutorial services during its administrative hearings, and further, to provide additional representation when the Board's decisions are appealed to the judiciary, and further, to provide legal representation to the Board and its staff when sued in their official capacities in a court of law; and

WHEREAS, the Board has worked with **Celia R. Cangelosi** in the same capacity for over fifteen years, providing the experience as prosecuting attorney, with additional experience in representing the Board's interests in the 19<sup>th</sup> Judicial District Court, the First Circuit Court of Appeals; and the Louisiana Supreme Court; and

WHEREAS, the Board's current contract with **Celia R. Cangelosi** specifies an hourly rate of one hundred ninety-five dollars (\$195) per hour of service, and further, provides for reimbursement of certain expenses when submitted in compliance with the Division of Administration's regulations governing such, and further, provides the total compensation, including all fees and reimbursements, shall not exceed eighty thousand dollars (\$80,000) for Fiscal Year 2014-2015; and

WHEREAS, there is no authority for payment of a contingency fee; and

WHEREAS, this resolution shall take effect immediately.

THEREFORE BE IT RESOLVED that the Louisiana Board of Pharmacy, pursuant to La. R.S. 42:262, does hereby retain and employ **Celia R. Cangelosi** as special counsel; and

BE IT FURTHER RESOLVED, that this Resolution and proposed contract described herein be submitted to the Attorney General for the State of Louisiana for approval.

The resolution having been submitted to a vote, the vote thereon was as follows:

YEAS:           —  
NAYS:           —  
ABSENT:       —  
NOT VOTING:  —

Whereupon the Resolution was declared adopted by the Louisiana Board of Pharmacy on the 13<sup>th</sup> day of November, 2014.

I, Carl W. Aron, President the Louisiana Board of Pharmacy, hereby certify the above and foregoing to be a true and exact copy of a resolution adopted by the Board at its meeting held November 13, 2014, at which a quorum was present, and the same has not been revoked, rescinded or altered in any manner, and is in full force and effect.

Witness my hand this 13<sup>th</sup> day of November, 2014.

\_\_\_\_\_



# Louisiana Board of Pharmacy

3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ Facsimile 225.925.6499  
[www.pharmacy.la.gov](http://www.pharmacy.la.gov) ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



## RESOLUTION

The following Motion and Resolution was offered by \_\_\_\_\_ who moved for its adoption, and seconded by \_\_\_\_\_ at the November 13, 2014 meeting of the Louisiana Board of Pharmacy (the "Board"):

WHEREAS, the Board has one attorney on staff and he supervises the Board's compliance officers' investigations, and further, the Board desires to avoid any appearance of impropriety that might arise should that attorney also attempt to serve as an advisor to the Board's Hearing Officer, and further, there is a need for an attorney experienced in administrative law to provide advisory services to the Board's Hearing Officer during its administrative hearings, or to serve as the Hearing Officer; and further, to provide legal representation to the Board and its staff when sued in their official capacities in a court of law, as well as other professional legal services as may be requested by the Board from time to time; and

WHEREAS, the Board has worked with **E. Wade Shows** in the same capacity for over ten years, where he has provided advisory services to the Board's Hearing Officer as well as serving as the Hearing Officer from time to time; and further, he represented the Board and its staff during a suit against the Board during 2013; and

WHEREAS, the Board's current contract with **E. Wade Shows** specifies an hourly rate of one hundred seventy-five dollars (\$175) per hour of service, and further, provides for reimbursement of certain expenses when submitted in compliance with the Division of Administration's regulations governing such, and further, provides the total compensation, including all fees and reimbursements, shall not exceed forty thousand dollars (\$40,000) for Fiscal Year 2014-2015; and

WHEREAS, there is no authority for payment of a contingency fee; and

WHEREAS, this resolution shall take effect immediately.

THEREFORE BE IT RESOLVED that the Louisiana Board of Pharmacy, pursuant to La. R.S. 42:262, does hereby retain and employ **E. Wade Shows** as special counsel; and

BE IT FURTHER RESOLVED, that this Resolution and proposed contract described herein be submitted to the Attorney General for the State of Louisiana for approval.

The resolution having been submitted to a vote, the vote thereon was as follows:

YEAS:           —  
NAYS:           —  
ABSENT:       —  
NOT VOTING:  —

Whereupon the Resolution was declared adopted by the Louisiana Board of Pharmacy on the 13<sup>th</sup> day of November, 2014.

I, Carl W. Aron, President the Louisiana Board of Pharmacy, hereby certify the above and foregoing to be a true and exact copy of a resolution adopted by the Board at its meeting held November 13, 2014, at which a quorum was present, and the same has not been revoked, rescinded or altered in any manner, and is in full force and effect.

Witness my hand this 13<sup>th</sup> day of November, 2014.

\_\_\_\_\_

*Title:* Declaratory Statements & Advisory Opinions

Policy No. I.A.2

Approved: 05-05-2004

Revised:

- .....
1. The statutory authority for these procedures is RS 49:962.
  2. The regulatory authority for these procedures is LAC 46:LIII.359.
  3. Petitioner shall be allotted a minimum of thirty (30) minutes to present his arguments in support of a written Petition for Declaratory Statement or Petition for Advisory Opinion validly entered into the record. The Chair may exercise his discretion in extending this period.
  4. General Counsel for the Louisiana Board of Pharmacy shall be allotted a minimum of thirty (30) minutes to respond to the Petition for Declaratory Statement or Petition for Advisory Opinion. The Chair may exercise his discretion in extending this period. At any time during General Counsel's presentation, additional comments, arguments and/or points of information may be presented by other Board representatives or staff with the Chair's approval.
  5. Petitioner shall have no more than fifteen (15) minutes for rebuttal. The Chair may exercise his discretion in extending this period.
  6. During the course of all arguments, the Chair may solicit comments from Board members, Board staff and audience members at his discretion.
  7. At the conclusion of all arguments, the Chair may solicit comments from Board members, Board staff and audience members at his discretion.
  8. All remarks by a member of the Board, Board staff or audience member shall be addressed through the Chair.
  9. Upon conclusion of all arguments, comments and points of information, the Chair may either direct the Board to rule on the matter at that time or, based on the complexity of the issues involved, may direct the Board members to take the Petition under advisement and direct a ruling at the next regularly scheduled meeting of the full Board.
  10. If the matter is taken under advisement, the Chair shall direct the petitioner to submit any written response to General Counsel's written arguments on the matter. The Chair shall allow a minimum of fifteen (15) days for the response to be submitted. The Chair may exercise his discretion in extending this period for good cause.

*Title:* Declaratory Statements & Advisory Opinions

Policy No. I.A.2

Approved: 05-05-2004

Revised:

.....

11. In accordance with Robert's Rules of Order, at the outset of the formal hearing, the Chair shall direct Board members, staff and audience members that decorum shall be maintained throughout the presentation and debate on the matter. After a preliminary verbal warning by the Chair to any individual disturbing the assembly, upon a second recognized instance by the Chair of this individual disrupting decorum, the individual may be escorted from the meeting room and prohibited reentry at the Chair's discretion.

12. The Board will not render declaratory statements or advisory opinions:

- a. On questions of fact or on matters where the relevant facts are in dispute;
- b. On questions scheduled for determination by a court or other administrative body, or where the prospect of litigation appears imminent; or
- c. On complex or important issues of law where the Board deems that the requestor should either seek a declaratory judgment or seek other courses of action that may be more appropriate than the issuance of a declaratory statement or advisory opinion.

*Title:* Declaratory Statements & Advisory Opinions

Policy No. I.A.2

Approved: 05-05-2004

Revised:



**Revision History**

02-12-2014      Added Item 12.

DRAFT

Title: Ebola Virus Disease

Policy No. II.I.4

Approved:

Revised:

- .....
1. The statutory authority for the Board to engage employees is found at La. R.S. 37:1182.B.6.
  2. The regulatory authority for Board employees is found at LAC 46:LIII.107.F.
  3. The authority of the Louisiana Department of State Civil Service relative to state employees is derived from Article X of the Louisiana State Constitution.
  4. The specific authority for this policy is found in Governor Bobby Jindal's Executive Order BJ 14-13 – Travel to Areas Impacted by Ebola Virus Disease.
  5. This policy shall apply to all employees of the Board, both classified and unclassified, and both full-time and part-time.
  6. Due to the World Health Organization declaring the Ebola Virus Disease outbreak as an international public health emergency, it is the Board's policy that its employees shall comply with the following procedures when an employee travels outside the United States of America to a country designated by the Centers for Disease Control & Prevention (CDC) as having a threat of contracting the Ebola Virus Disease.
  7. Procedures
    - a. When an employee is aware he intends to travel out of the United States of America, the employee shall review the CDC's website, <http://wwwnc.cdc.gov/travel/notices>, to determine if the country the employee intends to visit is on the list of countries identified as having a threat of contracting the Ebola Virus Disease.
    - b. If the country to which the employee intends to visit is identified by the CDC as having a threat of contracting the Ebola Virus Disease, the employee shall notify his Supervisor at least five (5) business days prior to initiating travel to that country; however, if the travel is to occur within the five (5) business days, the employee shall notify his Supervisor as soon as possible.
    - c. The Supervisor shall notify the Human Resources Manager as soon as he is made aware of the international travel of the employee.
    - d. If the employee is traveling to a country identified by the CDC as having a threat of contracting the Ebola Virus Disease, the Human Resources Manager shall notify (1) the Executive Director of the Board, (2) the Director and/or the Deputy Director of State Civil Service, and (3) the Department of Health and Hospital's Infectious Disease Epidemiology Section (EPI) within forty-eight (48) hours of receiving the information if prior to travel and/or

Title: Ebola Virus Disease

Policy No. II.I.4

Approved:

Revised:



- within twenty-four (24) hours of receiving the information if subsequent to travel.
- e. If the employee is traveling outside the United States of America, the employee shall notify his Supervisor if the employee falls ill during the international travel or within twenty-one (21) days of return. The employee shall remain off from work until a doctor of medicine has determined the employee can return to work.
  - f. If the employee intends to travel to a country identified by the CDC as having a threat of contracting the Ebola Virus, the employee shall provide his Supervisor with the following information:
    - i. Name of the person making the report. This shall include the reporter's phone number, email address, and the date/time of the report.
    - ii. Name of the employee who is or has traveled outside the United States to a country identified by the CDC as having a threat of contracting the Ebola Virus Disease.
    - iii. The complete dates of international travel, the traveler's phone number, email address, and the countries visited with dates of entry and departure if known.
    - iv. This report shall be submitted to the Department of Health and Hospitals, Infectious Disease Epidemiology Section by the Human Resources Manager within twenty-four (24) hours of receipt.
    - v. The Human Resources Manager shall file the report by email to EPI at [IDEPI@la.gov](mailto:IDEPI@la.gov).
  - g. If the employee travels to a country identified by the CDC as having a threat of contracting the Ebola Virus, the employee shall agree to the following:
    - i. The employee shall agree not to use any commercial transportation for twenty-one (21) days after departing the affected country.
    - ii. The employee shall agree not to visit any place where the general public congregates (including, but not limited to, restaurants, grocery stores, gymnasiums, theaters, or places of worship) for twenty-one (21) days after departing the affected country.
    - iii. The employee shall agree not to return to work for twenty-one (21) days after departing the affected country. The employee shall use sick leave or if the employee has no sick leave, annual leave for the days the employee will be absent from work during the twenty-one (21) days after departing the affected country. If the employee has exhausted sick leave and annual leave, the employee shall be placed on leave without pay (LWOP).

*Title:* Ebola Virus Disease

Policy No. II.I.4

Approved:

Revised:

- 
- iv. The employee shall agree, if requested by the Department of Health and Hospitals, to medical monitoring by public health officials for twenty-one (21) days after departing the affected country.

DRAFT



# Louisiana Board of Pharmacy

3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ Facsimile 225.925.6499  
[www.pharmacy.la.gov](http://www.pharmacy.la.gov) ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



## Report of Assistant Executive Director

---

**NOTE:** Pursuant to the Open Meetings Law, at LRS 42:6.1, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, or (4) discussions regarding personnel matters.



# Prescription Monitoring Program


Board Meeting  
November 13, 2014

Joe Fontenot, R.Ph. Assistant Executive Director  
Danielle C. Meadors, Administrative Assistant

# Number of Eligible Transactions Reported to the PMP

Total Reported as of  
September 30, 2014


**78,028,958**




# Prescriber & Pharmacist Access

(as of September 30, 2014)

Prescribers – Total  
Authorized 4,730




Pharmacist – Total  
Authorized 2,921



**Combined Totals – 7,651**

# Prescriber/Pharmacist Queries – 2014


Overall Query total = 936,941



# Prescriber/Pharmacist Queries


(01/01/2009 through 09/30/2014)

Overall Query total = 4,464,318



# Board and Regulatory Agencies

Profile Views by Boards & Regulatory Agencies Total = **8,089**  
(01/01/2009 through 09/30/2014)



# Law Enforcement Access and Requests

Number of Law Enforcement  
Requests Processed = **5,779**  
(01/01/2009 through 09/30/2014)

2009	2010	2011	2012	2013	2014
<b>680</b>	<b>889</b>	<b>1,230</b>	<b>845</b>	<b>1,150</b>	<b>985</b>

## Requests for Exemption from PMP Reporting November 13, 2014

In accordance with LA.R.S:40.4.X-A.1006.C. The board may issue a waiver to a dispenser who is unable to submit prescription information by electronic means. The waiver shall state the format and frequency with which the dispenser shall submit the required information. The board may issue an exemption from the reporting requirement to a dispenser whose practice activities are inconsistent with the intent of the program. The board may rescind any previously issued exemption without the need for an informal or formal hearing.

Permit	Permit Type	Name	Scope of Practice	DEA	City	State
2217	IR	Teche Action Clinic Pharmacy		Yes	Franklin	LA
5322	NR	Walgreen Mail Service	Mail Order	Yes	Orlando	FL
6068	NR	FarmVet.com	Veterinary Pharmacy	No	Franklin	TN
6930	NR	Walgreens #1219-2	Call Center	Yes	Miami Lakes	FL
6944	NU	Cardinal Health 414	Nuclear Pharmacy	No	West Monroe	LA
6950	NR	Leedstone	Veterinary Pharmacy	No	Melrose	MN
6952	NR	Praxis Rx Pharmacy	Specialty Medications	No	Tampa	FL
6959	NR	Pharmaceutical Specialties Express	Specialty Medications	Yes	Bogart	GA
6962	NR	Pet's Choice Pharmacy	Veterinary Pharmacy	No	Belleville	KS
6963	NR	Panther Specialty Pharmacy		Yes	Pittsburgh	PA

### **Staff Recommendation**

Approve the proposed waivers conditioned upon execution of the standard Consent Agreement:

### **WAIVER TO PRESCRIPTION MONITORING PROGRAM REPORTING REQUIREMENTS CONSENT AGREEMENT**

WHEREAS, in order to facilitate the pharmacy's request for a waiver to the reporting requirements to the Louisiana Board of Pharmacy's Prescription Monitoring Program (PMP) as required by law, the Pharmacy indicated below agrees to the following terms:

- (1) The Pharmacy shall not be authorized to dispense any controlled dangerous substances (CDS) or *drugs of concern*, with the exception of hospital inpatient dispensing, as identified by the Louisiana Board of Pharmacy (Board) by regulation.
- (2) Upon the first instance of receipt of evidence by the Board indicating the Pharmacy dispensed CDS or drugs of concern, the Pharmacy agrees to the following sanction:

***The Pharmacy agrees to pay a fine of \$5,000.00 and reimburse the Board \$250.00 in administrative hearing costs, with total payment due the Board of \$5,250.00, due by certified check or money order within 30 days of notice of this prohibited activity.***

- (3) Upon the second instance of receipt of evidence indicating the Pharmacy dispensed CDS or drugs of concern, the Pharmacy agrees to pay the above sanction, the termination of this waiver and the resumption of its reporting to the PMP.
- (4) The Pharmacy shall post a copy of this agreement adjacent or attached to its pharmacy permit.

By signing this Consent Agreement, Respondent agrees that the Board has jurisdiction in this matter and waives all rights to informal conference, to Notice of Hearing, to a formal Administrative Hearing, and to judicial review of this Consent Agreement.



# Louisiana Board of Pharmacy

3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ Facsimile 225.925.6499  
[www.pharmacy.la.gov](http://www.pharmacy.la.gov) ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



## Report of General Counsel

---

**NOTE:** Pursuant to the Open Meetings Law, at LRS 42:6.1, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, or (4) discussions regarding personnel matters.



# Louisiana Board of Pharmacy

3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ Facsimile 225.925.6499  
[www.pharmacy.la.gov](http://www.pharmacy.la.gov) ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



## Report of Executive Director

---

**NOTE:** Pursuant to the Open Meetings Law, at LRS 42:6.1, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, or (4) discussions regarding personnel matters.



# Louisiana Board of Pharmacy

3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ Facsimile 225.925.6499  
[www.pharmacy.la.gov](http://www.pharmacy.la.gov) ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



November 13, 2014

## Agenda Item 11-L: Report of Executive Director

1. Meeting Activity
2. Reports
3. Examinations
4. Operations
5. State Activities
6. National Activities
7. International Activities

### 1. **Meeting Activity**

In addition to Board and committee meetings, I have also participated in or attended the following meetings since the last Board meeting.

- |            |   |
|------------|---|
| Aug. 15    | P-1 Orientation – ULM School of Pharmacy                |
| Aug. 19    | P-1 Orientation – Xavier College of Pharmacy            |
| Aug. 30-31 | FIP World Congress – Bangkok, TH                        |
| Sep. 4-5   | MPJE Item Review Workshop @ NABP – Mount Prospect, IL   |
| Sep. 8     | Leadership Mtg – La. Sheriffs Association & DPSC        |
| Sep. 21-24 | NABP-AACP Districts 6-7-8 Annual Mtg – Whitefish, MT    |
| Oct. 14-15 | NABP Forum for Executive Directors – Mount Prospect, IL |
| Oct. 26-29 | MALTAGON Conference 2014 – St. Pete Beach, FL           |

### 2. **Reports** (all in the Boardroom Library)

- A. Census Reports
  1. Compliance Division – Practitioner Recovery Program & Discipline
  2. Credentials Division – CDS & Pharmacy Programs
- B. Credentials Division Production Reports
  1. Licensure Activity Report [new credentials in previous quarter]
  2. Application Activity Report [pending applications count]
- C. Exceptions Report
  1. PIC in Multiple Locations
  2. Resurrected Credentials / Special Work Permits

### 3. **Examinations**

- A. MPJE – the results for the second trimester of 2014 are available.
- B. NAPLEX – the results for the second trimester of 2014 are available.
- C. PARE – we conducted one repeat examination on July 16 in the Board office.
- D. PTCB – the results for the first half of 2014 are available.

#### **4. Operations**

##### **A. Credentials Division**

We opened the renewal cycles for pharmacists, pharmacies, and CDS licenses for pharmacies on November 1. The renewal cycles will close and those credentials will expire on December 31. As of the close of business on Friday, November 7:

- Of the 8,105 pharmacists who were noticed for renewal, 13% of them had renewed.
- Of the 1,902 pharmacies which were noticed for renewal, 16% of them had renewed.
- Of the 1,395 pharmacies holding a CDS license which were noticed for renewal, 13% of them had renewed.

##### **B. Compliance Division**

Our 5 pharmacist compliance officers are responsible for inspecting all the pharmacies and other facilities holding controlled substances (CDS). The census reports available for this meeting reflects 1,440 pharmacies within the state, as well as approximately 560 various types of facilities for CDS visits, including hospitals, ambulatory surgical centers, dialysis clinics, researchers, etc.

In addition to their routine site visits, the compliance officers are also responsible for investigating complaints filed with the Board. We began the fiscal year with 252 cases pending from the prior fiscal year. We have entered 149 new cases and closed 169, leaving 232 cases currently open. Of the 169 cases closed so far this fiscal year, 73% were disposed of through staff activities and the balance through committee and Board action.

##### **C. Administrative Division**

As you know, we are subject to an audit every year, conducted by either the Office of the Legislative Auditor (OLA), or more usually, by an auditor under contract with the OLA. During our last meeting, we indicated to you our understanding of the preliminary report. We received the final report, and we're happy to report the auditor's unqualified opinion. The short version of the good news can be found on Page 27 of their report, which has been posted in the Boardroom Library.

The state Division of Administration has imposed some new requirements on all state agencies, including boards and commissions, that will change the method by which we pay for certain travel expenses, including airfare, lodging, conference registrations, and vehicle rentals. We are in the process of applying for the required central billing account, and we will develop a guidance document to help you comply with the new procedures.

#### **5. State Activities**

##### **A. Dept. of Health and Hospitals (DHH)**

We continue to work with the department on their Emergency Department Utilization Work Group as they develop additional strategies to decrease the utilization of hospital emergency departments for primary care services.

As the Office of Public Health (OPH) opened its Emergency Operations Center to provide information about the Ebola Virus, we assisted them by sending their initial alert to all of our pharmacy and CDS licensees. OPH then requested our list of licensees' email addresses and pharmacy fax numbers for the purpose of communicating additional information; we provided those lists promptly and waived all fees.

##### **B. La. State Board of Medical Examiners (LSBME)**

As reported during the last Board meeting, the medical board has been directed to respond to a legislative study resolution relative to the over-prescribing of pain medication, and further, they were specifically instructed to solicit your input. We have a meeting with their staff leadership set for next week, and we will relate the information you provided during your meeting last week as well as additional information from the prescription monitoring program.

**6. National Activities**

A. National Association of Boards of Pharmacy (NABP)

For your planning purposes, the 2015 meeting will be held May 16-19 in New Orleans, LA. This conference is one of the three meetings for which your travel expenses are eligible for reimbursement, subject to the limitations itemized in the Board's travel policy as well as the state's travel policy in PPM-49.

B. NABP-AACP District 6 Annual Meeting

The members of District 6 voted to join with Districts 7 and 8 in Nevada for next year's conference. When that meeting information is available, we will forward it to you. As a reminder, this conference is one of the three meetings for which your travel expenses are eligible for reimbursement, subject to the limitations itemized in the Board's travel policy as well as the state's travel policy in PPM-49.

C. MALTAGON

Next year's conference will be hosted by the Kentucky Board of Pharmacy. When that meeting information is available, we will forward it to you. As a reminder, this conference is one of the three meetings for which your travel expenses are eligible for reimbursement, subject to the limitations itemized in the Board's travel policy as well as the state's travel policy in PPM-49.

D. U. S. Drug Enforcement Administration (DEA)

As you may recall, the US Congress passed the Secure and Responsible Drug Disposal Act of 2010. That legislation amended the federal Controlled Substances Act to give the DEA authority to promulgate new rules that will allow ultimate users to deliver unused controlled substances to appropriate entities for disposal in a safe and effective manner. The goal of the Disposal Act is to encourage public and private entities to develop a variety of methods of collection and disposal in a secure, convenient, and responsible manner.

The DEA published the Disposal Regulations in the September 8, 2014 edition of the Federal Register, and they became effective on October 9, 2014. The new rules allow authorized manufacturers, distributors, reverse distributors, narcotic treatment programs, hospitals and clinics with an on-site pharmacy, and retail pharmacies to collect controlled substances from ultimate users by voluntarily administering mail-back programs and maintaining collection receptacles. In addition, the rules allow authorized hospitals and clinics and retail pharmacies to voluntarily maintain collection receptacles at long-term care facilities. The new rules reorganize and consolidate previously existing regulations on disposal, including the role of reverse distributors.

Certain registrants, including pharmacies, that desire to serve their community as collection sites may apply to DEA to modify their DEA registration. Once approved by the DEA, these facilities will be recognized as Authorized Collectors. We believe it appropriate for the Board to be aware of which pharmacies have been designated as Authorized Collectors, so we added a question about that topic on the pharmacy permit renewal application just released earlier this month. We intend to establish a virtual credential which we can issue to a pharmacy permit (for no fee) that has obtained approval to serve as an Authorized Collector. The public should be able to search for Authorized Collectors on our website.

E. National Transportation Safety Board (NTSB)

The National Transportation Safety Board (NTSB) released the results of its study Drug Use Trends in Aviation: Assessing the Risk of Pilot Impairment in early September. In addition to the conclusions, the final report also issued recommendations, both to the Federal Aviation Administration (FAA) as well as to Governors of all 50 states. The two recommendations referred to state officials were further directed to the executive directors of the medical, nursing, and pharmacy boards. The recommendations encourage the inclusion of certain information in patient counseling sessions as well as communications via newsletters directed to medical professionals.

I posted a copy of the letter sent to Louisiana Governor Jindal as well as our office. The letter contains a link to the study itself. I would encourage your review of this

information and the development of a response to the NTSB.

**7. *International Activities***

A. International Pharmaceutical Federation (FIP)

Bangkok, Thailand hosted the 2014 World Congress of Pharmacy & Pharmaceutical Sciences on August 30 – September 4. During the meeting of the FIP Council (its governing body), Carmen Catizone and I made a formal presentation concerning NABP's .Pharmacy Project. The presentation was well received, generated substantial interest, and resulted in meetings with government and pharmacy leaders from several jurisdictions, including Spain, Argentina, Ireland, and the European Union. NABP is now accepting applications for domain names in the .Pharmacy registry, and we anticipate consumers should be able to search for legitimate online pharmacies in the .Pharmacy domain by spring of 2015.

For your planning purposes, the next three hosting sites have been identified: 2015 in Dusseldorf, Germany, 2016 in Buenos Aires, Argentina, and 2017 in Seoul, South Korea.

Respectfully submitted,  
Malcolm J Broussard  
Executive Director



Louisiana Board of Pharmacy  
 Credentials Division  
 Pharmacy Program

		06/30/06	06/30/07	06/30/08	06/30/09	06/30/10	06/30/11	06/30/12	06/30/13	06/30/14	11/06/14
PST-VI	LA	0	0	0	0	0	12	10	9	9	9
	NR	0	0	0	0	0	9	10	15	14	14
	<b>Total</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>21</b>	<b>20</b>	<b>24</b>	<b>23</b>	<b>23</b>
PST-GVI	LA	0	0	0	0	0	0	6	13	13	14
	NR	0	0	0	0	0	0	0	3	5	5
	<b>Total</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>6</b>	<b>16</b>	<b>18</b>	<b>19</b>
PST-M	LA	0	0	0	0	0	3	5	3	1	0
	NR	0	0	0	0	0	11	11	11	13	14
	<b>Total</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>14</b>	<b>16</b>	<b>14</b>	<b>14</b>	<b>14</b>
PST-G	LA	0	0	0	0	0	158	157	164	166	165
	NR	0	0	0	0	0	30	35	32	31	31
	<b>Total</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>188</b>	<b>192</b>	<b>196</b>	<b>197</b>	<b>196</b>
PST	LA	4,460	4,522	4,612	4,750	4,860	4,654	4,933	4,981	5,140	5,268
	NR	1,915	1,975	1,964	2,029	2,098	2,079	2,212	2,527	2,479	2,593
	<b>Total</b>	<b>6,375</b>	<b>6,497</b>	<b>6,576</b>	<b>6,779</b>	<b>6,958</b>	<b>6,733</b>	<b>7,145</b>	<b>7,508</b>	<b>7,619</b>	<b>7,861</b>
	<b>PST</b>	<b>6,375</b>	<b>6,497</b>	<b>6,576</b>	<b>6,779</b>	<b>6,958</b>	<b>6,935</b>	<b>7,353</b>	<b>7,758</b>	<b>7,871</b>	<b>8,113</b>
PNT	LA	980	1,079	1,074	1,035	965	907	938	942	948	932
	NR	109	117	67	84	153	137	128	128	127	142
	<b>Total</b>	<b>1,089</b>	<b>1,196</b>	<b>1,141</b>	<b>1,119</b>	<b>1,118</b>	<b>1,044</b>	<b>1,066</b>	<b>1,070</b>	<b>1,075</b>	<b>1,074</b>
PNT-FPG	<b>Total</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>5</b>	<b>0</b>	<b>3</b>	<b>6</b>	<b>3</b>
	<b>PNT</b>	<b>1,089</b>	<b>1,196</b>	<b>1,141</b>	<b>1,119</b>	<b>1,118</b>	<b>1,049</b>	<b>1,066</b>	<b>1,073</b>	<b>1,081</b>	<b>1,077</b>
CPT	LA	4,552	4,587	4,780	4,733	5,363	5,720	5,509	5,751	6,463	6,296
	NR	163	152	144	109	144	145	120	112	138	126
	<b>Total</b>	<b>4,715</b>	<b>4,739</b>	<b>4,924</b>	<b>4,842</b>	<b>5,507</b>	<b>5,865</b>	<b>5,629</b>	<b>5,863</b>	<b>6,601</b>	<b>6,422</b>
CPT-M	<b>Total</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>1</b>	<b>0</b>	<b>1</b>	<b>2</b>	<b>1</b>
	<b>CPT</b>	<b>4,715</b>	<b>4,739</b>	<b>4,924</b>	<b>4,842</b>	<b>5,507</b>	<b>5,866</b>	<b>5,629</b>	<b>5,864</b>	<b>6,603</b>	<b>6,423</b>
PTC	LA	1,081	1,389	1,446	1,510	1,679	1,574	1,665	1,658	1,870	1,843
	NR	32	32	23	32	35	35	39	37	37	33
	<b>PTC</b>	<b>1,113</b>	<b>1,421</b>	<b>1,469</b>	<b>1,542</b>	<b>1,714</b>	<b>1,609</b>	<b>1,704</b>	<b>1,695</b>	<b>1,907</b>	<b>1,876</b>
PHY	CH	12	12	11	12	14	12	12	12	12	12
	HOS	167	164	167	167	165	151	154	158	164	167
	HOX	0	0	0	0	0	19	18	14	11	10
	IN	35	36	37	37	27	14	10	12	12	11
	INX	0	0	0	0	0	11	14	13	11	11
	IR	681	620	588	592	587	570	568	558	583	586
	IRX	0	0	0	0	0	21	19	17	10	10
	NR	226	240	250	256	286	318	361	387	422	442
	NRN	0	0	0	0	0	0	0	0	9	9
	NRP	0	0	0	0	0	0	0	0	1	2
	NU	17	16	16	16	16	15	15	15	15	14
	PEN	0	0	0	0	0	0	0	0	0	0
	PEX	0	0	0	0	0	0	0	1	2	2
	SAT	0	0	0	0	0	0	0	0	1	1
RC	430	491	534	545	562	576	587	597	619	627	
<b>PHY</b>	<b>1,568</b>	<b>1,579</b>	<b>1,603</b>	<b>1,625</b>	<b>1,657</b>	<b>1,707</b>	<b>1,758</b>	<b>1,784</b>	<b>1,872</b>	<b>1,904</b>	
AMS	AMS	173	212	255	306	361	55	64	349	92	103
	AMS-X	0	0	0	0	0	301	302	289	359	351
	<b>AMS</b>	<b>173</b>	<b>212</b>	<b>255</b>	<b>306</b>	<b>361</b>	<b>356</b>	<b>366</b>	<b>638</b>	<b>451</b>	<b>454</b>
EDK	EDK	428	412	439	388	503	417	435	421	464	451
	EDK-X	0	0	0	0	0	13	13	10	10	10
	<b>EDK</b>	<b>428</b>	<b>412</b>	<b>439</b>	<b>388</b>	<b>503</b>	<b>430</b>	<b>448</b>	<b>431</b>	<b>474</b>	<b>461</b>
DME	LA							223	160	209	263
	NR								218	281	202
	<b>DME</b>								<b>378</b>	<b>490</b>	<b>465</b>
CDTM								41	41	42	
MAR								1,617	2,037	2,330	
SWP						58	78	126	38	46	
<b>TOTAL</b>									<b>21,405</b>	<b>22,865</b>	<b>23,191</b>

Louisiana Board of Pharmacy  
 Credentials Division  
 CDS Program

<i>Classification</i>	<u>06/30/08</u>	<u>06/30/09</u>	<u>06/30/10</u>	<u>06/30/11</u>	<u>06/30/12</u>	<u>06/30/13</u>	<u>06/30/14</u>	<u>11/06/14</u>
ACS Animal Control Shelter	0	0	1	1	1	1	1	1
AMS Automated Medication Sys	0	0	0	0	0	0	26	34
AMX Automated Medication Sys - Exempt	0	0	0	0	0	0	2	1
APN APRN	479	607	758	889	1,015	1,103	1,479	1,680
ASC Ambulatory Surgical Ctr	101	106	113	90	88	85	89	88
CRX Correctional Ctr - Exempt	0	0	0	7	6	5	6	6
DDS Dentist	2,177	2,267	2,363	2,027	2,048	1,902	2,123	2,112
DET Drug Detection / Canine	20	20	22	14	12	10	11	10
DEX Drug Detection / Canine - Exempt							1	1
DIS Distributor	322	363	400	279	288	273	324	330
DPM Podiatrist	153	161	165	139	136	118	133	133
DVM Veterinarian	936	1,000	1,065	922	901	852	1,002	1,025
DYS Dialysis Ctr	63	63	63	6	4	3	4	3
EMC Emergency Medical Ctr	17	17	18	14	16	17	22	22
EMS Emergency Medical Service	58	63	66	54	50	45	50	51
ETC Animal Euthanasia Tech - Cert	39	44	49	16	7	6	6	4
ETL Animal Euthanasia Tech - Lead	0	0	0	12	20	21	23	25
HOS Hospital	387	405	438	280	267	263	272	273
HOX Hospital - Exempt	0	0	0	12	14	5	6	7
LAB Laboratory	14	14	15	8	6	7	8	8
LAX Laboratory - Exempt	0	0	0	4	5	5	5	5
MD Physician	13,876	14,599	15,269	12,362	11,727	10,698	11,913	11,911
MDT Physician on Telemedicine	0	0	0	0	0	0	2	1
MED Medical Clinic	78	88	102	77	81	68	78	79
MEX Medical Clinic - Exempt	0	0	0	3	5	14	11	10
MFR Manufacturer	43	52	58	48	50	45	42	42
MIS Miscellaneous	73	58	59	11	10	9	11	11
MIX Miscellaneous - Exempt	0	0	0	9	4	3	2	2
MP Medical Psychologist	44	50	58	65	67	69	78	81
OD Optometrist	253	269	278	275	287	279	309	320
PA Physician Assistant	194	232	272	294	326	344	449	461
PHX Pharmacy - Exempt	0	0	0	50	47	41	30	28
PHY Pharmacy	0	0	0	1,307	1,318	1,329	1,357	1,367
REP Sales Representative	65	66	88	29	20	7	0	0
RES Researcher	110	119	156	109	110	98	113	108
RHC Rural Health Clinic	20	21	23	17	12	11	12	12
ROF Registered Outsourcing Facility	0	0	0	0	0	0	0	1
SAC Substance Abuse Clinic	14	14	17	7	9	9	9	9
SAX Subst. Abuse Clinc - Exempt	0	0	0	0	0	0	0	0
<b>Total</b>	<b>19,536</b>	<b>20,698</b>	<b>21,916</b>	<b>19,437</b>	<b>18,957</b>	<b>17,745</b>	<b>20,009</b>	<b>20,262</b>

Total Credentials Under Management

Pharmacy	16,407	16,601	17,818	18,260	18,625	21,405	22,865	23,191
CDS	<u>19,536</u>	<u>20,698</u>	<u>21,916</u>	<u>19,437</u>	<u>18,957</u>	<u>17,745</u>	<u>20,009</u>	<u>20,262</u>
<b>Total</b>	<b>35,943</b>	<b>37,299</b>	<b>39,734</b>	<b>37,697</b>	<b>37,582</b>	<b>39,150</b>	<b>42,874</b>	<b>43,453</b>

Louisiana Board of Pharmacy  
Census Report

<i>Type of Credential</i>	<u>3/17/1995</u>	<u>6/30/1996</u>	<u>3/19/1997</u>	<u>6/30/1998</u>	<u>6/30/1999</u>	<u>6/30/2000</u>	<u>6/30/2001</u>	<u>6/30/2002</u>	<u>6/30/2003</u>	<u>6/30/2004</u>	<u>6/30/2005</u>
Pharmacists											
In-state	3,642	3,660	4,143	4,247	4,269	4,830	3,887	4,386	4,435	4,486	4,532
Out-of-state	377	446	1,339	1,435	1,421	944	1,901	1,453	1,455	1,484	1,686
TOTAL	4,019	4,106	5,482	5,682	5,690	5,774	5,788	5,839	5,890	5,970	6,218
Pharmacy Interns											
In-state											
Out-of-state											
TOTAL							957	976	929	995	1,154
Pharmacy Technicians											
In-state											
Out-of-state											
TOTAL							3,216	3,453	3,505	4,114	4,455
Pharmacy Technician Candidates											
In-state											
Out-of-state											
TOTAL							2,896	2,372	1,336	1,069	1,074
Pharmacy Permits											
IR	651	634	636	609	621	585	584	576	573	633	729
RC	464	473	471	493	505	520	528	535	541	555	473
H	177	174	171	175	172	171	171	174	179	181	181
IN	46	45	38	39	19		17	18	19	27	36
NU	9	10	10	9	10		12	14	13	13	13
CH	4	4	4	7	4		8	9	11	12	12
PEN											
OS	122	152	168	175	216	223	262	313	353	339	200
PE	78	104	102	120	102			95	94	0	
CO	13	12	12	12	12		12	13	13	0	
TOTAL	1,564	1,608	1,612	1,639	1,668	1,663	1,717	1,771	1,818	1,760	1,644
Equipment Permits											
AMS							0	109	136	158	174
EDK							468	461	474	444	471

Louisiana Board of Pharmacy  
Census Report

<i>Type of Credential</i>	<u>6/30/2006</u>	<u>6/30/2007</u>	<u>6/30/2008</u>	<u>6/30/2009</u>	<u>6/30/2010</u>	<u>6/30/2011</u>	<u>6/30/2012</u>	<u>6/30/2013</u>	<u>6/30/2014</u>	<u>11/6/2014</u>
Pharmacists										
In-state	4,460	4,522	4,612	4,750	4,860	5,000	5,095	5,170	5,329	5,456
Out-of-state	1,915	1,975	1,964	2,029	2,098	2,179	2,258	2,588	2,542	2,657
TOTAL	6,375	6,497	6,576	6,779	6,958	7,179	7,353	7,758	7,871	8,113
Pharmacy Interns										
In-state	980	1,079	1,074	1,035	965	917	938	945	950	934
Out-of-state	109	117	67	84	153	137	128	128	131	143
TOTAL	1,089	1,196	1,141	1,119	1,118	1,054	1,066	1,073	1,081	1,077
Pharmacy Technicians										
In-state	4,552	4,587	4,780	4,733	5,363	5,722	5,509	5,752	6,463	6,296
Out-of-state	163	152	144	109	144	145	120	112	138	126
TOTAL	4,715	4,739	4,924	4,842	5,507	5,867	5,629	5,864	6,601	6,422
Pharmacy Technician Candidates										
In-state	1,081	1,389	1,446	1,510	1,679	1,574	1,665	1,658	1,870	1,843
Out-of-state	32	32	23	32	35	35	39	31	37	33
TOTAL	1,113	1,421	1,469	1,542	1,714	1,609	1,704	1,695	1,907	1,876
Pharmacy Permits										
IR	681	620	588	592	587	591	587	575	583	596
RC	430	491	534	545	562	576	587	597	619	627
H	167	164	167	167	165	170	172	172	175	177
IN	35	36	37	37	27	25	24	25	23	22
NU	17	16	16	16	16	15	15	15	15	14
CH	12	12	11	12	14	12	12	12	12	12
PEN								1	2	2
NR	226	240	250	256	286	318	361	387	432	453
TOTAL	1,568	1,579	1,603	1,625	1,657	1,707	1,758	1,784	1,861	1,903
Equipment Permits										
AMS	173	212	255	306	361	356	366	638	451	454
EDK	428	412	439	388	503	430	448	431	474	461
DME							223	378	490	465
Special Activity								41	41	42
CDTM										
MAR								1,617	2,037	2,330
Special Work Permit						58	78	126	38	46

Louisiana Board of Pharmacy  
CDS Program - Census Report

<i>Classification</i>	<u>6/30/2007</u>	<u>6/30/2008</u>	<u>6/30/2009</u>	<u>6/30/2010</u>	<u>6/30/2011</u>	<u>6/30/2012</u>	<u>6/30/2013</u>	<u>6/30/2014</u>	<u>11/6/2014</u>
ACS Animal Control Shelter	0	0	0	1	1	1	1	1	1
AMS Automated Medication System	0	0	0	0	0	0	0	28	35
APN Advanced Practice Registered Nurse	346	479	607	758	889	1,015	1,103	1,479	1,680
ASC Ambulatory Surgical Center	94	101	106	113	90	88	85	89	88
CRX Correctional Center	0	0	0	0	7	6	5	6	6
DDS Dentist	2,090	2,177	2,267	2,363	2,027	2,048	1,902	2,123	2,112
DET Drug Detection Canine	20	20	20	22	14	12	10	11	11
DIS Distributor	285	322	363	400	279	288	273	324	330
DPM Podiatrist	147	153	161	165	139	136	118	133	133
DVM Veterinarian	870	936	1,000	1,065	922	901	852	1,002	1,025
DYS Dialysis Center	63	63	63	63	6	4	3	4	3
EMC Emergency Medical Center	17	17	17	18	14	16	17	22	22
EMS Emergency Medical Service	57	58	63	66	54	50	45	50	51
ETC Animal Euthanasia Tech - Cert	31	39	44	49	28	27	27	29	29
HOS Hospital	369	387	405	438	292	281	268	278	280
LAB Analytical Laboratory	13	14	14	15	12	11	12	13	13
MD Physician	13,195	13,876	14,599	15,269	12,362	11,727	10,698	11,913	11,911
MDT Physician on Telemedicine	0	0	0	0	0	0	0	2	1
MED Medical Clinic	73	78	88	102	80	86	82	89	89
MFR Manufacturer	36	43	52	58	48	50	45	42	42
MIS Other	74	73	58	59	20	14	12	13	13
MP Medical Psychologist	37	44	50	58	65	67	69	78	81
OD Optometrist	230	253	269	278	275	287	279	309	320
PA Physician's Assistant	170	194	232	272	294	326	344	449	461
PHY Pharmacy	0	0	0	0	1357	1,365	1,370	1,387	1,395
REP Sales Representative	57	65	66	88	29	20	7	0	0
RES Researcher	100	110	119	156	109	110	98	113	108
RHC Rural Health Clinic	19	20	21	23	17	12	11	12	12
ROF Registered Outsourcing Facility	0	0	0	0	0	0	0	0	1
SAC Substance Abuse Clinic	<u>14</u>	<u>14</u>	<u>14</u>	<u>17</u>	<u>7</u>	<u>9</u>	<u>9</u>	<u>9</u>	<u>9</u>
<b>TOTAL</b>	<b>18,407</b>	<b>19,502</b>	<b>20,663</b>	<b>21,916</b>	<b>19,437</b>	<b>18,957</b>	<b>17,745</b>	<b>20,009</b>	<b>20,262</b>
Total Credentials Under Board Management									
Pharmacy Program	16,056	16,407	16,601	17,818	18,260	18,625	21,405	22,865	23191
CDS Program	<u>18,407</u>	<u>19,536</u>	<u>20,698</u>	<u>21,916</u>	<u>19,437</u>	<u>18,957</u>	<u>17,745</u>	<u>20,009</u>	<u>20262</u>
<b>TOTAL</b>	<b>34,463</b>	<b>35,943</b>	<b>37,299</b>	<b>39,734</b>	<b>37,697</b>	<b>37,582</b>	<b>39,150</b>	<b>42,874</b>	<b>43,453</b>

**New Credentials Issued  
3rd Quarter 2014  
July 1, 2014 - September 30, 2014**

Prefix	Subcategory	CredentialType	Total
AMS		Automated Medication System	19
AMS	X	Automated Medication System - Exempt	9
<b>Prefix Totals</b>			<b>28</b>
CDS	AMS	CDS License - Automated Medication System	14
CDS	APN	CDS License - APRN	173
CDS	DDS	CDS License - Dentist	16
CDS	DIS	CDS License - Distributor	7
CDS	DVM	CDS License - Veterinarian	40
CDS	ETL	CDS License - Animal Euthanasia Technician, Lead (AET-L)	3
CDS	HOS	CDS License - Hospital	6
CDS	HOX	CDS License - Hospital - Exempt	1
CDS	MD	CDS License - Physician	247
CDS	MED	CDS License - Medical Clinic	2
CDS	MFR	CDS License - Manufacturer	2
CDS	MP	CDS License - Medical Psychologist	3
CDS	OD	CDS License - Optometrist	12
CDS	PA	CDS License - Physician Assistant	21
CDS	PHY	CDS License - Pharmacy	22
CDS	RES	CDS License - Researcher	1
CDS	ROF	CDS License - Registered Outsourcing Facility	1
<b>Prefix Totals</b>			<b>571</b>
CDTM		Collaborative Drug Therapy Management (V)	1
CPT		Certified Pharmacy Technician	212
DME		Durable Medical Equipment (DME) Provider	29
EDK		Emergency Drug Kit	24
MA		Medication Administration (V)	151
PHY	HOS	Pharmacy - Hospital Inpatient	2
PHY	HOX	Pharmacy - Hospital Inpatient - Exempt	1
PHY	IR	Pharmacy - Community ~ Independent	15
PHY	NR	Pharmacy - Nonresident	21
PHY	NU	Pharmacy - Nuclear	1
PHY	RC	Pharmacy - Community ~ Chain	7
<b>Prefix Totals</b>			<b>47</b>
PIC		Pharmacist-in-Charge (V)	18
PMP	CDS	PMP - CDS Credential	368
PMP	PST	PMP - Pharmacist	151
<b>Prefix Totals</b>			<b>519</b>
PNT		Pharmacy Intern	97
PST		Pharmacist	195
PTC		Pharmacy Technician Candidate	337
SWP		Special Work Permit	18
<b>Grand Totals</b>			<b>2247</b>





# Louisiana Board of Pharmacy

3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ Facsimile 225.925.6499  
[www.pharmacy.la.gov](http://www.pharmacy.la.gov) ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



November 13, 2014

## Agenda Item 11-L: Report of Executive Director

### Section 2.C – Exceptions Report

#### 1. PIC at Multiple Pharmacies

Board Policy I.A.4 permits the Executive Director to approve requests from pharmacists wishing to serve as the Pharmacist-in-Charge (PIC) of more than one pharmacy at the same time. The policy requires the concurrence of the President, as well as notice to the Board at its next meeting. As authorized by the President, the Executive Director has delegated this authority to the General Counsel and the Assistant Executive Director.

*[None since last Board meeting]*

#### 2. Special Work Permits for military-trained applicants and their spouses

LAC Title 46: LIII §904 authorizes the Board to provide preferential licensing procedures for military-trained applicants and their spouses. As authorized by the President, the Executive Director has delegated this authority to the General Counsel and the Assistant Executive Director.

*[None since last Board meeting]*

#### 3. Special Work Permits

Board Policy I.A.7 permits the Executive Director to issue Special Work Permits to document the resurrection of expired non-renewable credentials and for other purposes as authorized by the Board. The policy requires the concurrence of the President, as well as notice to the Board at its next meeting. As authorized by the President, the Executive Director has delegated this authority to the General Counsel and the Assistant Executive Director.

- On July 29, 2014, Mr. Aron and Mr. Finalet concurred to grant a request of Deondra Sharae Skinner. She had previously obtained PTC.016907 which expired on April 25, 2012. Should she pass the PTCB by March 1, 2015, she is authorized to receive a special work permit to earn 600 hours of practical experience.
- On July 29, 2014, Mr. Aron and Mr. Finalet concurred to grant a request of Robbie Markel Antoine. She had previously obtained PTC.013787 which expired on October 1, 2009. She is PTCB-certified. She was issued a special work permit on March 7, 2013 but failed to earn the necessary hours under that credential by the expiration date of March 7, 2014. She was issued another special work permit to earn 600 hours of practical experience. This will be her last opportunity to do so.
- On August 11, 2014, Mr. Aron and Mr. Finalet concurred to grant a request of Laneadria Shawn'ta Fredrick. She had previously obtained PTC.018685 which expired on October 2, 2013. Should she pass the PTCB by April 1, 2015, she is authorized to receive a special work permit to earn 600 hours of practical experience.
- On August 15, 2014, Mr. Aron and Mr. Finalet concurred to grant a request of Darcel Ann Laurent. She had previously obtained PTC.011006 which expired on October 24, 2006. Should she pass the PTCB by April 1, 2015, she is authorized to receive a special work permit to earn 600 hours of practical experience.
- On August 19, 2014, Mr. Aron and Mr. Finalet concurred to grant a request of Shalon Loviel Carson. She had previously obtained PTC.017798 which expired on February 10, 2013. Should she pass the PTCB by April 1, 2015, she is authorized to receive a special

- work permit to earn 600 hours of practical experience.
- On August 19, 2014, Mr. Aron and Mr. Finalet concurred to grant a request of Detra Danyell Thomas. She had previously obtained PTC.018737 which expired on October 16, 2013. Should she pass the PTCB by April 1, 2015, she is authorized to receive a special work permit to earn 600 hours of practical experience.
  - On August 25, 2014, Mr. Aron and Mr. Finalet concurred to grant a request of Jeffery Tate Jones. He had previously obtained PTC.019305 which expired on April 1, 2014. He passed the PTCB and was issued a special work permit to earn 600 hours of practical experience.
  - On August 25, 2014, Mr. Aron and Mr. Finalet concurred to grant a request of Rosalind Lynell Green. She had previously obtained PTC.015453 which expired on February 17, 2011. Should she pass the PTCB by April 1, 2015, she is authorized to receive a special work permit to earn 600 hours of practical experience.
  - On August 28, 2014, Mr. Aron and Mr. Finalet concurred to grant a request of Amanda Marie Triche. She had previously obtained PTC.018654 which expired on September 27, 2013. Should she pass the PTCB by April 1, 2015, she is authorized to receive a special work permit to earn 600 hours of practical experience.
  - On August 28, 2014, Mr. Aron and Mr. Finalet concurred to grant a request of Kanicia Elnora Barnes. She had previously obtained PTC.012983 which expired on January 5, 2009. Should she pass the PTCB by April 1, 2015, she is authorized to receive a special work permit to earn 600 hours of practical experience.
  - On August 29, 2014, Mr. Aron and Mr. Finalet concurred to grant a request of Cheryl Ann Hebert. She had previously obtained PTC.017624 which expired on December 1, 2012. Should she pass the PTCB by April 1, 2015, she is authorized to receive a special work permit to earn 600 hours of practical experience.
  - On September 2, 2014, Mr. Aron and Mr. Finalet concurred to grant a request of Cureston Nickole Gary. She had previously obtained PTC.018168 which expired on May 9, 2013. She passed the PTCB and was issued a special work permit to earn 600 hours of practical experience.
  - On September 17, 2014, Mr. Aron and Mr. Finalet concurred to grant a request of Keangel Peaches Moore. She had previously obtained PTC.015932 which expired on July 19, 2011. Should she pass the PTCB by May 1, 2015, she is authorized to receive a special work permit to earn 600 hours of practical experience.
  - On September 17, 2014, Mr. Aron and Mr. Finalet concurred to grant a request of Elizabeth Ashley Ford. She had previously obtained PTC.018447 which expired on July 31, 2013. She passed the PTCB and was issued a special work permit to earn 600 hours of practical experience.
  - On September 17, 2014, Mr. Aron and Mr. Finalet concurred to grant a request of Brittney Antwonette Pleasant. She had previously obtained PTC.016068 which expired on August 22, 2011. Should she pass the PTCB by May 1, 2015, she is authorized to receive a special work permit to earn 600 hours of practical experience.
  - On September 19, 2014, Mr. Aron and Mr. Finalet concurred to grant a request of Tinisha Shaunette Hawkins. She had previously obtained PTC.018788 which expired on October 27, 2013. Should she pass the PTCB by May 1, 2015, she is authorized to receive a special work permit to earn 600 hours of practical experience.
  - On September 29, 2014, Mr. Aron and Mr. Finalet concurred to grant a request of Marlanna Cathleen Cimino. She had previously obtained PTC.01 which expired on September 19, 2014. Should she pass the PTCB by May 1, 2015, she is authorized to receive a special work permit to earn any remaining hours of practical experience towards the required 600 hours.
  - On September 29, 2014, Mr. Aron and Mr. Finalet concurred to grant a request of Marva Letonia Sege. She had previously obtained PTC.018915 which expired on December 4, 2013. Should she pass the PTCB by May 1, 2015, she is authorized to receive a special work permit to earn 600 hours of practical experience.
  - On October 3, 2014, Mr. Aron and Mr. Finalet concurred to grant a request of Ivaion Nichelle Taylor. She had previously obtained PTC.014505 which expired on April 21, 2010. Should she pass the PTCB by June 1, 2015, she is authorized to receive a special work permit to earn 600 hours of practical experience.

- On October 3, 2014, Mr. Aron and Mr. Finalet concurred to grant a request of Leonel Francisco Medina. He had previously obtained PTC.014271 which expired on February 26, 2010. He is PTCB-certified and was issued a special work permit to earn 600 hours of practical experience.
- On October 3, 2014, Mr. Aron and Mr. Finalet concurred to grant a request of Alexis Shanea Ransom. She had previously obtained PTC.017978 which expired on March 22, 2013. She is PTCB-certified and was previously issued a special work permit to earn 600 hours of practical experience but failed to do so by the deadline given. Mr. Aron has allowed for one last chance for her to earn those hours under another special work permit.
- On October 3, 2014, Mr. Aron and Mr. Finalet concurred to grant a request of Christy LaToya Sylvester. She had previously obtained PTC.014997 which expired on October 13, 2010. Should she pass the PTCB by June 1, 2015, she is authorized to receive a special work permit to earn 600 hours of practical experience.
- On October 8, 2014, Mr. Aron and Mr. Finalet concurred to grant a request of Rochelle Di'Shonne Cureaux. She had previously obtained PTC.015947 which expired on June 25, 2011. Should she pass the PTCB by June 1, 2015, she is authorized to receive a special work permit to earn 600 hours of practical experience.
- On October 9, 2014, Mr. Aron and Mr. Finalet concurred to grant a request of Terrell Perrier, Sr. He had previously obtained PTC.014119 which expired on January 7, 2010. He is PTCB-certified and was issued a special work permit to earn 600 hours of practical experience.
- On October 14, 2014, Mr. Aron and Mr. Finalet concurred to grant a request of LaToya Nicole Rideaux. She had previously obtained PTC.013535 which expired on June 9, 2009. Should she pass the PTCB by June 1, 2015, she is authorized to receive a special work permit to earn 600 hours of practical experience.
- On October 17, 2014, Mr. Aron and Mr. Finalet concurred to grant a request of Alexis R'shea Jackson. She had previously obtained PTC.016958 which expired on May 1, 2012. Should she pass the PTCB by June 1, 2015, she is authorized to receive a special work permit to earn 600 hours of practical experience.
- On October 17, 2014, Mr. Aron and Mr. Finalet concurred to grant a request of Michael Jermaine Griffin. He had previously obtained PTC.012736 which expired on September 18, 2008. He is PTCB-certified and was issued a special work permit to earn 600 hours of practical experience.
- On October 21, 2014, Mr. Aron and Mr. Finalet concurred to grant a request of Daraneike Debanire Williams. She had previously obtained PTC.019439 which expired on May 20, 2014. Should she pass the PTCB by June 1, 2015, she is authorized to receive a special work permit to earn 600 hours of practical experience.
- On October 21, 2014, Mr. Aron and Mr. Finalet concurred to grant a request of Adellah Hani Abdulwahab. She had previously obtained PTC.018015 which expired on April 4, 2013. Should she pass the PTCB by June 1, 2015, she is authorized to receive a special work permit to earn 600 hours of practical experience.
- On October 31, 2014, Mr. Aron and Mr. Finalet concurred to grant a request of Brittney Nicole Collins. She had previously obtained PTC.018867 which expired on November 21, 2013. Should she pass the PTCB by June 1, 2015, she is authorized to receive a special work permit to earn 600 hours of practical experience.



# Louisiana Board of Pharmacy

3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ Facsimile 225.925.6499  
[www.pharmacy.la.gov](http://www.pharmacy.la.gov) ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



## Multistate Pharmacy Jurisprudence Examination (MPJE™)

May 1 – August 31, 2014

School Reports  
Interpretation of Scores  
Frequency Distribution of Scaled Scores  
Cumulative Record (since January 2000)


November 13, 2014

## **Multistate Pharmacy Jurisprudence Examination (MPJE™)**

This computer adaptive competency assessment is administered by the National Association of Boards of Pharmacy (NABP). The examination blueprint is designed to assess the applicant's competency in federal and state laws relative to pharmacy practice and is therefore specific for a given state. The examination is administered via an open window process; applicants may schedule the examination at a local testing center at any time following approval by the state board and receipt of an Authorization to Test (ATT) document from NABP. Individual scores are available to applicants via secure web posting approximately 7-10 days following the examination. Summary reports are provided to the state boards on a calendar trimester basis.

### *Table of Contents*

Current Trimester Report for ULM School of Pharmacy	03
Cumulative Report (since January 2000) for ULM School of Pharmacy	11
Current Trimester Report for Xavier College of Pharmacy	15
Cumulative Report (since January 2000) for Xavier College of Pharmacy	25



**Multistate Pharmacy Jurisprudence Examination® (MPJE) ®  
School Summary Report**

**Test Window:** May 1, 2014 - August 31, 2014

**School Name:** University Louisiana Monroe

This MPJE score report consists of two levels of scores: school-aggregated scores and individual candidate scores. Summary information is provided separately for first-time examinees from ACPE schools/colleges and for all examinees, regardless of repeater status and/or the educational institution. Tables 1 and 2 contain school-specific as well as national pass rate information.

**Table 1 First Time Candidates**

School 1: Examinees testing in same state as respective college

School 2: Examinees testing in different states than respective college

	Candidates	Pass Rate %	Total Scaled Score Mean	Standard Deviation
School 1	62	95.16	81.44	4.74
School 2	57	98.25	83.58	5.10
State	252	89.29	80.62	5.25
National	15660	94.34	82.80	5.35

Candidates who did not answer enough questions to receive a score are reflected in pass rate data as a fail but are not included in mean scaled score data.

**Table 2 All Candidates**

	Candidates	Pass Rate %	Total Scaled Score Mean	Standard Deviation
School 1	62	95.16	81.44	4.74
School 2	60	96.67	83.32	5.20
State	273	86.08	80.18	5.47
National	16690	93.28	82.52	5.45

Candidates who did not answer enough questions to receive a score are reflected in pass rate data as a fail but are not included in mean scaled score data.

### Table 3 Candidate Summary Report

**Test Window:** May 1, 2014 - August 31, 2014

	Pass/Fail	Total Scaled Score	Test Date	Graduation Date	First Attempt	State
1	Fail	73	08/26/2014	05/10/2014	Y	LA
2	Pass	75	08/21/2014	05/10/2014	Y	LA
3	Pass	77	08/21/2014	05/10/2014	Y	LA
4	Pass	78	08/21/2014	05/10/2014	Y	LA
5	Pass	79	08/19/2014	05/10/2014	Y	LA
6	Pass	80	08/15/2014	05/10/2014	Y	LA
7	Pass	75	08/11/2014	05/10/2014	Y	GA
8	Pass	78	08/11/2014	05/10/2014	Y	LA
9	Pass	76	08/11/2014	05/10/2014	Y	LA
10	Pass	79	08/09/2014	05/10/2014	Y	LA
11	Pass	78	08/08/2014	05/10/2014	Y	TX
12	Pass	86	08/07/2014	05/10/2014	Y	LA
13	Pass	88	08/07/2014	05/10/2014	Y	LA
14	Fail	74	08/04/2014	05/10/2014	Y	LA
15	Pass	80	08/04/2014	05/10/2014	Y	LA
16	Pass	77	08/04/2014	05/10/2014	Y	LA
17	Pass	89	08/04/2014	05/10/2014	Y	LA
18	Pass	77	07/31/2014	05/10/2014	Y	MS
19	Pass	78	07/31/2014	05/10/2014	Y	LA
20	Pass	77	07/30/2014	05/10/2014	Y	LA
21	Pass	87	07/29/2014	05/10/2014	Y	LA
22	Pass	79	07/28/2014	05/10/2014	Y	LA
23	Pass	81	07/28/2014	05/10/2014	Y	LA
24	Pass	83	07/28/2014	05/10/2014	Y	LA
25	Pass	78	07/28/2014	05/10/2014	Y	LA
26	Pass	76	07/26/2014	05/10/2014	Y	GA
27	Pass	84	07/23/2014	05/10/2014	Y	MS
28	Pass	92	07/23/2014	05/10/2014	Y	TX
29	Pass	83	07/21/2014	05/10/2014	Y	LA
30	Pass	82	07/21/2014	05/10/2014	Y	LA
31	Pass	92	07/21/2014	05/10/2014	Y	LA
32	Pass	77	07/21/2014	05/10/2014	Y	LA
33	Pass	84	07/19/2014	05/10/2014	Y	LA
34	Pass	83	07/18/2014	05/10/2014	Y	TX
35	Pass	82	07/18/2014	05/10/2014	Y	LA
36	Pass	86	07/18/2014	05/10/2014	Y	TX
37	Pass	77	07/18/2014	05/10/2014	Y	AL
38	Pass	80	07/17/2014	05/10/2014	Y	LA
39	Pass	87	07/15/2014	05/10/2014	Y	TX
40	Pass	79	07/14/2014	05/10/2014	Y	LA
41	Pass	85	07/12/2014	05/10/2014	Y	LA
42	Fail	73	07/12/2014	05/10/2014	Y	LA
43	Pass	82	07/09/2014	05/10/2014	Y	LA
44	Pass	86	07/07/2014	05/10/2014	Y	LA

**Table 3 Candidate Summary Report**

	<b>Pass/Fail</b>	<b>Total Scaled Score</b>	<b>Test Date</b>	<b>Graduation Date</b>	<b>First Attempt</b>	<b>State</b>
45	Pass	79	07/05/2014	05/10/2014	Y	LA
46	Pass	86	07/02/2014	05/10/2014	Y	LA
47	Pass	87	07/02/2014	05/10/2014	Y	LA
48	Pass	89	07/02/2014	05/10/2014	Y	TX
49	Pass	80	07/02/2014	05/10/2014	Y	LA
50	Pass	94	07/01/2014	05/10/2014	Y	TX
51	Pass	80	06/28/2014	05/10/2014	Y	LA
52	Pass	81	06/28/2014	05/10/2014	Y	LA
53	Pass	92	06/26/2014	05/10/2014	Y	LA
54	Pass	83	06/25/2014	05/10/2014	Y	LA
55	Pass	86	06/25/2014	05/10/2014	Y	LA
56	Pass	81	06/24/2014	05/10/2014	Y	LA
57	Pass	80	06/23/2014	05/10/2014	Y	LA
58	Pass	86	06/21/2014	05/10/2014	Y	LA
59	Pass	80	06/20/2014	05/10/2014	Y	LA
60	Pass	81	06/19/2014	05/10/2014	Y	LA
61	Pass	91	06/14/2014	05/10/2014	Y	LA
62	Pass	88	06/14/2014	05/10/2014	Y	MD
63	Pass	89	06/14/2014	05/10/2014	Y	MD
64	Pass	83	06/14/2014	05/10/2014	Y	LA
65	Pass	76	06/13/2014	05/10/2014	Y	LA
66	Pass	88	06/13/2014	05/10/2014	Y	LA
67	Pass	88	06/11/2014	05/10/2014	Y	UT
68	Pass	88	06/10/2014	05/10/2014	Y	LA
69	Pass	83	06/07/2014	05/10/2014	Y	TX
70	Pass	83	06/03/2014	05/10/2014	Y	LA
71	Pass	88	08/04/2014	05/05/2014	Y	LA
72	Pass	87	08/19/2014	05/11/2013	Y	LA
73	Pass	80	06/26/2014	05/11/2013	Y	AL
74	Pass	88	06/24/2014	05/11/2013	Y	TX
75	Pass	83	06/26/2014	05/19/2012	Y	MO
76	Pass	87	06/04/2014	05/19/2012	Y	MD
77	Pass	75	05/20/2014	05/19/2012	Y	LA
78	Pass	76	05/17/2014	05/19/2012	Y	LA
79	Pass	94	06/03/2014	05/22/2010	Y	TX
80	Pass	84	06/03/2014	05/22/2010	Y	TX
81	Pass	76	07/10/2014	05/17/2008	Y	MS
82	Pass	78	06/05/2014	05/17/2008	Y	LA
83	Pass	81	08/21/2014	05/19/2007	N	MS
84	Pass	75	05/14/2014	05/19/2007	Y	LA
85	Pass	93	06/10/2014	05/21/2003	Y	CO
86	Pass	77	08/15/2014	12/01/2000	Y	AL
87	Pass	78	07/02/2014	12/01/2000	Y	WV
88	Pass	82	08/13/2014	12/01/1999	Y	LA

**Table 3 Candidate Summary Report**

	<b>Pass/Fail</b>	<b>Total Scaled Score</b>	<b>Test Date</b>	<b>Graduation Date</b>	<b>First Attempt</b>	<b>State</b>
89	Pass	83	07/10/2014	12/19/1998	Y	SC
90	Pass	81	08/11/2014	12/01/1998	Y	MD
91	Pass	81	07/18/2014	12/13/1997	Y	WV
92	Pass	80	07/24/2014	12/25/1996	Y	MI
93	Pass	81	07/09/2014	05/18/1996	Y	FL
94	Pass	84	08/07/2014	08/16/1995	Y	WV
95	Pass	82	06/11/2014	05/25/1995	N	MT
96	Pass	86	08/20/2014	08/14/1993	Y	KY
97	Pass	87	08/18/2014	08/14/1993	Y	NE
98	Pass	81	08/15/2014	08/14/1993	Y	MD
99	Pass	84	08/11/2014	08/14/1993	Y	TN
100	Pass	82	08/09/2014	08/14/1993	Y	AZ
101	Pass	85	08/05/2014	08/14/1993	Y	OR
102	Pass	87	07/14/2014	08/14/1993	Y	WV
103	Pass	78	06/21/2014	05/29/1993	Y	TN
104	Pass	91	05/19/2014	05/29/1993	Y	MS
105	Pass	84	08/27/2014	12/19/1992	Y	WV
106	Pass	76	08/11/2014	12/19/1992	Y	MS
107	Pass	81	08/04/2014	12/19/1992	Y	TN
108	Pass	81	07/18/2014	12/19/1992	Y	OR
109	Pass	86	07/02/2014	12/19/1992	Y	AZ
110	Pass	88	06/30/2014	12/21/1991	Y	KS
111	Pass	90	08/07/2014	12/17/1988	Y	SC
112	Pass	77	05/09/2014	08/08/1988	Y	GA
113	Pass	80	08/11/2014	08/19/1984	Y	LA
114	Pass	84	08/05/2014	08/17/1984	Y	AL
115	Pass	84	07/09/2014	08/17/1984	Y	WV
116	Pass	83	06/13/2014	05/18/1984	Y	MS
117	Pass	79	07/30/2014	05/14/1982	Y	OK
118	Fail	72	05/07/2014	05/14/1982	N	MT
119	Pass	88	07/18/2014	12/17/1977	Y	AL
120	Pass	90	05/29/2014	12/17/1977	Y	WV
121	Pass	83	08/21/2014	12/13/1975	Y	WA
122	Fail	73	05/20/2014	12/01/1974	Y	TN

**National Statistics for All Candidates**

**Mean Scaled Score: 82.52**  
**Standard Deviation: 5.45**  
**Range: 57 - 100**  
**Passing Rate (%): 93.28**

**National Statistics for First-Time Candidates**

**Mean Scaled Score: 82.80**  
**Standard Deviation: 5.35**  
**Range: 57 - 100**  
**Passing Rate (%): 94.34**

The following tables are scaled score frequency distributions for MPJE® candidates.

Candidates who did not answer enough questions to receive a score are not reflected in the frequency distributions.

**Table 4 National Frequency Distribution of Scaled Scores  
Based on Total Tests Administered (N = 16690 )**

**Test Window: May 1, 2014 - August 31, 2014**

Scaled Score	Frequency	Cumulative Percent of the Upper Limit of the Interval
0 - 4	0	0.0%
5 - 9	0	0.0%
10 - 14	0	0.0%
15 - 19	0	0.0%
20 - 24	0	0.0%
25 - 29	0	0.0%
30 - 34	0	0.0%
35 - 39	0	0.0%
40 - 44	0	0.0%
45 - 49	0	0.0%
50 - 54	0	0.0%
55 - 59	3	0.0%
60 - 64	21	0.1%
65 - 69	137	1.0%
70 - 74	959	6.7%
75 - 79	3657	28.6%
80 - 84	5998	64.6%
85 - 89	4280	90.2%
90 - 94	1393	98.6%
95 - 100	241	100.0%

**Table 5 National Frequency Distribution of Scaled Scores  
Based on First-Time Candidates from ACPE-Accredited Programs (N = 15660 )**

**Test Window: May 1, 2014 - August 31, 2014**

Scaled Score	Frequency	Cumulative Percent of the Upper Limit of the Interval
0 - 4	0	0.0%
5 - 9	0	0.0%
10 - 14	0	0.0%
15 - 19	0	0.0%
20 - 24	0	0.0%
25 - 29	0	0.0%
30 - 34	0	0.0%
35 - 39	0	0.0%
40 - 44	0	0.0%
45 - 49	0	0.0%
50 - 54	0	0.0%
55 - 59	3	0.0%
60 - 64	19	0.1%
65 - 69	116	0.9%
70 - 74	830	6.1%
75 - 79	3399	27.3%
80 - 84	5793	63.6%
85 - 89	4199	89.8%
90 - 94	1387	98.5%
95 - 100	241	100.0%

**Multistate Pharmacy Jurisprudence Examination (MPJE)**

**University of Louisiana at Monroe**

	<b>2000</b>		<b>2001</b>		<b>2002</b>		<b>2003</b>	
	<u>Jan - Jun</u>	<u>Jul - Dec</u>						
<b>TOTAL CANDIDATE GROUP</b>								
No. of Candidates	125	82	100	57	59	123	77	119
School Average Score:	83.27	82.76	80.84	81.37	80.17	80.41	78.57	80.04
State Average Score:	81.64	80.49	80.64	80.32	80.34	79.41	77.32	78.87
National Average Score:	82.24	81.75	82.25	81.51	90.78	79.85	79.92	79.33
School Pass Rate:	94.40	91.46	90.00	91.23	88.14	88.62	77.92	88.24
State Pass Rate:	89.89	86.25	87.84	90.00	92.00	85.98	72.88	84.67
National Pass Rate:	91.37	90.50	91.22	90.54	90.78	84.93	84.52	82.61
<b>FIRST-TIME CANDIDATE GROUP</b>								
No. of Candidates	117	78	92	51	55	111	59	110
School Average Score:	83.67	83.14	80.89	81.78	80.22	80.58	79.31	80.22
State Average Score:	82.14	80.97	80.67	80.51	80.30	79.41	77.69	79.23
National Average Score:	82.55	82.05	82.59	81.86	82.08	80.19	80.34	79.76
School Pass Rate:	96.58	93.59	90.22	90.20	89.09	88.29	81.36	88.18
State Pass Rate:	92.59	87.32	88.06	89.77	91.49	86.32	75.00	86.55
National Pass Rate:	92.57	91.37	92.45	91.75	92.15	86.45	86.58	84.67

**Multistate Pharmacy Jurisprudence Examination (MPJE)**

**University of Louisiana at Monroe**

	<b>2004</b>		<b>2005</b>		<b>2006</b>		<b>2007</b>	
	<u>Jan - Jun</u>	<u>Jul - Dec</u>						
<b>TOTAL CANDIDATE GROUP</b>								
No. of Candidates	62	110	59	146	68	111	50	151
School Average Score:	79.39	80.79	79.25	80.50	80.43	81.92	80.20	81.62
State Average Score:	78.58	80.03	80.50	80.03	80.01	81.34	80.15	81.47
National Average Score:	80.10	79.83	80.39	80.04	80.68	80.42	81.26	81.14
School Pass Rate:	91.94	91.82	89.83	87.67	88.24	92.79	90.00	92.05
State Pass Rate:	86.90	92.55	90.55	87.03	91.09	92.39	87.18	90.39
National Pass Rate:	85.63	84.75	86.57	85.69	87.25	87.82	89.38	89.78
<b>FIRST-TIME CANDIDATE GROUP</b>								
No. of Candidates	52	104	55	132	60	102	43	140
School Average Score:	79.73	80.96	79.33	80.66	80.80	82.14	81.05	81.83
State Average Score:	79.04	80.11	80.71	80.29	80.24	81.52	80.59	81.84
National Average Score:	80.58	80.25	80.80	80.44	81.09	80.80	81.72	81.51
School Pass Rate:	92.31	92.31	89.09	87.12	91.67	94.12	95.35	93.57
State Pass Rate:	90.14	92.53	91.38	88.69	92.31	93.53	91.18	92.49
National Pass Rate:	88.16	86.87	88.51	87.51	89.41	89.34	91.43	91.24

**Multistate Pharmacy Jurisprudence Examination (MPJE)**


**University of Louisiana at Monroe**

	<b>2008</b>		<b>2009</b>			<b>2010</b>			<b>2011</b>		
	<u>Jan - Jun</u>	<u>Jul - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>
<b>TOTAL CANDIDATE GROUP</b>											
No. of Candidates	61	137	42	120	36	38	104	35	5	71	12
Mean Scaled Score - School	81.26	81.99	80.95	82.58	80.75	81.47	82.14	81.89	82.60	82.73	83.83
Mean Scaled Score - State	81.33	81.34	79.57	81.69	80.35	81.37	80.88	81.64		81.01	80.41
Mean Scaled Score - National	81.59	81.27	80.29	82.39	80.25	80.45	82.51	80.57	80.27	82.23	80.46
School Pass Rate:	96.72	91.97	88.10	95.00	86.11	94.74	90.38	91.43	100.00	97.18	100.00
State Pass Rate:	91.75	91.05	81.03	94.52	85.92	90.00	92.64	95.79		89.91	90.99
National Pass Rate:	90.31	89.92	86.23	93.74	87.04	89.09	94.83	89.35	86.43	92.17	86.24
<b>FIRST-TIME CANDIDATE GROUP</b>											
No. of Candidates	58	127	37	117	34	34	96	30	5	66	11
Mean Scaled Score - School	81.52	82.13	81.30	82.56	81.09	82.12	82.67	82.33	82.60	83.08	84.18
Mean Scaled Score - State	81.53	81.62	79.69	81.76	80.98	82.07	80.93	82.07		81.52	81.14
Mean Scaled Score - National	81.97	81.57	80.75	82.58	80.63	80.82	82.67	80.94	81.17	82.86	81.76
School Pass Rate:	96.55	91.34	89.19	94.87	88.24	97.06	93.75	93.33	100.00	100.00	100.00
State Pass Rate:	92.31	91.95	80.77	94.34	89.66	93.44	92.92	97.56		94.06	94.32
National Pass Rate:	91.82	91.16	88.45	94.30	88.68	90.64	95.50	90.79	92.24	96.05	94.00

**Multistate Pharmacy Jurisprudence Examination (MPJE)**

**University of Louisiana at Monroe**

	<b>2012</b>			<b>2013</b>			<b>2014</b>			<b>2015</b>		
	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>
<b>TOTAL CANDIDATE GROUP</b>												
No. of Candidates	4	126	87	47	94	30	32	122				
<i>* testing in same/different state</i>		72 / 54	11 / 34	11 / 36	40 / 54	2 / 28	5 / 27	62 / 60				
Mean Scale Score - School *	82.25	82.44/82.70	80.09/79.85	81.45/84.03	82.50/82.59	80.50/82.79	79.40/81.41	81.44/83.32				
<i>* testing in same/different state</i>												
Mean Scaled Score - State	81.18	80.91	79.62	81.33	80.82	80.43	80.36	80.18				
Mean Scaled Score - National	80.41	82.43	80.55	80.92	82.50	80.52	81.04	82.52				
School Pass Rate: *	100.00	97.22/90.74	90.91/85.29	100/97.22	95.00/98.15	100 / 92.86	100 / 85.19	95.16/96.67				
<i>* testing in same/different state</i>												
State Pass Rate:	90.41	90.69	81.61	93.98	90.51	85.21	82.52	86.08				
National Pass Rate:	84.54	92.76	86.85	87.18	92.98	87.01	87.62	93.28				
<b>FIRST-TIME CANDIDATE GROUP</b>												
No. of Candidates	4	124	70	44	93	28	29	119				
<i>* testing in same/different state</i>		72 / 52	10 / 29	10 / 34	39 / 54	1 / 27	5 / 24	62 / 57				
Mean Scaled Score - School *	82.25	82.44/83.02	80.62/79.90	81.80/84.26	82.77/82.59	82.00/83.19	79.40/82.29	81.44/83.58				
<i>* testing in same/different state</i>												
Mean Scaled Score - State	81.75	81.03	80.21	81.90	81.03	81.08	81.05	80.62				
Mean Scaled Score - National	81.44	82.75	81.26	81.78	82.76	81.22	81.82	82.80				
School Pass Rate: *	100.00	97.22/92.31	89.66/90.00	100.00/97.06	97.44/98.15	100 / 96.30	100 / 91.67	95.16/98.25				
<i>* testing in same/different state</i>												
State Pass Rate:	93.22	91.03	85.71	97.22	91.88	87.29	85.88	89.29				
National Pass Rate:	89.13	93.94	89.60	91.08	93.95	90.04	90.85	94.34				



**Multistate Pharmacy Jurisprudence Examination® (MPJE) ®  
School Summary Report**

**Test Window:** May 1, 2014 - August 31, 2014

**School Name:** Xavier University of Louisiana

This MPJE score report consists of two levels of scores: school-aggregated scores and individual candidate scores. Summary information is provided separately for first-time examinees from ACPE schools/colleges and for all examinees, regardless of repeater status and/or the educational institution. Tables 1 and 2 contain school-specific as well as national pass rate information.

**Table 1 First Time Candidates**

School 1: Examinees testing in same state as respective college

School 2: Examinees testing in different states than respective college

	Candidates	Pass Rate %	Total Scaled Score Mean	Standard Deviation
School 1	76	80.26	78.83	5.68
School 2	100	90.00	80.23	4.63
State	252	89.29	80.62	5.25
National	15660	94.34	82.80	5.35

Candidates who did not answer enough questions to receive a score are reflected in pass rate data as a fail but are not included in mean scaled score data.

**Table 2 All Candidates**

	Candidates	Pass Rate %	Total Scaled Score Mean	Standard Deviation
School 1	82	76.83	78.35	5.76
School 2	111	90.09	79.98	4.60
State	273	86.08	80.18	5.47
National	16690	93.28	82.52	5.45

Candidates who did not answer enough questions to receive a score are reflected in pass rate data as a fail but are not included in mean scaled score data.

### Table 3 Candidate Summary Report

**Test Window:** May 1, 2014 - August 31, 2014

	Pass/Fail	Total Scaled Score	Test Date	Graduation Date	First Attempt	State
1	Pass	79	08/19/2014	06/28/2014	Y	LA
2	Pass	77	08/12/2014	06/13/2014	Y	NC
3	Pass	78	08/04/2014	05/11/2014	Y	MI
4	Pass	84	08/26/2014	05/10/2014	Y	LA
5	Pass	87	08/26/2014	05/10/2014	Y	MS
6	Pass	81	08/25/2014	05/10/2014	Y	MS
7	Pass	85	08/25/2014	05/10/2014	Y	LA
8	Pass	79	08/25/2014	05/10/2014	Y	LA
9	Fail	74	08/25/2014	05/10/2014	Y	LA
10	Pass	78	08/25/2014	05/10/2014	Y	LA
11	Pass	77	08/25/2014	05/10/2014	Y	LA
12	Pass	78	08/25/2014	05/10/2014	N	MS
13	Pass	80	08/23/2014	05/10/2014	Y	MS
14	Pass	81	08/22/2014	05/10/2014	Y	MS
15	Pass	79	08/22/2014	05/10/2014	Y	MS
16	Fail	66	08/21/2014	05/10/2014	Y	LA
17	Pass	79	08/21/2014	05/10/2014	Y	TX
18	Pass	82	08/21/2014	05/10/2014	Y	LA
19	Fail	72	08/19/2014	05/10/2014	Y	LA
20	Pass	75	08/14/2014	05/10/2014	Y	AL
21	Pass	90	08/14/2014	05/10/2014	Y	OK
22	Pass	81	08/13/2014	05/10/2014	Y	AL
23	Pass	77	08/13/2014	05/10/2014	Y	MS
24	Fail	72	08/13/2014	05/10/2014	N	LA
25	Pass	80	08/11/2014	05/10/2014	Y	LA
26	Fail	72	08/09/2014	05/10/2014	Y	LA
27	Pass	78	08/09/2014	05/10/2014	Y	LA
28	Fail	72	08/09/2014	05/10/2014	Y	LA
29	Pass	83	08/09/2014	05/10/2014	Y	LA
30	Pass	75	08/09/2014	05/10/2014	Y	LA
31	Fail	65	08/09/2014	05/10/2014	Y	LA
32	Pass	78	08/09/2014	05/10/2014	Y	LA
33	Pass	78	08/08/2014	05/10/2014	Y	LA
34	Pass	83	08/08/2014	05/10/2014	Y	TX
35	Pass	87	08/07/2014	05/10/2014	Y	TX
36	Pass	83	08/06/2014	05/10/2014	Y	LA
37	Pass	83	08/05/2014	05/10/2014	Y	TX
38	Pass	75	08/05/2014	05/10/2014	Y	TX
39	Pass	75	08/05/2014	05/10/2014	Y	MO
40	Pass	86	08/04/2014	05/10/2014	Y	LA
41	Pass	87	08/04/2014	05/10/2014	Y	OK
42	Pass	85	08/04/2014	05/10/2014	Y	LA
43	Pass	86	08/04/2014	05/10/2014	Y	LA
44	Pass	81	08/04/2014	05/10/2014	Y	TX

**Table 3 Candidate Summary Report**

	<b>Pass/Fail</b>	<b>Total Scaled Score</b>	<b>Test Date</b>	<b>Graduation Date</b>	<b>First Attempt</b>	<b>State</b>
45	Pass	77	08/02/2014	05/10/2014	Y	MS
46	Pass	76	08/01/2014	05/10/2014	Y	LA
47	Pass	88	07/31/2014	05/10/2014	Y	MS
48	Pass	82	07/31/2014	05/10/2014	Y	LA
49	Pass	76	07/31/2014	05/10/2014	Y	LA
50	Fail	72	07/31/2014	05/10/2014	Y	TX
51	Pass	75	07/31/2014	05/10/2014	Y	LA
52	Pass	78	07/31/2014	05/10/2014	Y	IL
53	Fail	72	07/30/2014	05/10/2014	Y	LA
54	Pass	75	07/30/2014	05/10/2014	Y	LA
55	Fail	72	07/30/2014	05/10/2014	Y	LA
56	Fail	73	07/29/2014	05/10/2014	Y	LA
57	Fail	73	07/29/2014	05/10/2014	Y	LA
58	Pass	78	07/28/2014	05/10/2014	Y	MS
59	Pass	79	07/28/2014	05/10/2014	Y	LA
60	Pass	83	07/28/2014	05/10/2014	Y	LA
61	Pass	75	07/28/2014	05/10/2014	Y	LA
62	Fail	72	07/28/2014	05/10/2014	Y	WA
63	Pass	82	07/28/2014	05/10/2014	Y	LA
64	Fail	74	07/26/2014	05/10/2014	Y	LA
65	Pass	76	07/26/2014	05/10/2014	Y	AL
66	Pass	77	07/26/2014	05/10/2014	Y	LA
67	Fail	71	07/23/2014	05/10/2014	Y	MS
68	Pass	81	07/21/2014	05/10/2014	Y	LA
69	Pass	86	07/21/2014	05/10/2014	Y	TX
70	Pass	86	07/21/2014	05/10/2014	Y	TX
71	Pass	83	07/21/2014	05/10/2014	Y	TX
72	Pass	76	07/19/2014	05/10/2014	Y	NC
73	Pass	77	07/19/2014	05/10/2014	Y	MS
74	Pass	78	07/18/2014	05/10/2014	Y	IN
75	Pass	83	07/18/2014	05/10/2014	Y	LA
76	Pass	89	07/18/2014	05/10/2014	Y	MS
77	Pass	80	07/17/2014	05/10/2014	Y	LA
78	Pass	79	07/15/2014	05/10/2014	Y	AL
79	Pass	83	07/14/2014	05/10/2014	Y	GA
80	Pass	84	07/14/2014	05/10/2014	Y	LA
81	Pass	75	07/12/2014	05/10/2014	Y	LA
82	Pass	91	07/12/2014	05/10/2014	Y	LA
83	Pass	88	07/11/2014	05/10/2014	Y	TX
84	Pass	83	07/09/2014	05/10/2014	Y	LA
85	Pass	75	07/09/2014	05/10/2014	Y	LA
86	Pass	84	07/09/2014	05/10/2014	Y	LA
87	Pass	83	07/09/2014	05/10/2014	Y	TX
88	Pass	79	07/09/2014	05/10/2014	Y	LA

**Table 3 Candidate Summary Report**

	<b>Pass/Fail</b>	<b>Total Scaled Score</b>	<b>Test Date</b>	<b>Graduation Date</b>	<b>First Attempt</b>	<b>State</b>
89	Pass	80	07/09/2014	05/10/2014	Y	LA
90	Pass	86	07/09/2014	05/10/2014	Y	TX
91	Pass	88	07/09/2014	05/10/2014	Y	LA
92	Fail	65	07/08/2014	05/10/2014	Y	LA
93	Pass	84	07/07/2014	05/10/2014	Y	MS
94	Pass	82	07/07/2014	05/10/2014	Y	LA
95	Pass	78	07/03/2014	05/10/2014	Y	LA
96	Pass	78	07/02/2014	05/10/2014	Y	FL
97	Pass	84	07/01/2014	05/10/2014	Y	LA
98	Pass	78	07/01/2014	05/10/2014	Y	LA
99	Pass	87	07/01/2014	05/10/2014	Y	LA
100	Pass	80	06/30/2014	05/10/2014	Y	LA
101	Pass	79	06/30/2014	05/10/2014	Y	AK
102	Pass	82	06/27/2014	05/10/2014	Y	TX
103	Pass	77	06/27/2014	05/10/2014	Y	AL
104	Pass	75	06/26/2014	05/10/2014	Y	LA
105	Pass	87	06/25/2014	05/10/2014	Y	LA
106	Pass	84	06/24/2014	05/10/2014	Y	LA
107	Pass	76	06/23/2014	05/10/2014	Y	LA
108	Pass	84	06/21/2014	05/10/2014	Y	LA
109	Pass	83	06/21/2014	05/10/2014	Y	LA
110	Pass	79	06/19/2014	05/10/2014	Y	LA
111	Pass	89	06/16/2014	05/10/2014	Y	LA
112	Pass	79	06/12/2014	05/10/2014	Y	IL
113	Pass	81	06/11/2014	05/10/2014	Y	MS
114	Pass	81	06/07/2014	05/10/2014	Y	LA
115	Fail	73	08/26/2014	12/13/2013	Y	IL
116	Pass	76	07/31/2014	12/13/2013	Y	MS
117	Pass	75	07/02/2014	12/13/2013	N	LA
118	Fail	68	06/07/2014	12/13/2013	Y	LA
119	Fail	71	05/15/2014	12/13/2013	N	LA
120	Pass	85	07/08/2014	06/29/2013	N	TX
121	Pass	75	06/18/2014	06/29/2013	Y	LA
122	Fail	72	08/22/2014	05/11/2013	Y	AZ
123	Fail	72	08/11/2014	05/11/2013	Y	LA
124	Pass	76	08/02/2014	05/11/2013	Y	GA
125	Pass	88	07/26/2014	05/11/2013	Y	AL
126	Pass	75	07/12/2014	05/11/2013	N	LA
127	Pass	78	07/09/2014	05/11/2013	Y	TX
128	Pass	77	06/21/2014	05/11/2013	Y	FL
129	Pass	78	06/02/2014	05/11/2013	Y	TX
130	Pass	86	05/17/2014	05/11/2013	Y	TX
131	Fail	69	05/07/2014	05/11/2013	Y	LA
132	Pass	76	05/07/2014	05/11/2013	Y	LA

**Table 3 Candidate Summary Report**

	<b>Pass/Fail</b>	<b>Total Scaled Score</b>	<b>Test Date</b>	<b>Graduation Date</b>	<b>First Attempt</b>	<b>State</b>
133	Pass	85	05/03/2014	05/11/2013	Y	LA
134	Fail	69	05/02/2014	05/11/2013	N	LA
135	Pass	82	08/09/2014	05/12/2012	N	WA
136	Pass	78	08/04/2014	05/12/2012	Y	LA
137	Pass	79	07/16/2014	05/12/2012	N	TX
138	Pass	79	06/12/2014	05/12/2012	Y	MS
139	Pass	77	06/05/2014	05/12/2012	Y	TX
140	Pass	91	06/03/2014	05/12/2012	Y	MO
141	Pass	76	05/05/2014	05/12/2012	Y	TX
142	Pass	84	07/31/2014	05/07/2011	Y	MS
143	Pass	77	07/21/2014	05/07/2011	Y	GA
144	Pass	78	08/23/2014	05/08/2010	Y	MS
145	Pass	85	08/08/2014	05/08/2010	Y	AL
146	Pass	77	08/04/2014	05/08/2010	Y	MS
147	Pass	84	07/26/2014	05/08/2010	Y	WA
148	Pass	84	07/14/2014	05/08/2010	Y	MS
149	Pass	82	06/13/2014	05/08/2010	Y	MS
150	Pass	80	08/19/2014	05/05/2010	Y	AL
151	Pass	79	07/19/2014	05/05/2010	Y	WV
152	Pass	88	07/26/2014	05/09/2009	Y	GA
153	Fail	72	07/02/2014	05/09/2009	N	LA
154	Pass	78	06/07/2014	05/09/2009	Y	GA
155	Pass	85	05/16/2014	05/09/2009	Y	MS
156	Pass	75	07/03/2014	12/18/2008	N	MS
157	Fail	70	05/15/2014	12/18/2008	Y	MS
158	Pass	87	08/07/2014	05/10/2008	Y	NE
159	Pass	87	07/29/2014	05/10/2008	Y	LA
160	Pass	79	07/18/2014	05/10/2008	N	KY
161	Pass	77	06/21/2014	05/10/2008	Y	SC
162	Fail	74	06/10/2014	05/10/2008	Y	KY
163	Fail	71	05/08/2014	05/10/2008	Y	TX
164	Pass	77	07/15/2014	05/20/2006	N	TX
165	Pass	82	07/11/2014	05/20/2006	Y	AL
166	Pass	85	08/23/2014	05/01/2004	Y	AZ
167	Pass	79	08/15/2014	05/01/2004	Y	FL
168	Pass	79	05/20/2014	05/01/2004	Y	DC
169	Pass	82	08/21/2014	05/16/2003	Y	HI
170	Pass	80	07/10/2014	05/01/2002	Y	OK
171	Pass	79	07/02/2014	05/15/2001	Y	AL
172	Pass	84	05/27/2014	05/01/2001	Y	AZ
173	Pass	81	05/29/2014	08/01/2000	Y	NE
174	Pass	76	07/25/2014	05/01/2000	N	MS
175	Fail	70	05/31/2014	05/01/2000	N	MS
176	Pass	87	05/30/2014	05/12/1997	Y	TN

**Table 3 Candidate Summary Report**

	<b>Pass/Fail</b>	<b>Total Scaled Score</b>	<b>Test Date</b>	<b>Graduation Date</b>	<b>First Attempt</b>	<b>State</b>
177	Pass	84	08/07/2014	05/10/1997	Y	LA
178	Pass	81	07/19/2014	05/10/1997	Y	LA
179	Pass	81	08/09/2014	05/12/1995	Y	CO
180	Pass	83	05/15/2014	05/12/1995	Y	NM
181	Pass	82	07/30/2014	05/01/1993	Y	KY
182	Pass	84	07/03/2014	05/01/1993	Y	MS
183	Pass	79	05/27/2014	05/01/1993	Y	WV
184	Pass	82	05/23/2014	05/01/1993	Y	OR
185	Pass	80	05/20/2014	05/01/1993	Y	AZ
186	Pass	78	08/04/2014	12/14/1992	N	KY
187	Fail	74	06/17/2014	12/14/1992	Y	KY
188	Pass	78	08/28/2014	05/10/1989	Y	CO
189	Pass	77	05/13/2014	05/10/1989	Y	OK
190	Pass	80	08/01/2014	05/18/1986	Y	KY
191	Pass	82	05/29/2014	05/18/1986	Y	SC
192	Pass	76	06/21/2014	12/20/1974	N	MS
193	Fail	74	05/03/2014	12/20/1974	Y	MS

**National Statistics for All Candidates**

**Mean Scaled Score: 82.52**  
**Standard Deviation: 5.45**  
**Range: 57 - 100**  
**Passing Rate (%): 93.28**

**National Statistics for First-Time Candidates**

**Mean Scaled Score: 82.80**  
**Standard Deviation: 5.35**  
**Range: 57 - 100**  
**Passing Rate (%): 94.34**

The following tables are scaled score frequency distributions for MPJE® candidates.

Candidates who did not answer enough questions to receive a score are not reflected in the frequency distributions.

**Table 4 National Frequency Distribution of Scaled Scores**

**Based on Total Tests Administered (N = 16690 )**

**Test Window: May 1, 2014 - August 31, 2014**

Scaled Score	Frequency	Cumulative Percent of the Upper Limit of the Interval
0 - 4	0	0.0%
5 - 9	0	0.0%
10 - 14	0	0.0%
15 - 19	0	0.0%
20 - 24	0	0.0%
25 - 29	0	0.0%
30 - 34	0	0.0%
35 - 39	0	0.0%
40 - 44	0	0.0%
45 - 49	0	0.0%
50 - 54	0	0.0%
55 - 59	3	0.0%
60 - 64	21	0.1%
65 - 69	137	1.0%
70 - 74	959	6.7%
75 - 79	3657	28.6%
80 - 84	5998	64.6%
85 - 89	4280	90.2%
90 - 94	1393	98.6%
95 - 100	241	100.0%

**Table 5 National Frequency Distribution of Scaled Scores  
Based on First-Time Candidates from ACPE-Accredited Programs (N = 15660 )**

**Test Window: May 1, 2014 - August 31, 2014**

Scaled Score	Frequency	Cumulative Percent of the Upper Limit of the Interval
0 - 4	0	0.0%
5 - 9	0	0.0%
10 - 14	0	0.0%
15 - 19	0	0.0%
20 - 24	0	0.0%
25 - 29	0	0.0%
30 - 34	0	0.0%
35 - 39	0	0.0%
40 - 44	0	0.0%
45 - 49	0	0.0%
50 - 54	0	0.0%
55 - 59	3	0.0%
60 - 64	19	0.1%
65 - 69	116	0.9%
70 - 74	830	6.1%
75 - 79	3399	27.3%
80 - 84	5793	63.6%
85 - 89	4199	89.8%
90 - 94	1387	98.5%
95 - 100	241	100.0%

**Multistate Pharmacy Jurisprudence Examination (MPJE)**

**Xavier College of Pharmacy**

	<b>2000</b>		<b>2001</b>		<b>2002</b>		<b>2003</b>	
	<u>Jan - Jun</u>	<u>Jul - Dec</u>						
<b>TOTAL CANDIDATE GROUP</b>								
No. of Candidates	25	94	53	126	43	122	71	158
School Average Score:	78.92	78.90	77.43	79.86	79.12	78.18	76.75	77.99
State Average Score:	81.64	80.49	80.64	80.32	80.34	79.41	77.32	78.87
National Average Score:	82.24	81.75	82.25	81.51	81.72	79.85	79.92	79.33
School Pass Rate:	80.00	80.85	69.81	88.10	81.40	77.05	67.61	75.95
State Pass Rate:	89.89	86.25	87.84	90.00	92.00	85.98	72.88	84.67
National Pass Rate:	91.37	90.50	91.22	90.54	90.78	84.93	84.52	82.61
<b>FIRST-TIME CANDIDATE GROUP</b>								
No. of Candidates	23	86	38	107	38	102	53	122
School Average Score:	79.04	79.01	77.58	79.92	79.58	78.18	77.04	78.48
State Average Score:	82.14	80.97	80.67	80.51	80.30	79.41	77.69	79.23
National Average Score:	82.55	82.05	82.59	81.86	82.08	80.19	80.34	79.76
School Pass Rate:	78.26	80.23	71.05	86.92	86.84	78.43	71.70	78.69
State Pass Rate:	92.59	87.32	88.06	89.77	91.49	86.32	75.00	86.55
National Pass Rate:	92.57	91.37	92.45	91.75	92.15	86.45	86.58	84.67

**Multistate Pharmacy Jurisprudence Examination (MPJE)**

**Xavier College of Pharmacy**

	<b>2004</b>		<b>2005</b>		<b>2006</b>		<b>2007</b>	
	<u>Jan - Jun</u>	<u>Jul - Dec</u>						
<b>TOTAL CANDIDATE GROUP</b>								
No. of Candidates	66	123	82	135	139	181	77	169
School Average Score:	77.36	78.64	78.06	78.96	79.04	79.82	78.47	79.76
State Average Score:	78.58	80.03	80.50	80.03	80.01	81.34	80.15	81.47
National Average Score:	80.10	79.83	80.39	80.04	80.68	80.42	81.26	81.14
School Pass Rate:	78.79	80.49	76.83	82.22	87.77	86.19	77.92	87.57
State Pass Rate:	86.90	92.55	90.55	87.03	91.09	92.39	87.18	90.39
National Pass Rate:	85.63	84.75	86.57	85.69	87.25	87.82	89.38	89.78
<b>FIRST-TIME CANDIDATE GROUP</b>								
No. of Candidates	56	101	63	121	121	156	62	154
School Average Score:	77.73	79.19	78.57	79.36	79.14	80.27	79.47	80.03
State Average Score:	79.04	80.11	80.71	80.29	80.24	81.52	80.59	81.84
National Average Score:	80.58	80.25	80.80	80.44	81.09	80.80	81.72	81.51
School Pass Rate:	80.36	84.16	79.37	85.12	87.60	89.10	85.48	88.96
State Pass Rate:	90.14	92.53	91.38	88.69	92.31	93.53	91.18	92.49
National Pass Rate:	88.16	86.87	88.51	87.51	89.41	89.34	91.43	91.24

**Multistate Pharmacy Jurisprudence Examination (MPJE)**

**Xavier College of Pharmacy**

	<b>2008</b>		<b>2009</b>			<b>2010</b>			<b>2011</b>		
	<u>Jan - Jun</u>	<u>Jul - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>
<b>TOTAL CANDIDATE GROUP</b>											
No. of Candidates	55	208	63	162	68	42	160	83	10	77	44
Mean Scaled Score - School	78.25	79.49	78.03	80.20	78.10	78.93	79.89	78.17	76.50	79.32	78.93
Mean Scaled Score - State	81.33	81.34	79.57	81.69	80.35	81.37	80.88	81.64		81.01	80.41
Mean Scaled Score - National	81.59	81.27	80.29	82.39	80.25	80.45	82.51	80.57	80.27	82.23	80.46
School Pass Rate:	80	83.17	74.60	88.27	77.94	80.95	88.75	78.31	70.00	81.82	81.82
State Pass Rate:	91.75	91.05	81.03	94.52	85.92	90.00	92.64	95.79		89.91	90.99
National Pass Rate:	90.31	89.92	86.23	93.74	87.04	89.08	94.83	89.35	86.43	92.17	86.24
<b>FIRST-TIME CANDIDATE GROUP</b>											
No. of Candidates	45	181	44	150	47	32	157	61	7	67	29
Mean Scaled Score - School	79.02	79.71	78.55	80.35	78.79	79.66	79.95	78.48	78.14	79.84	80.14
Mean Scaled Score - State	81.53	81.62	79.69	81.76	80.98	82.07	80.93	82.07		81.52	81.14
Mean Scaled Score - National	81.97	81.57	80.75	82.58	80.63	80.82	82.67	80.94	81.17	82.86	81.76
School Pass Rate:	88.89	85.64	79.55	88.67	82.98	84.38	89.17	78.69	85.71	86.57	89.66
State Pass Rate:	92.31	91.95	80.77	94.34	89.66	93.44	92.92	97.56		94.06	94.32
National Pass Rate:	91.82	91.16	88.45	94.30	88.68	90.64	95.50	90.89	92.24	96.05	94.00

**Multistate Pharmacy Jurisprudence Examination (MPJE)**

**Xavier College of Pharmacy**

	<b>2012</b>			<b>2013</b>			<b>2014</b>			<b>2015</b>		
	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sep - Dec</u>
<b>TOTAL CANDIDATE GROUP</b>												
No. of Candidates	13	181	87	53	188	115	52	193				
* <i>testing in same/different state</i>		94 / 87	23 / 65	6 / 47	95 / 93	46 / 69	12 / 40	82 / 111				
Mean Scaled Score - School *	79.69	79.27/78.48	76.96/79.95	78.17/79.09	79.46/79.55	77.33/78.72	76 / 79.28	78.35/79.98				
* <i>testing in same/different state</i>												
Mean Scaled Score - State	81.18	80.91	79.62	81.33	80.82	80.43	80.36	80.18				
Mean Scaled Score - National	80.41	82.43	80.55	80.92	82.50	80.52	81.04	82.52				
School Pass Rate: *	84.62	84.04/81.61	60.87/86.15	83.33/76.60	85.26/81.72	71.74/76.81	50 / 82.50	76.83/90.09				
* <i>testing in same/different state</i>												
State Pass Rate:	90.41	90.69	81.61	93.98	90.51	85.21	82.52	86.08				
National Pass Rate:	84.54	92.76	86.85	87.18	92.98	87.01	87.62	93.28				
<b>FIRST-TIME CANDIDATE GROUP</b>												
No. of Candidates	9	163	70	43	171	86	43	176				
* <i>testing in same/different state</i>		87 / 76	11 / 54	3 / 40	89 / 82	31 / 55	8 / 35	76 / 100				
Mean Scaled Score - School *	79.78	79.34/78.70	77.55/80.57	81.33/79.38	79.66/79.94	77.03/78.85	76.63/79.31	78.83/80.23				
* <i>testing in same/different state</i>												
Mean Scaled Score - State	81.75	81.03	80.21	81.90	81.03	81.08	81.05	80.62				
Mean Scaled Score - National	81.44	82.75	81.26	81.78	82.76	81.22	81.82	82.80				
School Pass Rate: *	88.89	83.91/84.24	63.64/87.04	100 / 77.50	87.64/82.93	67.74/74.55	50 / 80	80.26/90.00				
* <i>testing in same/different state</i>												
State Pass Rate:	93.22	91.03	85.71	97.22	91.88	87.29	85.88	89.29				
National Pass Rate:	89.13	93.94	89.60	91.08	93.95	90.04	90.85	94.34				



# Louisiana Board of Pharmacy

3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ Facsimile 225.6499  
[www.pharmacy.la.gov](http://www.pharmacy.la.gov) ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



## North American Pharmacist Licensure Examination (NAPLEX™)

May 1 – August 31, 2014

School Reports  
Interpretation of Scores  
Frequency Distribution of Scaled Scores  
Cumulative Record (since January 2000)


November 13, 2014

## **North American Pharmacist Licensure Examination (NAPLEX™)**

This computer adaptive competency assessment is administered by the National Association of Boards of Pharmacy (NABP). The examination blueprint is designed to assess the applicant's competency in basic pharmacy practice and is recognized by pharmacy regulatory authorities in all of the states and territories within the USA. The examination is administered via an open window process; applicants may schedule the examination at a local testing center at any time following approval by the state board and receipt of an Authorization to Test (ATT) document from NABP. Individual scores are available to applicants via secure web posting approximately 7-10 days following the examination. Summary reports are provided to the state boards on a calendar trimester basis.

### *Table of Contents*

Current Trimester Report for ULM College of Pharmacy	03
Cumulative Report (since January 2000) for ULM College of Pharmacy	11
Current Trimester Report for Xavier College of Pharmacy	15
Cumulative Report (since January 2000) for Xavier College of Pharmacy	25



**North American Pharmacist Licensure Examination® (NAPLEX) ®  
School Summary Report**

**Test Window:** May 1, 2014 - August 31, 2014

**School Name:** University Louisiana Monroe

This NAPLEX score report consists of two levels of scores: school-aggregated scores and individual candidate scores. Summary information is provided separately for first-time examinees from ACPE schools/colleges and for all examinees, regardless of repeater status and/or the educational institution.

Tables 1 and 2 contain school-specific as well as national pass rate information and mean area scores for each of the three main NAPLEX competency areas:

- Area 1 - Assess Pharmacotherapy to Assure Safe and Effective Therapeutic Outcomes (56%),
- Area 2 - Assess Safe and Accurate Preparation and Dispensing of Medications (33%), and
- Area 3 - Assess, Recommend and Provide Health Care Information that Promotes Public Health (11%).

**Table 1 First-Time Candidates, ACPE-Accredited Programs Only**

Candidates	Pass Rate %	Total Scaled Score Mean	Standard Deviation	Area 1 Scaled Score Mean	Standard Deviation	Area 2 Scaled Score Mean	Standard Deviation	Area 3 Scaled Score Mean	Standard Deviation	
School	68	89.71	95.10	14.47	11.84	1.11	12.32	1.15	12.15	1.57
State	165	92.12	96.96	14.57	12.09	1.10	12.20	1.22	12.34	1.66
National	12191	95.61	102.80	14.83	12.50	1.18	12.59	1.31	12.82	1.70

**Candidates who did not answer enough questions to receive a score are reflected in pass rate data as a fail but are not included in mean scaled score data.**

**Table 2 All Candidates**

Candidates	Pass Rate %	Total Scaled Score Mean	Standard Deviation	Area 1 Scaled Score Mean	Standard Deviation	Area 2 Scaled Score Mean	Standard Deviation	Area 3 Scaled Score Mean	Standard Deviation	
School	68	89.71	95.10	14.47	11.84	1.11	12.32	1.15	12.15	1.57
State	173	90.75	96.45	15.00	12.06	1.12	12.17	1.23	12.25	1.68
National	12746	93.86	101.71	16.02	12.44	1.23	12.52	1.35	12.74	1.75

**Candidates who did not answer enough questions to receive a score are reflected in pass rate data as a fail but are not included in mean scaled score data.**

### Interpretation and Uses of Candidate Scores

At the candidate level, two sets of scores are produced: an overall, composite scaled score and individual area scores. Only overall scores are used to make pass/fail decisions. Area scores are intended to provide insight into areas of strength and weakness and can be used as a tool for self-assessment and subsequent remediation.

Area scores are numerical performance indicators for each of the three main competency areas of the NAPLEX. There are a total of three area scores, one per main competency area. Area scores are always reported on a scale of [6, 18], where a score of 6 is the lowest possible score and a score of 18 is the highest possible score. This reporting scale does not have a number-correct interpretation. In other words, a score of 6 does not mean that the candidate answered 6 questions correctly. Instead, area scores are computed from ability estimates that are created for sets of items that map to each of the three content areas.

Reference Tables 3 and 4 contain summative data for all first-time test takers from ACPE-accredited programs (2013). In table 3, scaled scores were ordered and divided into four equi-sized bins for the computation of quartile values. The column labeled "Top (1st) Quartile" applies to the highest scoring group of examinees. The column labeled "Bottom (4th) Quartile" applies to the lowest scoring group. Table 4 contains similar information but is based on pass/fail status of examinees.

**Reference Table 3 NAPLEX  
Mean Area Score Summary (2013) by Quartiles**

	Top (1st) Quartile	2nd Quartile	3rd Quartile	Bottom (4th) Quartile
Mean Area 1 Scaled Score	13.88	12.83	12.05	10.86
Mean Area 2 Scaled Score	13.68	12.69	11.93	10.74
Mean Area 3 Scaled Score	13.95	12.98	12.24	10.92
Mean Overall Scaled Score	119.26	107.79	96.71	74.67
Scaled Score Range	[138, 114]	[113, 104]	[103, 91]	[90, 0]
# Examinees per bin	3,748	3,748	3,748	3,748

In the quartile table (above), the mean overall scaled score for the bottom quartile is 74.67 which is greater than the NAPLEX passing threshold of 75. Because the set of overall scaled scores is not normally distributed, the scores and subsequent interpretations should be evaluated carefully.

**Reference Table 4 NAPLEX  
Mean Area Score Summary (2013) by Pass/Fail Status**

	Pass	Fail
Mean Area 1 Scaled Score	12.63	10.18
Mean Area 2 Scaled Score	12.49	10.01
Mean Area 3 Scaled Score	12.77	10.13
Mean Overall Scaled Score	103.64	60.39
Scaled Score Range	[138, 75]	[74, 0]
# Examinees per bin	13,593	1,399

## Table 5 Candidate Summary Report

Test Window: May 1, 2014 - August 31, 2014

Candidate	Pass/Fail	Total Scaled Score	Area 1 Scaled Score	Area 2 Scaled Score	Area 3 Scaled Score	Test Date	Graduation Date	First Attempt
1	Pass	87	11	13	11	08/27/2014	05/10/2014	Y
2	Pass	80	11	11	11	08/26/2014	05/10/2014	Y
3	Pass	107	13	12	14	08/14/2014	05/10/2014	Y
4	Pass	82	11	11	10	08/13/2014	05/10/2014	Y
5	Fail	70	10	10	12	08/13/2014	05/10/2014	Y
6	Pass	84	11	12	11	08/09/2014	05/10/2014	Y
7	Pass	90	11	13	10	08/07/2014	05/10/2014	Y
8	Pass	98	12	13	12	08/05/2014	05/10/2014	Y
9	Pass	89	12	12	10	08/04/2014	05/10/2014	Y
10	Pass	83	12	11	11	08/04/2014	05/10/2014	Y
11	Pass	91	12	11	12	08/04/2014	05/10/2014	Y
12	Pass	99	12	13	12	08/01/2014	05/10/2014	Y
13	Pass	109	13	13	14	07/28/2014	05/10/2014	Y
14	Fail	72	11	10	13	07/28/2014	05/10/2014	Y
15	Pass	80	11	11	11	07/28/2014	05/10/2014	Y
16	Pass	108	13	12	13	07/28/2014	05/10/2014	Y
17	Pass	88	11	12	12	07/28/2014	05/10/2014	Y
18	Pass	105	13	13	13	07/25/2014	05/10/2014	Y
19	Pass	109	13	13	11	07/25/2014	05/10/2014	Y
20	Fail	73	10	12	10	07/25/2014	05/10/2014	Y
21	Pass	108	13	13	11	07/23/2014	05/10/2014	Y
22	Pass	99	12	12	13	07/23/2014	05/10/2014	Y
23	Pass	105	13	12	13	07/23/2014	05/10/2014	Y
24	Fail	67	10	10	11	07/23/2014	05/10/2014	Y
25	Pass	100	12	12	13	07/23/2014	05/10/2014	Y
26	Pass	90	11	12	12	07/21/2014	05/10/2014	Y
27	Pass	80	11	12	11	07/21/2014	05/10/2014	Y
28	Pass	105	13	12	16	07/17/2014	05/10/2014	Y
29	Pass	93	11	13	10	07/17/2014	05/10/2014	Y
30	Fail	71	10	11	13	07/16/2014	05/10/2014	Y
31	Pass	93	12	12	12	07/15/2014	05/10/2014	Y
32	Pass	98	11	14	11	07/15/2014	05/10/2014	Y
33	Pass	100	12	13	11	07/14/2014	05/10/2014	Y
34	Pass	98	11	13	14	07/14/2014	05/10/2014	Y
35	Pass	103	12	14	13	07/14/2014	05/10/2014	Y
36	Fail	73	11	12	8	07/14/2014	05/10/2014	Y
37	Pass	95	12	12	12	07/14/2014	05/10/2014	Y
38	Pass	94	11	13	12	07/14/2014	05/10/2014	Y
39	Pass	91	11	12	12	07/14/2014	05/10/2014	Y
40	Pass	75	11	11	11	07/12/2014	05/10/2014	Y
41	Pass	92	11	12	12	07/12/2014	05/10/2014	Y
42	Pass	113	13	13	13	07/12/2014	05/10/2014	Y
43	Fail	74	11	11	10	07/12/2014	05/10/2014	Y
44	Pass	103	12	13	14	07/09/2014	05/10/2014	Y

**Table 5 Candidate Summary Report**

Candidate	Pass/Fail	Total Scaled Score	Area 1 Scaled Score	Area 2 Scaled Score	Area 3 Scaled Score	Test Date	Graduation Date	First Attempt
45	Pass	81	11	11	10	07/09/2014	05/10/2014	Y
46	Pass	96	12	12	14	07/09/2014	05/10/2014	Y
47	Pass	112	13	12	15	07/08/2014	05/10/2014	Y
48	Pass	98	12	13	11	07/03/2014	05/10/2014	Y
49	Pass	106	12	15	12	06/30/2014	05/10/2014	Y
50	Pass	101	12	13	13	06/26/2014	05/10/2014	Y
51	Pass	84	11	11	12	06/26/2014	05/10/2014	Y
52	Pass	104	13	12	11	06/24/2014	05/10/2014	Y
53	Pass	129	15	15	13	06/23/2014	05/10/2014	Y
54	Pass	123	14	15	14	06/23/2014	05/10/2014	Y
55	Pass	109	13	12	12	06/21/2014	05/10/2014	Y
56	Pass	88	11	12	12	06/20/2014	05/10/2014	Y
57	Pass	81	10	12	12	06/20/2014	05/10/2014	Y
58	Pass	87	11	12	12	06/19/2014	05/10/2014	Y
59	Pass	102	12	13	11	06/19/2014	05/10/2014	Y
60	Pass	87	11	11	12	06/16/2014	05/10/2014	Y
61	Pass	76	11	11	11	06/14/2014	05/10/2014	Y
62	Pass	89	11	12	12	06/14/2014	05/10/2014	Y
63	Pass	112	13	14	14	06/14/2014	05/10/2014	Y
64	Pass	108	13	13	14	06/13/2014	05/10/2014	Y
65	Pass	127	14	15	15	06/13/2014	05/10/2014	Y
66	Pass	120	14	14	14	06/13/2014	05/10/2014	Y
67	Pass	120	14	13	17	06/13/2014	05/10/2014	Y
68	Pass	103	12	13	12	07/17/2014	05/05/2014	Y

**National Statistics for All NAPLEX Candidates**

**Mean Scaled Score: 101.71**  
**Standard Deviation: 16.02**  
**Range: 5 - 138**  
**Passing Rate (%): 93.86**

**National Statistics for First-Time NAPLEX Candidates**

**Mean Scaled Score: 102.80**  
**Standard Deviation: 14.83**  
**Range: 5 - 138**  
**Passing Rate (%): 95.61**

The following tables are scaled score frequency distributions for NAPLEX candidates. Candidates who did not answer enough questions to receive a score are not reflected in the frequency distributions.

**Table 6 National Frequency Distribution of Scaled Scores  
Based on Total Tests Administered (N = 12746 )**

**Test Window: May 1, 2014 - August 31, 2014**

Scaled Score	Frequency	Cumulative Percent of the Upper Limit of the Interval
0 - 4	0	0.0%
5 - 9	1	0.0%
10 - 14	2	0.0%
15 - 19	1	0.0%
20 - 24	4	0.1%
25 - 29	7	0.1%
30 - 34	6	0.2%
35 - 39	13	0.3%
40 - 44	16	0.4%
45 - 49	33	0.7%
50 - 54	47	1.0%
55 - 59	60	1.5%
60 - 64	109	2.3%
65 - 69	166	3.7%
70 - 74	299	6.0%
75 - 79	405	9.2%
80 - 84	595	13.9%
85 - 89	812	20.2%
90 - 94	1099	28.9%
95 - 99	1383	39.7%
100 - 104	1542	51.9%
105 - 109	1650	64.8%
110 - 114	1633	77.7%
115 - 119	1433	88.9%
120 - 124	885	95.9%
125 - 129	406	99.1%
130 - 134	107	99.9%
135 - 139	13	100.0%
140 - 144	0	100.0%
145 - 150	0	100.0%

**Table 7 National Frequency Distribution of Scaled Scores**  
**Based on First-Time Candidates from ACPE-Accredited Programs (N = 12191 )**

**Test Window: May 1, 2014 - August 31, 2014**

<b>Scaled Score</b>	<b>Frequency</b>	<b>Cumulative Percent of the Upper Limit of the Interval</b>
0 - 4	0	0.0%
5 - 9	1	0.0%
10 - 14	2	0.0%
15 - 19	1	0.0%
20 - 24	2	0.0%
25 - 29	4	0.1%
30 - 34	6	0.1%
35 - 39	9	0.2%
40 - 44	12	0.3%
45 - 49	24	0.5%
50 - 54	34	0.8%
55 - 59	44	1.1%
60 - 64	85	1.8%
65 - 69	126	2.8%
70 - 74	261	4.9%
75 - 79	376	8.0%
80 - 84	554	12.5%
85 - 89	771	18.7%
90 - 94	1077	27.4%
95 - 99	1356	38.4%
100 - 104	1525	50.7%
105 - 109	1636	63.9%
110 - 114	1624	77.1%
115 - 119	1428	88.6%
120 - 124	884	95.8%
125 - 129	405	99.0%
130 - 134	107	99.9%
135 - 139	13	100.0%
140 - 144	0	100.0%
145 - 150	0	100.0%

**North American Pharmacist Licensure Examination (NAPLEX)**

**University of Louisiana at Monroe**

	<b>2000</b>			<b>2001</b>			<b>2002</b>			<b>2003</b>		
	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>
<b>TOTAL CANDIDATE GROUP</b>												
No. of Candidates	76	47	18	40	30	10	13	62	27	10	70	24
School Average Score:	96.51	91.62	88.61	88.93	87.30	87.00	82.85	100.24	89.56	78.40	101.44	92.50
State Average Score:	96.75	88.52	86.05	84.66	93.82	82.05	75.50	101.46	87.48	77.50	99.40	87.33
National Average Score:	91.78	99.86	91.21	90.25	101.70	90.50	90.81	101.21	90.02	91.50	101.40	89.40
School Pass Rate:	96.05	82.98	88.89	85.00	90.00	90.00	84.62	85.48	77.78	60.00	95.71	87.50
State Pass Rate:	92.50	78.57	77.27	75.86	89.29	70.00	50.00	85.90	70.37	62.50	94.90	80.00
National Pass Rate:	82.95	92.05	83.04	81.07	94.38	83.69	81.52	93.76	81.73	82.77	93.84	79.55
<b>FIRST-TIME CANDIDATE GROUP</b>												
No. of Candidates	71	33	9	37	20	6	13	61	20	2	64	16
School Average Score:	97.13	96.00	94.00	88.32	86.90	90.67	82.85	100.44	92.80	73.50	102.69	98.56
State Average Score:	97.49	93.61	87.77	88.78	95.92	85.93	81.89	103.71	91.15	74.00	100.41	92.38
National Average Score:	96.51	101.85	96.48	94.54	103.35	94.22	95.13	103.00	94.62	97.39	103.38	95.88
School Pass Rate:	95.77	96.97	100.00	83.78	85.00	100.00	84.62	85.25	75.00	50.00	96.88	100.00
State Pass Rate:	94.59	93.18	84.62	83.33	91.84	73.33	77.78	90.28	70.00	66.67	95.65	90.48
National Pass Rate:	91.44	95.44	91.39	87.91	96.75	90.10	89.27	96.74	88.52	91.47	96.54	89.64

**North American Pharmacist Licensure Examination (NAPLEX)**

**University of Louisiana at Monroe**

	<b>2004</b>			<b>2005</b>			<b>2006</b>			<b>2007</b>		
	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>
<b>TOTAL CANDIDATE GROUP</b>												
No. of Candidates	3	64	18	9	72	17	2	60	10	3	90	23
School Average Score:	85.67	105.30	94.83	82.67	104.17	101.65	98.00	113.17	95.80	107.67	117.27	101.57
State Average Score:	81.33	103.47	96.71	95.00	101.77	92.50	86.67	111.87	96.07	88.00	117.29	94.73
National Average Score:	92.13	102.16	91.70	91.32	104.85	87.72	86.89	107.02	93.18	89.95	113.33	94.18
School Pass Rate:	100.00	96.88	94.44	88.89	90.28	94.12	100.00	93.33	80.00	100.00	95.56	78.26
State Pass Rate:	83.33	96.12	100.00	100.00	87.83	78.57	77.78	89.17	79.31	63.64	95.52	74.51
National Pass Rate:	83.22	95.11	84.79	82.88	89.15	71.73	68.82	90.52	77.07	71.38	94.47	78.76
<b>FIRST-TIME CANDIDATE GROUP</b>												
No. of Candidates	2	58	17	5	70	11	2	58	4	3	89	19
School Average Score:	87.00	107.34	93.47	81.40	105.09	110.09	98.00	114.59	125.00	107.67	117.66	103.05
State Average Score:	84.00	105.61	99.73	101.50	103.64	98.94	93.33	112.95	95.41	103.40	118.18	95.00
National Average Score:	100.14	104.14	96.60	98.84	107.67	95.89	97.18	110.34	99.96	102.16	116.00	102.19
School Pass Rate:	100.00	100.00	94.12	80.00	91.43	100.00	100.00	94.83	100.00	100.00	95.51	78.95
State Pass Rate:	100.00	100.00	100.00	100.00	90.09	88.89	100.00	90.38	70.59	100.00	96.69	76.74
National Pass Rate:	95.07	97.38	92.22	91.31	92.86	82.12	81.12	94.49	84.74	84.09	97.23	88.12

**North American Pharmacist Licensure Examination (NAPLEX)**


**University of Louisiana at Monroe**

	<b>2008</b>			<b>2009</b>			<b>2010</b>			<b>2011</b>		
	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>
<b>TOTAL CANDIDATE GROUP</b>												
No. of Candidates	11	98	12	6	91	8	3	67	6	2	91	9
Mean Scaled Score - School	94.73	106.39	93.83	97.83	113.84	77.25	98.00	99.97	93.17	67.50	97.40	87.22
Mean Scaled Score - State	93.70	103.31	95.41	94.80	108.26	84.32	83.15	94.22	80.13		99.66	85.27
Mean Scaled Score - National	96.76	112.08	96.61	93.72	112.51	93.62	84.75	101.11	84.90	83.97	103.27	88.08
School Pass Rate:	90.91	92.86	83.33	83.33	95.60	50.00	100.00	95.52	100.00	0.00	89.01	77.78
State Pass Rate:	90.00	90.34	82.76	80.00	92.64	63.16	61.54	83.24	65.00		90.81	73.17
National Pass Rate:	83.11	95.48	81.96	76.40	95.03	78.20	65.07	92.39	72.20	67.85	94.16	76.57
<b>FIRST-TIME CANDIDATE GROUP</b>												
No. of Candidates	3	97	5	3	88	3	0	67	2	1	87	3
Mean Scaled Score - School	110.33	106.76	95.80	93.00	115.34	78.33	0.00	99.97	97.00	62.00	99.39	84.67
Mean Scaled Score - State	96.00	104.42	95.82	86.00	108.80	84.10	92.00	94.46	90.75		100.88	83.70
Mean Scaled Score - National	106.63	114.11	103.62	106.27	114.65	102.87	100.12	103.06	94.26	96.99	105.03	96.71
School Pass Rate:	100.00	93.81	80.00	66.67	96.59	33.33	0.00	95.52	100.00	0.00	93.10	66.67
State Pass Rate:	83.33	92.35	82.35	57.14	93.04	60.00	66.67	84.15	83.33		93.18	74.07
National Pass Rate:	92.24	97.44	90.66	90.76	97.50	89.51	88.38	95.31	86.71	87.50	96.57	89.24

**North American Pharmacist Licensure Examination (NAPLEX)**

**University of Louisiana at Monroe**

	<b>2012</b>			<b>2013</b>			<b>2014</b>			<b>2015</b>		
	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>
<b>TOTAL CANDIDATE GROUP</b>												
No. of Candidates	6	80	17	3	40	7	1	68				
Mean Scaled Score - School	75.33	97.14	85.41	92.00	100.45	88.43	101.00	95.10				
Mean Scaled Score - State	81.25	98.42	86.95	77.25	98.66	86.88	73.85	96.45				
Mean Scaled Score - National	83.15	102.81	88.15	80.17	102.78	87.03	80.22	101.71				
School Pass Rate:	83.33	92.50	82.35	100.00	90.00	100.00	100.00	89.71				
State Pass Rate:	68.75	93.82	76.19	55.56	92.95	81.82	53.85	90.75				
National Pass Rate:	68.33	95.21	77.86	61.07	94.65	75.91	63.24	93.86				
<b>FIRST-TIME CANDIDATE GROUP</b>												
No. of Candidates	2	80	9	3	38	4	1	68				
Mean Scaled Score - School	49.50	97.14	87.11	92.00	101.68	92.00	101.00	95.10				
Mean Scaled Score - State	84.00	99.47	91.00	80.75	99.30	88.33	85.00	96.96				
Mean Scaled Score - National	94.87	104.13	95.75	92.48	104.02	92.69	90.89	102.80				
School Pass Rate:	50.00	92.50	77.78	100.00	92.11	100.00	100.00	89.71				
State Pass Rate:	75.00	95.35	72.73	75.00	94.08	83.33	100.00	92.12				
National Pass Rate:	87.69	97.19	90.14	85.14	96.57	84.46	83.15	95.61				



**North American Pharmacist Licensure Examination® (NAPLEX) ®  
School Summary Report**

**Test Window:** May 1, 2014 - August 31, 2014

**School Name:** Xavier University of Louisiana

This NAPLEX score report consists of two levels of scores: school-aggregated scores and individual candidate scores. Summary information is provided separately for first-time examinees from ACPE schools/colleges and for all examinees, regardless of repeater status and/or the educational institution.

Tables 1 and 2 contain school-specific as well as national pass rate information and mean area scores for each of the three main NAPLEX competency areas:

- Area 1 - Assess Pharmacotherapy to Assure Safe and Effective Therapeutic Outcomes (56%),
- Area 2 - Assess Safe and Accurate Preparation and Dispensing of Medications (33%), and
- Area 3 - Assess, Recommend and Provide Health Care Information that Promotes Public Health (11%).

**Table 1 First-Time Candidates, ACPE-Accredited Programs Only**

Candidates	Pass Rate %	Total Scaled Score Mean	Standard Deviation	Area 1 Scaled Score Mean	Standard Deviation	Area 2 Scaled Score Mean	Standard Deviation	Area 3 Scaled Score Mean	Standard Deviation	
School	131	93.89	97.15	14.41	12.20	1.00	12.01	1.27	12.17	1.56
State	165	92.12	96.96	14.57	12.09	1.10	12.20	1.22	12.34	1.66
National	12191	95.61	102.80	14.83	12.50	1.18	12.59	1.31	12.82	1.70

**Candidates who did not answer enough questions to receive a score are reflected in pass rate data as a fail but are not included in mean scaled score data.**

**Table 2 All Candidates**

Candidates	Pass Rate %	Total Scaled Score Mean	Standard Deviation	Area 1 Scaled Score Mean	Standard Deviation	Area 2 Scaled Score Mean	Standard Deviation	Area 3 Scaled Score Mean	Standard Deviation	
School	138	92.75	96.29	14.85	12.16	1.02	11.95	1.27	12.08	1.57
State	173	90.75	96.45	15.00	12.06	1.12	12.17	1.23	12.25	1.68
National	12746	93.86	101.71	16.02	12.44	1.23	12.52	1.35	12.74	1.75

**Candidates who did not answer enough questions to receive a score are reflected in pass rate data as a fail but are not included in mean scaled score data.**

### Interpretation and Uses of Candidate Scores

At the candidate level, two sets of scores are produced: an overall, composite scaled score and individual area scores. Only overall scores are used to make pass/fail decisions. Area scores are intended to provide insight into areas of strength and weakness and can be used as a tool for self-assessment and subsequent remediation.

Area scores are numerical performance indicators for each of the three main competency areas of the NAPLEX. There are a total of three area scores, one per main competency area. Area scores are always reported on a scale of [6, 18], where a score of 6 is the lowest possible score and a score of 18 is the highest possible score. This reporting scale does not have a number-correct interpretation. In other words, a score of 6 does not mean that the candidate answered 6 questions correctly. Instead, area scores are computed from ability estimates that are created for sets of items that map to each of the three content areas.

Reference Tables 3 and 4 contain summative data for all first-time test takers from ACPE-accredited programs (2013). In table 3, scaled scores were ordered and divided into four equi-sized bins for the computation of quartile values. The column labeled "Top (1st) Quartile" applies to the highest scoring group of examinees. The column labeled "Bottom (4th) Quartile" applies to the lowest scoring group. Table 4 contains similar information but is based on pass/fail status of examinees.

**Reference Table 3 NAPLEX  
Mean Area Score Summary (2013) by Quartiles**

	Top (1st) Quartile	2nd Quartile	3rd Quartile	Bottom (4th) Quartile
Mean Area 1 Scaled Score	13.88	12.83	12.05	10.86
Mean Area 2 Scaled Score	13.68	12.69	11.93	10.74
Mean Area 3 Scaled Score	13.95	12.98	12.24	10.92
Mean Overall Scaled Score	119.26	107.79	96.71	74.67
Scaled Score Range	[138, 114]	[113, 104]	[103, 91]	[90, 0]
# Examinees per bin	3,748	3,748	3,748	3,748

In the quartile table (above), the mean overall scaled score for the bottom quartile is 74.67 which is greater than the NAPLEX passing threshold of 75. Because the set of overall scaled scores is not normally distributed, the scores and subsequent interpretations should be evaluated carefully.

**Reference Table 4 NAPLEX  
Mean Area Score Summary (2013) by Pass/Fail Status**

	Pass	Fail
Mean Area 1 Scaled Score	12.63	10.18
Mean Area 2 Scaled Score	12.49	10.01
Mean Area 3 Scaled Score	12.77	10.13
Mean Overall Scaled Score	103.64	60.39
Scaled Score Range	[138, 75]	[74, 0]
# Examinees per bin	13,593	1,399

## Table 5 Candidate Summary Report

Test Window: May 1, 2014 - August 31, 2014

Candidate	Pass/Fail	Total Scaled Score	Area 1 Scaled Score	Area 2 Scaled Score	Area 3 Scaled Score	Test Date	Graduation Date	First Attempt
1	Pass	101	13	11	13	08/27/2014	06/28/2014	Y
2	Fail	74	10	11	11	08/26/2014	06/28/2014	Y
3	Pass	87	12	11	10	08/11/2014	06/28/2014	Y
4	Pass	79	12	10	11	05/08/2014	06/28/2014	N
5	Pass	99	13	11	11	08/12/2014	06/13/2014	Y
6	Pass	84	12	11	11	07/15/2014	05/11/2014	Y
7	Fail	69	11	11	9	08/28/2014	05/10/2014	Y
8	Pass	79	11	11	11	08/27/2014	05/10/2014	Y
9	Pass	106	13	13	12	08/25/2014	05/10/2014	Y
10	Pass	100	12	12	12	08/25/2014	05/10/2014	Y
11	Pass	78	11	11	12	08/25/2014	05/10/2014	Y
12	Pass	100	12	14	11	08/23/2014	05/10/2014	Y
13	Pass	101	12	12	13	08/23/2014	05/10/2014	Y
14	Pass	99	12	12	13	08/20/2014	05/10/2014	Y
15	Pass	107	13	13	13	08/20/2014	05/10/2014	Y
16	Pass	105	13	12	15	08/20/2014	05/10/2014	Y
17	Pass	79	11	11	11	08/19/2014	05/10/2014	Y
18	Pass	112	13	15	13	08/19/2014	05/10/2014	Y
19	Pass	106	13	12	13	08/19/2014	05/10/2014	Y
20	Pass	99	11	13	15	08/19/2014	05/10/2014	Y
21	Pass	97	12	11	12	08/15/2014	05/10/2014	Y
22	Pass	101	12	12	13	08/14/2014	05/10/2014	Y
23	Pass	100	12	12	12	08/12/2014	05/10/2014	Y
24	Pass	119	14	14	14	08/11/2014	05/10/2014	Y
25	Pass	97	12	11	13	08/11/2014	05/10/2014	Y
26	Pass	109	13	12	12	08/11/2014	05/10/2014	Y
27	Pass	85	11	12	11	08/09/2014	05/10/2014	Y
28	Pass	77	11	11	10	08/09/2014	05/10/2014	Y
29	Pass	78	11	10	12	08/08/2014	05/10/2014	Y
30	Fail	71	11	11	9	08/08/2014	05/10/2014	Y
31	Pass	87	11	11	13	08/07/2014	05/10/2014	Y
32	Pass	100	12	12	12	08/07/2014	05/10/2014	Y
33	Pass	95	11	12	13	08/04/2014	05/10/2014	Y
34	Pass	98	13	13	15	08/04/2014	05/10/2014	Y
35	Pass	78	12	10	10	08/04/2014	05/10/2014	Y
36	Pass	104	12	13	12	08/04/2014	05/10/2014	Y
37	Pass	78	12	10	10	08/04/2014	05/10/2014	Y
38	Pass	105	12	13	14	08/01/2014	05/10/2014	Y
39	Pass	98	13	11	12	08/01/2014	05/10/2014	Y
40	Pass	99	12	12	14	08/01/2014	05/10/2014	Y
41	Pass	90	12	12	10	07/31/2014	05/10/2014	Y
42	Pass	104	12	12	13	07/31/2014	05/10/2014	Y
43	Pass	109	13	13	13	07/31/2014	05/10/2014	Y
44	Pass	114	13	14	12	07/30/2014	05/10/2014	Y

**Table 5 Candidate Summary Report**

Candidate	Pass/Fail	Total Scaled Score	Area 1 Scaled Score	Area 2 Scaled Score	Area 3 Scaled Score	Test Date	Graduation Date	First Attempt
45	Pass	84	11	11	12	07/30/2014	05/10/2014	Y
46	Pass	122	14	14	14	07/30/2014	05/10/2014	Y
47	Fail					07/30/2014	05/10/2014	Y
48	Fail	70	12	10	9	07/29/2014	05/10/2014	Y
49	Pass	96	12	12	11	07/28/2014	05/10/2014	Y
50	Pass	98	12	12	11	07/28/2014	05/10/2014	Y
51	Pass	116	14	13	15	07/28/2014	05/10/2014	Y
52	Pass	108	13	13	13	07/28/2014	05/10/2014	Y
53	Pass	82	11	11	12	07/28/2014	05/10/2014	Y
54	Pass	75	11	11	10	07/24/2014	05/10/2014	Y
55	Pass	121	13	15	15	07/23/2014	05/10/2014	Y
56	Pass	116	13	14	12	07/23/2014	05/10/2014	Y
57	Pass	97	12	11	15	07/23/2014	05/10/2014	Y
58	Pass	100	12	13	11	07/22/2014	05/10/2014	Y
59	Pass	96	11	14	12	07/21/2014	05/10/2014	Y
60	Pass	112	13	12	15	07/19/2014	05/10/2014	Y
61	Pass	84	11	11	12	07/19/2014	05/10/2014	Y
62	Pass	90	12	11	11	07/18/2014	05/10/2014	Y
63	Fail	66	11	10	9	07/18/2014	05/10/2014	Y
64	Pass	96	12	12	12	07/17/2014	05/10/2014	Y
65	Pass	126	15	14	13	07/17/2014	05/10/2014	Y
66	Pass	81	12	12	13	07/17/2014	05/10/2014	Y
67	Pass	105	13	12	12	07/17/2014	05/10/2014	Y
68	Pass	104	12	13	12	07/17/2014	05/10/2014	Y
69	Pass	112	13	13	13	07/16/2014	05/10/2014	Y
70	Pass	96	12	12	10	07/16/2014	05/10/2014	Y
71	Pass	105	12	13	12	07/16/2014	05/10/2014	Y
72	Pass	79	12	10	10	07/16/2014	05/10/2014	Y
73	Pass	103	13	13	10	07/15/2014	05/10/2014	Y
74	Pass	101	12	13	10	07/15/2014	05/10/2014	Y
75	Pass	121	14	14	14	07/15/2014	05/10/2014	Y
76	Pass	104	13	12	11	07/15/2014	05/10/2014	Y
77	Pass	106	12	13	12	07/15/2014	05/10/2014	Y
78	Pass	105	12	13	13	07/15/2014	05/10/2014	Y
79	Pass	91	11	12	12	07/15/2014	05/10/2014	Y
80	Pass	79	12	10	12	07/15/2014	05/10/2014	Y
81	Pass	102	13	11	15	07/15/2014	05/10/2014	Y
82	Pass	104	13	12	12	07/15/2014	05/10/2014	Y
83	Pass	109	13	12	13	07/15/2014	05/10/2014	Y
84	Pass	75	10	12	9	07/14/2014	05/10/2014	Y
85	Pass	109	13	12	10	07/14/2014	05/10/2014	Y
86	Pass	105	13	12	13	07/14/2014	05/10/2014	Y
87	Pass	125	15	14	14	07/14/2014	05/10/2014	Y
88	Pass	100	12	13	11	07/14/2014	05/10/2014	Y

**Table 5 Candidate Summary Report**

Candidate	Pass/Fail	Total Scaled Score	Area 1 Scaled Score	Area 2 Scaled Score	Area 3 Scaled Score	Test Date	Graduation Date	First Attempt
89	Pass	124	14	14	14	07/14/2014	05/10/2014	Y
90	Pass	111	12	14	14	07/14/2014	05/10/2014	Y
91	Pass	85	11	11	12	07/14/2014	05/10/2014	Y
92	Pass	88	12	11	11	07/12/2014	05/10/2014	Y
93	Pass	113	14	12	13	07/12/2014	05/10/2014	Y
94	Pass	85	12	10	11	07/12/2014	05/10/2014	Y
95	Pass	91	12	11	11	07/10/2014	05/10/2014	Y
96	Pass	107	12	14	13	07/09/2014	05/10/2014	Y
97	Pass	112	13	14	12	07/09/2014	05/10/2014	Y
98	Pass	78	12	10	9	07/09/2014	05/10/2014	Y
99	Pass	75	11	11	11	07/08/2014	05/10/2014	Y
100	Pass	100	13	11	13	07/08/2014	05/10/2014	Y
101	Pass	83	11	12	10	07/08/2014	05/10/2014	Y
102	Pass	109	13	12	14	07/07/2014	05/10/2014	Y
103	Pass	85	12	10	12	07/05/2014	05/10/2014	Y
104	Pass	110	13	12	12	07/02/2014	05/10/2014	Y
105	Pass	115	13	14	13	07/02/2014	05/10/2014	Y
106	Pass	84	11	10	14	07/02/2014	05/10/2014	Y
107	Pass	101	12	14	13	07/02/2014	05/10/2014	Y
108	Pass	123	14	14	15	07/02/2014	05/10/2014	Y
109	Pass	100	12	12	13	07/02/2014	05/10/2014	Y
110	Pass	94	12	11	13	07/01/2014	05/10/2014	Y
111	Pass	86	11	12	12	06/30/2014	05/10/2014	Y
112	Pass	97	12	11	12	06/30/2014	05/10/2014	Y
113	Pass	88	12	10	12	06/30/2014	05/10/2014	Y
114	Pass	108	13	12	13	06/28/2014	05/10/2014	Y
115	Pass	86	11	12	12	06/25/2014	05/10/2014	Y
116	Pass	103	13	12	13	06/25/2014	05/10/2014	Y
117	Pass	82	11	11	10	06/25/2014	05/10/2014	Y
118	Pass	98	12	12	11	06/24/2014	05/10/2014	Y
119	Pass	109	13	13	12	06/24/2014	05/10/2014	Y
120	Pass	89	11	12	12	06/24/2014	05/10/2014	Y
121	Pass	110	13	12	15	06/21/2014	05/10/2014	Y
122	Pass	108	13	12	12	06/18/2014	05/10/2014	Y
123	Pass	98	13	11	12	06/17/2014	05/10/2014	Y
124	Pass	85	12	10	12	06/14/2014	05/10/2014	Y
125	Pass	97	12	12	13	06/12/2014	05/10/2014	Y
126	Pass	111	13	12	15	06/11/2014	05/10/2014	Y
127	Pass	104	12	14	15	06/07/2014	05/10/2014	Y
128	Pass	119	14	14	14	06/07/2014	05/10/2014	Y
129	Pass	122	14	14	14	06/07/2014	05/10/2014	Y
130	Fail	70	10	11	10	05/27/2014	12/13/2013	Y
131	Pass	76	11	11	11	05/20/2014	12/13/2013	Y
132	Fail	57	10	9	10	05/20/2014	12/13/2013	Y

**Table 5 Candidate Summary Report**

<b>Candidate</b>	<b>Pass/Fail</b>	<b>Total Scaled Score</b>	<b>Area 1 Scaled Score</b>	<b>Area 2 Scaled Score</b>	<b>Area 3 Scaled Score</b>	<b>Test Date</b>	<b>Graduation Date</b>	<b>First Attempt</b>
133	Pass	97	13	11	11	06/18/2014	05/11/2013	N
134	Pass	99	13	12	10	05/08/2014	05/11/2013	N
135	Fail	66	10	11	10	05/08/2014	05/11/2013	N
136	Fail	59	10	10	10	05/02/2014	05/11/2013	N
137	Pass	78	11	11	11	05/12/2014	05/12/2012	N
138	Pass	84	11	11	10	06/30/2014	05/10/2008	N

**National Statistics for All NAPLEX Candidates**

**Mean Scaled Score: 101.71**  
**Standard Deviation: 16.02**  
**Range: 5 - 138**  
**Passing Rate (%): 93.86**

**National Statistics for First-Time NAPLEX Candidates**

**Mean Scaled Score: 102.80**  
**Standard Deviation: 14.83**  
**Range: 5 - 138**  
**Passing Rate (%): 95.61**

The following tables are scaled score frequency distributions for NAPLEX candidates. Candidates who did not answer enough questions to receive a score are not reflected in the frequency distributions.

**Table 6 National Frequency Distribution of Scaled Scores  
Based on Total Tests Administered (N = 12746 )**

**Test Window: May 1, 2014 - August 31, 2014**

Scaled Score	Frequency	Cumulative Percent of the Upper Limit of the Interval
0 - 4	0	0.0%
5 - 9	1	0.0%
10 - 14	2	0.0%
15 - 19	1	0.0%
20 - 24	4	0.1%
25 - 29	7	0.1%
30 - 34	6	0.2%
35 - 39	13	0.3%
40 - 44	16	0.4%
45 - 49	33	0.7%
50 - 54	47	1.0%
55 - 59	60	1.5%
60 - 64	109	2.3%
65 - 69	166	3.7%
70 - 74	299	6.0%
75 - 79	405	9.2%
80 - 84	595	13.9%
85 - 89	812	20.2%
90 - 94	1099	28.9%
95 - 99	1383	39.7%
100 - 104	1542	51.9%
105 - 109	1650	64.8%
110 - 114	1633	77.7%
115 - 119	1433	88.9%
120 - 124	885	95.9%
125 - 129	406	99.1%
130 - 134	107	99.9%
135 - 139	13	100.0%
140 - 144	0	100.0%
145 - 150	0	100.0%

**Table 7 National Frequency Distribution of Scaled Scores  
Based on First-Time Candidates from ACPE-Accredited Programs (N = 12191 )**

**Test Window: May 1, 2014 - August 31, 2014**

<b>Scaled Score</b>	<b>Frequency</b>	<b>Cumulative Percent of the Upper Limit of the Interval</b>
0 - 4	0	0.0%
5 - 9	1	0.0%
10 - 14	2	0.0%
15 - 19	1	0.0%
20 - 24	2	0.0%
25 - 29	4	0.1%
30 - 34	6	0.1%
35 - 39	9	0.2%
40 - 44	12	0.3%
45 - 49	24	0.5%
50 - 54	34	0.8%
55 - 59	44	1.1%
60 - 64	85	1.8%
65 - 69	126	2.8%
70 - 74	261	4.9%
75 - 79	376	8.0%
80 - 84	554	12.5%
85 - 89	771	18.7%
90 - 94	1077	27.4%
95 - 99	1356	38.4%
100 - 104	1525	50.7%
105 - 109	1636	63.9%
110 - 114	1624	77.1%
115 - 119	1428	88.6%
120 - 124	884	95.8%
125 - 129	405	99.0%
130 - 134	107	99.9%
135 - 139	13	100.0%
140 - 144	0	100.0%
145 - 150	0	100.0%

**North American Pharmacist Licensure Examination (NAPLEX)**

**Xavier College of Pharmacy**

	<b>2000</b>			<b>2001</b>			<b>2002</b>			<b>2003</b>		
	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>
<b>TOTAL CANDIDATE GROUP</b>												
No. of Candidates	10	80	43	28	85	40	22	69	48	19	90	40
School Average Score:	77.60	87.99	81.67	76.50	93.14	85.15	76.00	93.23	86.98	79.42	94.46	84.33
State Average Score:	96.75	88.52	86.05	84.66	93.82	82.05	75.50	101.46	87.48	77.50	99.40	87.33
National Average Score:	91.78	99.86	91.21	90.25	101.70	83.69	90.81	101.21	90.02	91.50	101.40	89.40
School Pass Rate:	60.00	77.50	62.79	57.14	85.88	82.50	54.55	79.71	85.42	68.42	90.00	75.00
State Pass Rate:	92.50	78.57	77.27	75.86	89.29	70.00	50.00	85.90	70.37	62.50	94.90	80.00
National Pass Rate:	82.95	92.05	83.04	81.07	94.38	83.69	81.52	93.76	81.73	82.77	93.84	79.55
<b>FIRST-TIME CANDIDATE GROUP</b>												
No. of Candidates	1	77	23	10	74	29	8	63	40	8	83	26
School Average Score:	95.00	88.19	82.13	74.80	95.92	86.48	80.63	95.00	88.60	87.75	95.34	88.04
State Average Score:	97.49	93.61	87.77	88.78	95.92	85.93	81.89	103.71	91.15	74.00	100.41	92.38
National Average Score:	96.51	101.85	96.48	94.54	103.35	94.22	95.13	103.00	94.62	97.39	103.38	95.88
School Pass Rate:	100.00	77.92	65.22	50.00	90.54	82.76	75.00	84.13	90.00	87.50	90.36	80.77
State Pass Rate:	94.59	93.18	84.62	83.33	91.84	73.33	77.78	90.28	70.00	66.67	95.65	90.48
National Pass Rate:	91.44	95.44	91.39	87.91	96.75	90.10	89.27	96.74	88.52	91.47	96.54	89.64

**North American Pharmacist Licensure Examination (NAPLEX)**

**Xavier College of Pharmacy**

	<b>2004</b>			<b>2005</b>			<b>2006</b>			<b>2007</b>		
	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>
<b>TOTAL CANDIDATE GROUP</b>												
No. of Candidates	10	82	19	6	95	30	20	94	48	17	81	56
School Average Score:	76.40	98.99	91.68	83.00	98.92	73.07	72.15	106.20	92.81	74.18	109.07	86.77
State Average Score:	81.33	103.47	96.71	95.00	101.77	92.50	86.67	111.87	96.07	88.00	117.29	94.73
National Average Score:	92.13	102.16	91.70	91.32	104.85	87.72	86.89	107.02	93.18	89.95	113.33	94.18
School Pass Rate:	70.00	96.34	84.21	83.33	86.32	56.67	50.00	82.98	77.08	52.94	83.95	64.29
State Pass Rate:	83.33	96.12	100.00	100.00	87.83	78.57	77.78	89.17	79.31	63.64	95.52	74.51
National Pass Rate:	83.22	95.11	84.79	82.88	89.15	71.73	68.82	90.52	77.07	71.38	94.47	78.76
<b>FIRST-TIME CANDIDATE GROUP</b>												
No. of Candidates	2	79	10	3	90	19	5	87	31	3	68	46
School Average Score:	72.50	100.06	98.80	85.00	101.34	79.79	69.40	109.32	93.10	94.67	114.60	90.50
State Average Score:	84.00	105.61	99.73	101.50	103.64	98.94	93.33	112.95	95.41	103.40	118.18	95.00
National Average Score:	100.14	104.14	96.60	98.84	107.67	95.89	97.18	110.34	99.96	102.16	116.00	102.19
School Pass Rate:	50.00	98.73	100.00	66.67	88.89	68.42	40.00	86.21	77.42	100.00	92.65	71.74
State Pass Rate:	100.00	100.00	100.00	100.00	90.09	88.89	100.00	90.38	70.59	100.00	96.69	76.74
National Pass Rate:	95.07	97.38	92.22	91.31	92.86	82.12	81.12	94.49	84.74	84.09	97.23	88.12

**North American Pharmacist Licensure Examination (NAPLEX)**

**Xavier College of Pharmacy**

	<b>2008</b>			<b>2009</b>			<b>2010</b>			<b>2011</b>		
	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>
<b>TOTAL CANDIDATE GROUP</b>												
No. of Candidates	22	138	55	18	138	28	19	148	52	25	124	45
Mean Scaled Score - School	81.36	96.77	89.82	80.33	97.59	86.96	73.63	89.73	77.15	76.00	99.13	85.04
Mean Scaled Score - State	93.70	103.31	95.41	94.80	108.26	84.32	83.15	94.22	80.13		99.66	85.27
Mean Scaled Score - National	96.76	112.08	96.61	93.72	112.51	93.62	84.75	101.11	84.90	83.97	103.27	88.08
School Pass Rate:	68.18	81.88	76.36	61.11	83.33	71.43	42.11	75.00	59.62	64.00	87.10	75.56
State Pass Rate:	90.00	90.34	82.76	80.00	92.64	63.16	61.54	83.24	65.00		90.81	73.17
National Pass Rate:	83.11	95.48	81.96	76.40	95.03	78.20	65.07	92.39	72.20	67.85	94.16	76.57
<b>FIRST-TIME CANDIDATE GROUP</b>												
No. of Candidates	5	124	36	6	127	12	6	143	16	6	115	33
Mean Scaled Score - School	85.40	98.77	92.47	81.00	99.77	83.33	79.83	90.78	84.00	61.00	101.95	85.45
Mean Scaled Score - State	96.00	104.42	95.82	86.00	108.80	84.10	92.00	94.46	90.75		100.88	83.70
Mean Scaled Score - National	106.63	114.11	103.62	106.27	114.65	102.87	100.12	103.06	94.26	96.99	105.03	96.71
School Pass Rate:	80.00	84.68	80.56	50.00	86.61	66.67	50.00	76.92	75.00	16.67	92.17	81.82
State Pass Rate:	83.33	92.35	82.35	57.14	93.04	60.00	66.67	84.15	83.33		93.18	74.07
National Pass Rate:	92.24	97.44	90.66	90.76	97.50	89.51	88.38	95.31	86.71	87.50	96.57	89.24

**North American Pharmacist Licensure Examination (NAPLEX)**

**Xavier College of Pharmacy**

	<b>2012</b>			<b>2013</b>			<b>2014</b>			<b>2015</b>		
	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>	<u>Jan - Apr</u>	<u>May - Aug</u>	<u>Sept - Dec</u>
<b>TOTAL CANDIDATE GROUP</b>												
No. of Candidates	13	120	21	10	136	43	18	138				
Mean Scaled Score - School	76.69	95.13	83.24	68.67	95.13	81.47	70.72	96.29				
Mean Scaled Score - State	81.25	98.42	86.95	77.25	98.66	86.88	73.85	96.45				
Mean Scaled Score - National	83.15	102.81	88.15	80.17	102.78	87.03	80.22	101.71				
School Pass Rate:	46.15	90.00	61.90	40.00	86.03	65.12	50.00	92.75				
State Pass Rate:	68.75	93.82	76.19	55.56	92.95	81.82	53.85	90.75				
National Pass Rate:	68.33	95.21	77.86	61.07	94.65	75.91	63.24	93.86				
<b>FIRST-TIME CANDIDATE GROUP</b>												
No. of Candidates	3	111	12	1	131	29	3	131				
Mean Scaled Score - School	84.67	97.71	95.58	47.00	96.65	82.76	61.00	97.15				
Mean Scaled Score - State	84.00	99.47	91.00	80.75	99.30	88.33	85.00	96.96				
Mean Scaled Score - National	94.87	104.13	95.75	92.48	104.02	92.69	90.89	102.80				
School Pass Rate:	66.67	93.69	91.67	0.00	89.31	68.97	66.67	93.89				
State Pass Rate:	75.00	95.35	72.73	75.00	94.08	83.33	100.00	92.12				
National Pass Rate:	87.69	97.19	90.14	85.14	96.57	84.46	83.15	95.61				



# Louisiana Board of Pharmacy

3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ Facsimile 225.925.6499  
[www.pharmacy.la.gov](http://www.pharmacy.la.gov) ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



## Pharmacy Technician Certification Examination (PTCE™)

January 1 – June 30, 2014

Cumulative Record (since January 2000)

November 13, 2014

## **Pharmacy Technician Certification Examination (PTCE™)**

This computer adaptive competency assessment is administered by the Pharmacy Technician Certification Board (PTCB). The examination blueprint is designed to assess the applicant's competency in basic pharmacy practice and is recognized by pharmacy regulatory authorities in most of the states and territories within the USA. The examination is administered via an open window process; applicants may schedule the examination at a designated testing center at any time following approval by PTCB and receipt of an Authorization to Test (ATT) document from PTCB. Individual scores are available to applicants immediately after the test; certificates are mailed to the applicant within 30 days following the examination. Summary reports are provided to the state boards on a semi-annual basis.

### *Table of Contents*

Cumulative Report (since January 2000)

03

Louisiana Board of Pharmacy

Pharmacy Technician Certification Board (PTCB) Examination

	1995-1999									
<b><u>National Data</u></b>	<u>Data</u>	<u>3/25/2000</u>	<u>7/22/2000</u>	<u>11/18/2000</u>	<u>3/10/2001</u>	<u>7/14/2001</u>	<u>11/10/2001</u>	<u>3/16/2002</u>	<u>7/27/2002</u>	<u>11/16/2002</u>
No. of Candidates Attempting	58,382	8,101	12,317	12,941	8,442	12,057	10,608	8,874	13,399	11,521
No. of Candidates Passing	47,973	6,206	10,006	9,520	6,116	9,799	8,354	7,072	10,681	9,164
Passing Score										
Average Score										
Pass Rate	82%	77%	81%	74%	72%	81%	79%	80%	80%	80%
<b>Louisiana Data</b>										
No. of Candidates Attempting	514	141	346	327	187	310	324	269	383	308
No. of Candidates Passing	390	92	271	221	125	227	228	184	269	213
Average Score										
Pass Rate	76%	65%	78%	68%	67%	73%	70%	68%	70%	69%
<hr/>										
	2000-2002									
<b><u>National Data</u></b>	<u>Data</u>	<u>3/29/2003</u>	<u>7/26/2003</u>	<u>11/15/2003</u>	<u>3/20/2004</u>	<u>7/17/2004</u>	<u>11/13/2004</u>	<u>3/19/2005</u>	<u>7/23/2005</u>	<u>11/19/2005</u>
No. of Candidates Attempting	98,260	12,147	14,162	13,401	11,508	15,942	13,795	13,673	18,250	14,068
No. of Candidates Passing	76,918	9,506	11,720	11,006	9,100	12,196	10,818	11,009	14,246	10,583
Passing Score										650
Average Score										702
Pass Rate	78%	78%	83%	82%	79%	77%	78%	81%	78%	75%
<b>Louisiana Data</b>										
No. of Candidates Attempting	2,595	385	384	351	285	382	290	337	488	216
No. of Candidates Passing	1,830	294	286	271	211	281	214	274	351	167
Average Score										688
Pass Rate	71%	76%	74%	77%	74%	74%	74%	81%	72%	77%

Louisiana Board of Pharmacy

Pharmacy Technician Certification Board (PTCB) Examination

	2000-2005 Data	3/11/2006	7/22/2006	9/9/2006	11/18/2006	2000-2006 Data	2/5/2007 3/9/2007	4/24/2007 5/25/2007	8/27/2007 9/28/2007	11/26/2007 12/31/2007
<b>National Data</b>										
No. of Candidates Attempting	225,206	12,383	18,992	3,029	15,285	274,895	8,768	10,730	14,666	10,881
No. of Candidates Passing	177,102	8,559	12,609	2,006	9,145	209,421	6,034	7,487	10,497	7,472
Passing Score		650	650	650	650	650	650	650	650	650
Average Score		688	683	683	668					
Pass Rate	79%	69%	66%	66%	60%	76%	69%	70%	72%	69%
<b>Louisiana Data</b>										
No. of Candidates Attempting	5,713	288	420	59	312	6,792	216	306	266	207
No. of Candidates Passing	4,179	181	239	37	137	4,773	133	196	177	121
Average Score		673	664	685	641					
Pass Rate	73%	63%	57%	63%	44%	70%	62%	64%	67%	58%
<hr/>										
	2000-2007 Data	2/4/2008 3/14/2008	4/28/2008 6/20/2008	8/18/2008 10/10/2008	11/10/2008 12/19/2008	2000-2008 Data	1/1/2009 3/31/2009	4/1/2009 6/30/2009	7/1/2009 9/30/2009	10/1/2009 12/31/2009
<b>National Data</b>										
No. of Candidates Attempting	319,940	7,547	14,291	16,385	11,792	369,955	13,087	8,424	13,735	10,674
No. of Candidates Passing	240,911	5,165	10,155	11,781	7,770	275,782	9,141	6,363	10,067	7,682
Passing Score	650	650	650	650	650	650	650	650	650	650
Average Score										
Pass Rate	75%	68%	72%	72%	66%	75%	70%	76%	73%	72%
<b>Louisiana Data</b>										
No. of Candidates Attempting	7,787	128	392	304	215	8,826	301	260	238	218
No. of Candidates Passing	5,400	72	233	182	118	6,005	184	196	166	137
Average Score										
Pass Rate	69%	56%	59%	60%	55%	68%	61%	75%	70%	63%

Louisiana Board of Pharmacy

Pharmacy Technician Certification Board (PTCB) Examination

	2000-2009 Data	1/1/2010 3/31/2010	4/1/2010 6/30/2010	7/1/2010 9/30/2010	10/1/2010 12/31/2010	2000-2010 Data	1/1/2011 3/31/2011	4/1/2011 6/30/2011	7/1/2011 9/30/2011	10/1/2011 12/31/2011
<b>National Data</b>										
No. of Candidates Attempting	415,875	11,611	15,033	16,025	12,774	471,318	11,219	14,026	12,356	14,031
No. of Candidates Passing	309,035	8,521	11,216	12,349	9,275	350,396	8,366	10,472	9,565	10,826
Passing Score	650	650	650	650	650	650	650	650	650	650
Average Score										
Pass Rate	74%	73%	75%	77%	73%	74%	75%	75%	77%	77%
<b>Louisiana Data</b>										
No. of Candidates Attempting	9,843	217	421	320	268	11,069	247	437	268	257
No. of Candidates Passing	6,688	121	287	219	166	7,481	161	306	182	168
Average Score										
Pass Rate	68%	56%	68%	68%	62%	68%	65%	70%	68%	65%
<hr/>										
	2000-2011 Data	1/1/2012 3/31/2012	4/1/2012 6/30/2012	7/1/2012 9/30/2012	10/1/2012 12/31/2012	2000-2012 Data	Changed to semi-annual reports 1/1/2013 to 6/30/2013		7/1/2013 to 12/31/2013	
<b>National Data</b>										
No. of Candidates Attempting	522,950	11,851	14,356	14,375	11,180	574,712	25,448		28,797	
No. of Candidates Passing	389,625	9,232	11,044	10,982	8,471	429,354	19,581		21,745	
Passing Score	650	650	650	650	650	650	650		650	
Average Score										
Pass Rate	75%	78%	77%	76%	76%	75%	77%		76%	
<b>Louisiana Data</b>										
No. of Candidates Attempting	12,278	246	368	329	239	13,460	622		537	
No. of Candidates Passing	8,298	158	269	226	168	9,119	412		351	
Average Score										
Pass Rate	68%	64%	73%	69%	70%	68%	66%		65%	

Louisiana Board of Pharmacy

Pharmacy Technician Certification Board (PTCB) Examination

	2000-2013 Data	<u>1/1/2014 to 6/30/2014</u>	<u>7/1/2014 to 12/31/2014</u>	2000-2014 Data	<u>1/1/2015 to 6/30/2015</u>	<u>7/1/2015 to 12/31/2015</u>
<b>National Data</b>						
No. of Candidates Attempting	628,957	26,423				
No. of Candidates Passing	470,680	15,233				
Passing Score	650	650				
Average Score						
Pass Rate	75%	58%				
<b>Louisiana Data</b>						
No. of Candidates Attempting	11,002	630				
No. of Candidates Passing	7,451	287				
Average Score						
Pass Rate	68%	46%				
<hr/>						
	2000-2015 Data	<u>1/1/2016 to 6/30/2016</u>	<u>7/1/2016 to 12/31/2016</u>	2000-2016 Data	<u>1/1/2017 to 6/30/2017</u>	<u>7/1/2017 to 12/31/2017</u>
<b>National Data</b>						
No. of Candidates Attempting						
No. of Candidates Passing						
Passing Score						
Average Score						
Pass Rate						
<b>Louisiana Data</b>						
No. of Candidates Attempting						
No. of Candidates Passing						
Average Score						
Pass Rate						

## DISPOSAL REGULATIONS: REGISTRANT FACT SHEET

On September 8, 2014, the Drug Enforcement Administration (DEA) made available for public view a final rule regarding the disposal of pharmaceutical controlled substances in accordance with the Controlled Substance Act, as amended by the Secure and Responsible Drug Disposal Act of 2010 (“Disposal Act”). The final rule is available for public view at <http://www.federalregister.gov/public-inspection>. The final rule will officially publish in the *Federal Register* on September 9, 2014, and will be available on <http://www.regulations.gov>, and our website, <http://www.DEAdiversion.usdoj.gov>. This Registrant Fact Sheet contains a general summary of some of the effects of the new rule on registrants. For detailed information, please visit our website or contact your local DEA office.

### **1. What is the Disposal Act?**

- The Disposal Act amended the Controlled Substances Act (CSA) to give the DEA authority to promulgate new regulations, within the framework of the CSA, that will allow ultimate users to deliver unused pharmaceutical controlled substances to appropriate entities for disposal in a safe and effective manner consistent with effective controls against diversion. The goal of the Disposal Act is to encourage public and private entities to develop a variety of methods of collection and disposal in a secure, convenient, and responsible manner.

### **2. What do the implementing regulations do?**

- Effective October 9, 2014, the implementing regulations allow authorized manufacturers, distributors, reverse distributors, narcotic treatment programs, hospitals/clinics with an on-site pharmacy, and retail pharmacies to collect pharmaceutical controlled substances from ultimate users by voluntarily administering mail-back programs and maintaining collection receptacles. In addition, the regulations allow authorized hospitals/clinics and retail pharmacies to voluntarily maintain collection receptacles at long-term care facilities.
- The new regulations reorganize and consolidate previously existing regulations on disposal, including the role of reverse distributors. Effective October 9, 2014, the existing regulation on disposal of controlled substances, 21 C.F.R. 1307.21, will be removed. New requirements on proper disposal procedure and security will be in a new part 1317.
- As of October 9, 2014, all Memoranda of Agreement (MOA) and Memoranda of Understanding (MOU) issued pursuant to current 21 C.F.R. 1307.21 will be null and void. Registrants should consult 21 C.F.R. 1317.05(a) for information on new MOAs and MOUs for the disposal of controlled substances.
- Effective October 9, 2014, the existing regulation on return and recall, 21 C.F.R. 1307.12, will be removed. New return and recall requirements for registrants and non-registrants are incorporated into new 21 C.F.R. 1317.10 and 1317.85.
- Effective October 9, 2014, registrants must use DEA Form 41 to record the destruction of controlled substances. However, a controlled substance dispensed for immediate administration pursuant to an order for medication in an institutional setting remains under the custody and control of that registered institution even if the substance is not fully exhausted (*e.g.*, some of the substance remains in a vial, tube, transdermal patch, or syringe after administration but cannot or may not be further utilized, commonly referred to as “drug wastage” and “pharmaceutical wastage”). Such remaining substance must be properly recorded, stored, and

destroyed in accordance with DEA regulations (*e.g.*, 21 C.F.R. 1304.22(c)), and all applicable Federal, State, tribal, and local laws and regulations, although the destruction need not be recorded on a DEA Form 41.

**3. Who is an “ultimate user”?**

- The CSA defines an “ultimate user” as “a person who has lawfully obtained, and who possesses, a controlled substance for his own use or for the use of a member of his household or for an animal owned by him or a member of his household.”

**4. What is “collection”?**

- “Collection” means to receive a controlled substance for the purpose of destruction from an ultimate user, a person lawfully entitled to dispose of an ultimate user decedent’s property, or a long-term care facility on behalf of an ultimate user who resides or has resided at that facility. The term “collector” means a registered manufacturer, distributor, reverse distributor, narcotic treatment program, hospital/clinic with an on-site pharmacy, or retail pharmacy that is authorized to so receive a controlled substance for the purpose of destruction.

**5. How can a registrant become an “authorized collector”?**

- Manufacturers, distributors, reverse distributors, narcotic treatment programs, hospitals/clinics with an on-site pharmacy, and retail pharmacies that desire to be collectors may do so by modifying their registration to obtain authorization to be a collector. Registrants may modify their registration online at <http://www.DEAdiversion.usdoj.gov>. Once authorized, these entities are “authorized collectors.”
- Eligible registrants must have authority to handle schedule II controlled substances.
- Collectors are not authorized to conduct take-back events. Law enforcement may continue to conduct take-back events at any time. Any person or community group, registrant or non-registrant, may partner with law enforcement to conduct take-back events.

**6. Who can operate a collection receptacle for the collection of pharmaceutical controlled substances?**

- Authorized collectors may maintain collection receptacles inside their registered location; and Federal, State, tribal, or local law enforcement may continue to maintain collection receptacles inside their physical location.
- Authorized hospitals/clinics with an on-site pharmacy, and retail pharmacies, may maintain collection receptacles at long-term care facilities.

**7. Who can operate a mail-back program for the collection of pharmaceutical controlled substances?**

- Authorized collectors with an on-site method of destruction may operate a mail-back program.

**8. If I become an authorized collector and decide to stop, how do I do so?**

- *Collection receptacle:* Authorized collectors maintaining a collection receptacle must dispose of all collected pharmaceutical controlled substances in their possession in accordance with the new rule, and notify the DEA that collection activities are ceasing, in writing or online at <http://www.DEAdiversion.usdoj.gov>.

- *Mail-back program:* Authorized collectors operating a mail-back program must make a reasonable effort to notify the public prior to discontinuing or ceasing collection; obtain the written agreement of another collector to receive all remaining mail-back packages; and notify the DEA that collection activities are ceasing, in writing or online at <http://www.DEAdiversion.usdoj.gov>.

**9. What can I collect as an authorized collector?**

- An authorized collector may collect pharmaceutical controlled substances and non-controlled substances. Controlled and non-controlled pharmaceuticals may be co-mingled in a single collection receptacle, however it is not required.
- Controlled substances that are collected from ultimate users shall not be co-mingled with a registrant's inventory/stock of controlled substances (*i.e.*, registrants shall not dispose of controlled substance inventory in a collection receptacle or mail-back package, or through a take-back event).

**10. Can ultimate users dispose of illicit drugs through a collection receptacle, mail-back package, or take-back event?**

- No. Ultimate users may not dispose of illicit drugs (*e.g.*, schedule I controlled substances such as marijuana, heroin, LSD) through any of the three disposal methods.

**11. I am a pharmacist. If my pharmacy chooses to become an authorized collector, will we need to collect and retain information about persons who utilize the collection receptacle, such as a person's name, prescription information, or physician information?**

- No. A collector shall not require any person to provide any personally identifying information.

**12. How does a registrant dispose of controlled substances when 21 C.F.R. 1307.21 is removed?**

- The authorized methods and procedures regarding disposal are outlined, in 21 C.F.R. 1317.05, according to whether the substances being disposed of are practitioner inventory, non-practitioner inventory, or collected controlled substances.

**13. How can a registrant destroy controlled substances?**

- The new regulations do not require a particular method of destruction, so long as the desired result is achieved. Pharmaceutical controlled substances must be rendered "non-retrievable" in compliance with all applicable Federal, State, tribal and local laws. This standard is intended to allow public and private entities to develop a variety of destruction methods that are secure, convenient, and responsible, consistent with preventing the diversion of such substances.
- "Non-retrievable" means the condition or state to which a controlled substance shall be rendered following a process that permanently alters that controlled substance's physical or chemical condition or state through irreversible means and thereby renders the controlled substance unavailable and unusable for all practical purposes. A controlled substance is considered "non-retrievable" when it cannot be transformed to a physical or chemical condition or state as a controlled substance or controlled substance analogue.



# National Transportation Safety Board

Washington, DC 20594

## Safety Recommendation

---

**Date:** September 23, 2014

**In reply refer to:** I-14-1 and -2

The Honorable Bobby Jindal  
Governor of Louisiana  
PO Box 94004  
Baton Rouge, LA 70804

---

The National Transportation Safety Board (NTSB) is an independent federal agency charged by Congress with investigating every civil aviation accident in the United States and significant accidents in other modes of transportation—railroad, highway, marine, and pipeline. We determine the probable cause of the accidents and issue safety recommendations aimed at preventing future accidents. In addition, we carry out special studies concerning transportation safety and coordinate the resources of the federal government and other organizations to provide assistance to victims and their family members affected by major transportation disasters. We are providing the following information to urge the state of Louisiana to take action on the safety recommendations being issued in this letter.

On September 9, 2014, we adopted our safety study, *Drug Use Trends in Aviation: Assessing the Risk of Pilot Impairment*.<sup>1</sup> Additional information about this topic and the resulting recommendations may be found in the study, which can be accessed at our website, <http://www.nts.gov>, under report number SS-14/01.

As a result of this safety study, we issued six new recommendations, including four recommendations to the Federal Aviation Administration and the following two recommendations to the 50 states (including the state of Louisiana), the District of Columbia, and the Commonwealth of Puerto Rico:

### I-14-1

Include in all state guidelines regarding prescribing controlled substances for pain a recommendation that health care providers discuss with patients the effect their

---

<sup>1</sup> *Drug Use Trends in Aviation: Assessing the Risk of Pilot Impairment*, September 9, 2014, SS-14/01.

medical condition and medication use may have on their ability to safely operate a vehicle in any mode of transportation.

I-14-2

Use existing newsletters or other routine forms of communication with licensed health care providers and pharmacists to highlight the importance of routinely discussing with patients the effect their diagnosed medical conditions or recommended drugs may have on their ability to safely operate a vehicle in any mode of transportation.

An informational article that could be distributed to fulfill Safety Recommendation I-14-2 is enclosed for your consideration.

Acting Chairman HART, and Members SUMWALT, ROSEKIND, and WEENER concurred in these recommendations.

The NTSB is vitally interested in these recommendations because they are designed to prevent accidents and save lives. We would appreciate receiving a response from you within 90 days detailing the actions you have taken or intend to take to implement them. When replying, please refer to the safety recommendations by number. We encourage you to submit your response electronically to [correspondence@ntsb.gov](mailto:correspondence@ntsb.gov). If it exceeds 10 megabytes, including attachments, please e-mail us at the same address for instructions. Please do not submit both an electronic copy and a hard copy of the same response.

By:

Enclosure

cc: Cecilia A. Mouton, MD  
Executive Director  
Louisiana State Board of Medical Examiners

Karen C. Lyon, PhD, RN, ACNS, NEA  
Executive Director  
Louisiana State Board of Nursing

Mr. Malcolm J. Broussard  
Executive Director  
Louisiana Board of Pharmacy

## **Evidence That Pilots Are Increasingly Using Over-the-Counter, Prescription, and Illicit Drugs**

The National Transportation Safety Board (NTSB) recently analyzed toxicology tests from 6,677 pilots who died in a total of 6,597 aviation accidents between 1990 and 2012. The results demonstrate a significant increase in the use of a variety of potentially impairing drugs.

The study found significantly increasing trends in pilots' use of all drugs, potentially impairing drugs (those with a US Food and Drug Administration warning about sedation or behavior changes in routine use), controlled substances, and illicit drugs (those defined as Schedule I by the US Drug Enforcement Administration). The final report, *Drug Use Trends in Aviation: Assessing the Risk of Pilot Impairment*, is available on the NTSB's [Safety Studies](#) web page under report number SS-14/01.

In this study, the pilot was considered to be positive for a drug if it could be qualitatively or quantitatively identified in blood or tissue; drugs identified only in urine or used as part of resuscitative efforts were excluded.

Overall, 98% of the study pilots were male and 96% were flying privately rather than for commercial purposes. The average age of study pilots increased from 46 to 57 years over the study period.

Over the course of the study, for fatally injured pilots, the following was found:

The proportion of pilots testing positive for at least one drug increased from 10% to 40%.

More than 20% of all pilots from 2008-2012 were positive for a potentially impairing drug, and 6% of all pilots were positive for more than one potentially impairing drug.

Overall, the most common potentially impairing drug pilots had used was diphenhydramine, a sedating antihistamine (the active ingredient in many Benadryl and Unisom products).

During the most recent 5 years studied, 8% of all pilots tested positive for controlled substances; hydrocodone and diazepam each accounted for 20% of the positive findings.

The percentage of pilots testing positive for marijuana use increased to about 3% during the study period, mostly in the last 10 years.

The large increase in the proportion of fatally injured pilots with evidence of potentially impairing drugs suggests an increasing risk of impairment in general aviation. Aviation is the only transportation mode in which a fatally injured operator (pilot) routinely undergoes extensive toxicology testing; no similar testing is routinely performed for fatally injured operators of boats, trains, trucks, or cars. Given the general increase in drug use in the population, it is likely that there has been a similar trend in drug use among operators across all modes of transportation.

These results highlight the importance of routine discussions between health care providers and pharmacists and their patients about the potential risks that drugs and medical conditions can create when patients are operating a vehicle in any mode of transportation.



# Louisiana Board of Pharmacy

3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ Facsimile 225.925.6499  
[www.pharmacy.la.gov](http://www.pharmacy.la.gov) ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



## Announcements

---

**NOTE:** Pursuant to the Open Meetings Law, at LRS 42:6.1, the committee may, upon 2/3 affirmative vote of those members present and voting, enter into executive session for the limited purposes of (1) discussion of the character, professional competence, or physical or mental health of a licensee, (2) investigative proceedings regarding allegations of misconduct, (3) strategy sessions or negotiations with respect to litigation, or (4) discussions regarding personnel matters.



# Louisiana Board of Pharmacy

3388 Brentwood Drive  
Baton Rouge, Louisiana 70809-1700  
Telephone 225.925.6496 ~ Facsimile 225.925.6499  
[www.pharmacy.la.gov](http://www.pharmacy.la.gov) ~ E-mail: [info@pharmacy.la.gov](mailto:info@pharmacy.la.gov)



November 13, 2014

## Agenda Item 12: Announcements

Nov. 27 – 28	Thanksgiving Day – <i>Board office closed</i>
Dec. 7-11	ASHP MidYear Meeting – Anaheim, CA
Dec. 10-11	Violations Committee Informal Conference
Dec. 25 – 26	Christmas Day – <i>Board office closed</i>
Jan. 1 – 2	New Year's Day – <i>Board office closed</i>
Jan. 14	Louisiana Pharmacy Congress NABP Inspection Blueprint Workshop – Mount Prospect, IL
Jan. 19	Martin Luther King, Jr. Day – <i>Board office closed</i>
Jan. 21	Prescription Monitoring Program (PMP) Advisory Council
Feb. 17	Mardi Gras Day – <i>Board office closed</i>
Feb. 24	Reinstatement & Impairment Committees
Feb. 25	Reciprocity Committee & Board Meeting
Feb. 26	Administrative Hearing

## ***Board Meeting Schedule for Calendar Year 2015***

Feb. 24-26	May 5-7	Aug. 11-13	Nov. 17-19
------------	---------	------------	------------